☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
WALGREENS BOOTS ALLIANCE, INC.
|
||
(Exact name of registrant as specified in its charter)
|
||
Delaware
|
47-1758322
|
|
(State of incorporation)
|
(I.R.S. Employer Identification No.)
|
|
108 Wilmot Road, Deerfield, Illinois
|
60015
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Name of each exchange on which registered
|
|
Common Stock ($.01 Par Value)
|
The NASDAQ Stock Market LLC
|
|
2.875% Notes due 2020
|
New York Stock Exchange
|
|
3.600% Notes due 2025
|
New York Stock Exchange
|
|
2.125% Notes due 2026
|
New York Stock Exchange
|
Large accelerated filer ☒
|
Accelerated filer ☐
|
||
Non-accelerated filer ☐
|
Smaller reporting company ☐
|
Page
|
||
Item 1.
|
1
|
|
Item 1A.
|
8
|
|
Item 1B.
|
26
|
|
Item 2.
|
26
|
|
Item 3.
|
27
|
|
Item 4.
|
27
|
|
27
|
||
Part II
|
||
Item 5.
|
29
|
|
Item 6.
|
31
|
|
Item 7.
|
32
|
|
Item 7A.
|
53
|
|
Item 8.
|
54
|
|
Item 9.
|
98
|
|
Item 9A.
|
98
|
|
Item 9B.
|
99
|
|
Part III
|
||
Item 10.
|
99
|
|
Item 11.
|
99
|
|
Item 12.
|
99
|
|
Item 13.
|
99
|
|
Item 14.
|
100
|
|
Part IV
|
||
Item 15.
|
100
|
|
|
111
|
· |
Retail Pharmacy USA;
|
· |
Retail Pharmacy International; and
|
· |
Pharmaceutical Wholesale.
|
Fiscal 2016
|
Fiscal 2015
|
Fiscal 2014
|
||||||||||
Pharmacy
|
67
|
%
|
66
|
%
|
64
|
%
|
||||||
Retail
|
33
|
%
|
34
|
%
|
36
|
%
|
||||||
Total
|
100
|
%
|
100
|
%
|
100
|
%
|
Fiscal 2016
|
Fiscal 2015(1)
|
Fiscal 2014
|
||||||||
Pharmacy
|
35
|
%
|
37
|
%
|
NA
|
|||||
Retail
|
65
|
%
|
63
|
%
|
NA
|
|||||
Total
|
100
|
%
|
100
|
%
|
NA
|
(1) |
Fiscal 2015 includes periods subsequent to the Second Step Transaction, for the months of January through August 2015.
|
·
|
compliance with a wide variety of foreign laws and regulations, including retail and wholesale pharmacy, licensing, tax, foreign trade, intellectual property, privacy and data protection, currency, political and other business restrictions and requirements and local laws and regulations, whose interpretation and enforcement vary significantly among jurisdictions and can change significantly over time;
|
·
|
additional U.S. and other regulation of non-domestic operations, including regulation under the Foreign Corrupt Practices Act, the U.K. Bribery Act and other anti-corruption laws;
|
·
|
potential difficulties in managing foreign operations, mitigating credit risks in foreign markets, enforcing agreements and collecting receivables through foreign legal systems;
|
·
|
price controls imposed by foreign countries;
|
·
|
tariffs, duties or other restrictions on foreign currencies or trade sanctions and other trade barriers imposed by foreign countries that restrict or prohibit business transactions in certain markets;
|
·
|
potential adverse tax consequences, including tax withholding laws and policies and restrictions on repatriation of funds to the United States;
|
·
|
fluctuations in currency exchange rates, including uncertainty regarding the Euro;
|
·
|
impact of recessions and economic slowdowns in economies outside the United States, including foreign currency devaluation, higher interest rates, inflation, and increased government regulation or ownership of traditional private businesses;
|
·
|
the instability of foreign economies, governments and currencies and unexpected regulatory, economic or political changes in foreign markets; and
|
·
|
developing and emerging markets may be especially vulnerable to periods of instability and unexpected changes, and consumers in those markets may have relatively limited resources to spend on products and services.
|
·
|
requiring us to dedicate significant cash flow from operations to the payment of principal, interest and other amounts payable on our debt, which would reduce the funds we have available for other purposes, such as working capital, capital expenditures, acquisitions, share repurchases and dividends;
|
·
|
making it more difficult or expensive for us to obtain any necessary future financing for working capital, capital expenditures, debt service requirements, debt refinancing, acquisitions or other purposes;
|
·
|
reducing our flexibility in planning for or reacting to changes in our industry and market conditions;
|
·
|
making us more vulnerable in the event of a downturn in our business operations; and
|
·
|
exposing us to interest rate risk given that a portion of our debt obligations is at variable interest rates.
|
·
|
actual or anticipated variations in quarterly operating results and the results of competitors;
|
·
|
changes in financial estimates by us or by any securities analysts that might cover us;
|
·
|
conditions or trends in the industry, including regulatory changes or changes in the securities marketplace;
|
·
|
announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
|
·
|
announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
|
·
|
additions or departures of key personnel; and
|
·
|
issuances or sales of our common stock, including sales of shares by our directors and officers or key investors, including the SP Investors and the KKR Investors.
|
·
|
If we are unsuccessful in establishing effective advertising, marketing and promotional programs, our sales or sales margins could be negatively affected.
|
·
|
Our operating costs may be subject to increases outside the control of our businesses, whether due to inflation, new or increased taxes, adverse fluctuations in foreign currency exchange rates, changes in market conditions or otherwise.
|
·
|
Our success depends on our ability to attract, engage and retain store, professional and management personnel, including in executive and other key strategic positions, and the loss of key personnel could have an adverse effect on the results of our operations, financial condition or cash flow.
|
·
|
Natural disasters, civil unrest, severe weather conditions, terrorist activities, global political and economic developments, war, health epidemics or pandemics or the prospect of these events can interrupt or otherwise adversely impact our operations or damage our facilities or those of our strategic partners, vendors and customers and have an adverse impact on consumer confidence levels and spending on our products and services.
|
·
|
If we or our affiliates were to incur significant liabilities or expense relating to the protection of the environment, related health and safety matters, environmental remediation or compliance with environmental laws and regulations, including those governing exposure to, and the management and disposal of, hazardous substances, it could have a material adverse effect on our results of operations, financial condition and cash flow.
|
·
|
The long-term effects of climate change on general economic conditions and the pharmacy industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses.
|
·
|
If negative publicity, even if unwarranted, related to safety or quality, human and workplace rights, or other issues damage our brand image and corporate reputation, or that of our vendors or strategic allies, our businesses may suffer.
|
Retail Stores
|
||||
Retail Pharmacy USA:
|
||||
United States
|
8,054
|
|||
Puerto Rico
|
120
|
|||
U.S. Virgin Islands
|
1
|
|||
Total Retail Pharmacy USA
|
8,175
|
|||
Retail Pharmacy International:
|
||||
United Kingdom
|
2,509
|
|||
Mexico
|
1,118
|
|||
Chile
|
438
|
|||
Thailand
|
272
|
|||
Norway
|
161
|
|||
Ireland
|
84
|
|||
The Netherlands
|
65
|
|||
Lithuania
|
26
|
|||
Total Retail Pharmacy International
|
4,673
|
|||
Total
|
12,848
|
Name
|
Age
|
Office(s) Held
|
James A. Skinner
|
71
|
Executive Chairman of the Board
|
Stefano Pessina
|
75
|
Executive Vice Chairman and Chief Executive Officer
|
Ornella Barra
|
62
|
Co-Chief Operating Officer
|
George R. Fairweather
|
59
|
Executive Vice President and Global Chief Financial Officer
|
Alexander W. Gourlay
|
56
|
Co-Chief Operating Officer
|
Ken Murphy
|
50
|
Executive Vice President, Chief Commercial Officer and President of Global Brands
|
Marco Pagni
|
54
|
Executive Vice President, Global Chief Administrative Officer and General Counsel
|
Kimberly R. Scardino
|
45
|
Senior Vice President, Global Controller and Chief Accounting Officer
|
Kathleen Wilson-Thompson
|
59
|
Executive Vice President and Global Chief Human Resources Officer
|
Quarter Ended
|
|||||||||||||||||||||
November
|
February
|
May
|
August
|
Fiscal Year
|
|||||||||||||||||
Fiscal 2016
|
High
|
$
|
95.74
|
$
|
87.05
|
$
|
86.84
|
$
|
85.09
|
$
|
95.74
|
||||||||||
|
Low |
78.90
|
71.50
|
75.74
|
77.22
|
71.50
|
|||||||||||||||
Fiscal 2015
|
High
|
$
|
69.37
|
$
|
83.77
|
$
|
93.42
|
$
|
97.30
|
$
|
97.30
|
||||||||||
Low |
58.39
|
66.46
|
81.01
|
76.01
|
58.39
|
Quarter Ended
|
2016
|
2015
|
||||||
November
|
$
|
0.3600
|
$
|
0.3375
|
||||
February
|
0.3600
|
0.3375
|
||||||
May
|
0.3600
|
0.3375
|
||||||
August
|
0.3750
|
0.3600
|
||||||
$
|
1.4550
|
$
|
1.3725
|
Issuer Purchases of Equity Securities
|
||||||||||||||||
Period
|
Total
Number of
Shares
Purchased
|
Average
Price Paid
per Share
|
Total Number of Shares
Purchased as Part of Publicly
Announced Repurchase
Programs (1)
|
Approximate Dollar Value of
Shares That May Yet be
Purchased Under the Plans or
Program (1)
|
||||||||||||
6/1/16 - 6/30/16
|
-
|
$
|
-
|
-
|
$
|
2,163,991,385
|
||||||||||
7/1/16 - 7/31/16
|
-
|
-
|
-
|
2,163,991,385
|
||||||||||||
8/1/16 - 8/31/16
|
-
|
-
|
-
|
2,163,991,385
|
||||||||||||
Total
|
-
|
$
|
-
|
-
|
$
|
2,163,991,385
|
(1) |
In August 2014, our Board of Directors approved the 2014 share repurchase program which authorized the purchase of up to $3.0 billion of our common stock prior to its expiration on August 31, 2016.
|
Fiscal Year
|
2016(5)
|
2015(5)
|
2014
|
2013
|
2012
|
|||||||||||||||
Sales
|
$
|
117,351
|
$
|
103,444
|
$
|
76,392
|
$
|
72,217
|
$
|
71,633
|
||||||||||
Cost of sales
|
87,477
|
76,691
|
54,823
|
51,098
|
51,291
|
|||||||||||||||
Gross Profit
|
29,874
|
26,753
|
21,569
|
21,119
|
20,342
|
|||||||||||||||
Selling, general and administrative expenses
|
23,910
|
22,400
|
17,992
|
17,543
|
16,878
|
|||||||||||||||
Gain on sale of business
|
-
|
-
|
-
|
20
|
-
|
|||||||||||||||
Equity earnings in AmerisourceBergen(1)
|
37
|
-
|
-
|
-
|
-
|
|||||||||||||||
Equity earnings in Alliance Boots(2)
|
-
|
315
|
617
|
496
|
-
|
|||||||||||||||
Operating Income
|
6,001
|
4,668
|
4,194
|
4,092
|
3,464
|
|||||||||||||||
Gain on previously held equity interest(3)
|
-
|
563
|
-
|
-
|
-
|
|||||||||||||||
Other income (expense)(4)
|
(261
|
)
|
685
|
(481
|
)
|
120
|
-
|
|||||||||||||
Earnings Before Interest and Income Tax Provision
|
5,740
|
5,916
|
3,713
|
4,212
|
3,464
|
|||||||||||||||
Interest expense, net
|
596
|
605
|
156
|
165
|
88
|
|||||||||||||||
Earnings Before Income Tax Provision
|
5,144
|
5,311
|
3,557
|
4,047
|
3,376
|
|||||||||||||||
Income tax provision
|
997
|
1,056
|
1,526
|
1,499
|
1,249
|
|||||||||||||||
Post tax earnings from other equity method investments
|
44
|
24
|
-
|
-
|
-
|
|||||||||||||||
Net Earnings
|
4,191
|
4,279
|
2,031
|
2,548
|
2,127
|
|||||||||||||||
Net earnings attributable to noncontrolling interests
|
18
|
59
|
99
|
-
|
-
|
|||||||||||||||
Net Earnings attributable to Walgreens Boots Alliance, Inc.
|
$
|
4,173
|
$
|
4,220
|
$
|
1,932
|
$
|
2,548
|
$
|
2,127
|
||||||||||
Per Common Share
|
||||||||||||||||||||
Net earnings
|
||||||||||||||||||||
Basic
|
$
|
3.85
|
$
|
4.05
|
$
|
2.03
|
$
|
2.69
|
$
|
2.43
|
||||||||||
Diluted
|
3.82
|
4.00
|
2.00
|
2.67
|
2.42
|
|||||||||||||||
Dividends declared
|
1.46
|
1.37
|
1.28
|
1.14
|
0.95
|
|||||||||||||||
Balance Sheet
|
||||||||||||||||||||
Total Assets
|
$
|
72,688
|
$
|
68,782
|
$
|
37,250
|
$
|
35,632
|
$
|
33,453
|
||||||||||
Long-term debt
|
18,705
|
13,315
|
3,716
|
4,451
|
4,066
|
|||||||||||||||
Total Walgreens Boots Alliance, Inc. Shareholders’ Equity
|
29,880
|
30,861
|
20,513
|
19,558
|
18,236
|
|||||||||||||||
Noncontrolling interests
|
401
|
439
|
104
|
-
|
-
|
|||||||||||||||
Total Equity
|
$
|
30,281
|
$
|
31,300
|
$
|
20,617
|
$
|
19,558
|
$
|
18,236
|
(1) |
Effective March 18, 2016, the Company accounts for its investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag.
|
(2) |
On August 2, 2012, the Company completed the acquisition of 45% of the issued and outstanding share capital of Alliance Boots GmbH in exchange for cash and Company shares. The Company accounted for this investment under the equity method until the completion of the Second Step Transaction on December 31, 2014. As a result, fiscal 2015 includes the results of Alliance Boots for eight months (January through August 2015) on a fully consolidated basis and four months (September through December 2014) as equity earnings in Alliance Boots reflecting Walgreens’ pre-merger 45% interest.
|
(3) |
In fiscal 2015, as a result of acquiring the remaining 55% interest in Alliance Boots, our previously held 45% interest was remeasured to fair value, resulting in a gain of $563 million.
|
(4) |
In fiscal 2016, 2015, 2014 and 2013, the Company recorded other income (expense) of $(517) million, $779 million, $385 million and $120 million, respectively, from fair value adjustments of the AmerisourceBergen warrants and the amortization of the deferred credit associated with the initial value of the warrants. Fiscal 2016 also includes income of $268 million related to the change in accounting method for our investment in AmerisourceBergen. Fiscal 2015 also includes a $94 million loss on derivative contracts that were not designated as accounting hedges. In fiscal 2014, the Company recognized a non-cash loss of $866 million related to the amendment and exercise of the Alliance Boots call option to acquire the remaining 55% share capital of Alliance Boots.
|
(5) |
To improve comparability, certain classification changes have been made to prior period cost of sales and selling, general and administrative expenses. This change has no impact on operating income.
|
(in millions, except per share amounts)
|
||||||||||||
2016
|
2015(1)
|
2014(1)
|
||||||||||
Sales
|
$
|
117,351
|
$
|
103,444
|
$
|
76,392
|
||||||
Gross Profit
|
29,874
|
26,753
|
21,569
|
|||||||||
Selling, general and administrative expenses
|
23,910
|
22,400
|
17,992
|
|||||||||
Operating Income
|
6,001
|
4,668
|
4,194
|
|||||||||
Adjusted Operating Income (Non-GAAP measure)(2)
|
7,208
|
6,157
|
4,866
|
|||||||||
Earnings Before Interest and Income Tax Provision
|
5,740
|
5,916
|
3,713
|
|||||||||
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
|
4,173
|
4,220
|
1,932
|
|||||||||
Adjusted Net Earnings Attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)(2)
|
5,009
|
4,085
|
3,170
|
|||||||||
Net earnings per common share – diluted
|
3.82
|
4.00
|
2.00
|
|||||||||
Adjusted net earnings per common share – diluted (Non-GAAP measure)(2)
|
4.59
|
3.88
|
3.28
|
Percentage Increases (Decreases)
|
||||||||||||
2016
|
2015
|
2014
|
||||||||||
Sales
|
13.4
|
35.4
|
5.8
|
|||||||||
Gross Profit
|
11.7
|
24.0
|
2.1
|
|||||||||
Selling, general and administrative expenses
|
6.7
|
24.5
|
2.6
|
|||||||||
Operating Income
|
28.6
|
11.3
|
2.5
|
|||||||||
Adjusted Operating Income (Non-GAAP measure)(2)
|
17.1
|
26.5
|
0.8
|
|||||||||
Earnings Before Interest and Income Tax Provision
|
(3.0
|
)
|
59.3
|
(11.8
|
)
|
|||||||
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
|
(1.1
|
)
|
118.4
|
(24.2
|
)
|
|||||||
Adjusted Net Earnings Attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)(2)
|
22.6
|
28.9
|
2.2
|
|||||||||
Net earnings per common share – diluted
|
(4.5
|
)
|
100.0
|
(25.1
|
)
|
|||||||
Adjusted net earnings per common share – diluted (Non-GAAP measure)(2)
|
18.3
|
18.3
|
0.9
|
Percent to Sales
|
||||||||||||
2016
|
2015
|
2014
|
||||||||||
Gross Margin
|
25.5
|
25.9
|
28.2
|
|||||||||
Selling, general and administrative expenses
|
20.4
|
21.7
|
23.6
|
(1) |
See “--Comparability” above.
|
(2) |
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with generally accepted accounting principles in the United States (“GAAP”).
|
(in millions, except location amounts)
|
||||||||||||
2016
|
2015
|
2014
|
||||||||||
Sales
|
$
|
83,802
|
$
|
80,974
|
$
|
76,392
|
||||||
Gross Profit
|
22,323
|
21,822
|
21,569
|
|||||||||
Selling, general and administrative expenses
|
17,918
|
18,247
|
17,992
|
|||||||||
Operating Income
|
4,405
|
3,890
|
4,194
|
|||||||||
Adjusted Operating Income (Non-GAAP measure)(1)
|
5,357
|
5,098
|
4,866
|
|||||||||
Number of Prescriptions(2)
|
740.1
|
723.2
|
698.9
|
|||||||||
30-Day Equivalent Prescriptions(2)(3)
|
928.5
|
893.8
|
856.4
|
|||||||||
Number of Locations at period end
|
8,184
|
8,182
|
8,309
|
Percentage Increases (Decreases)
|
||||||||||||
2016
|
2015
|
2014
|
||||||||||
Sales
|
3.5
|
6.0
|
5.8
|
|||||||||
Gross Profit
|
2.3
|
1.2
|
2.1
|
|||||||||
Selling, general and administrative expenses
|
(1.8
|
)
|
1.4
|
2.6
|
||||||||
Operating Income
|
13.2
|
(7.2
|
)
|
2.5
|
||||||||
Adjusted Operating Income (Non-GAAP measure)(1)
|
5.1
|
4.8
|
0.8
|
|||||||||
Comparable Store Sales(4)(5)
|
3.8
|
6.4
|
4.9
|
|||||||||
Pharmacy Sales
|
5.5
|
8.2
|
7.9
|
|||||||||
Comparable Pharmacy Sales(4)(5)
|
6.0
|
9.3
|
6.8
|
|||||||||
Retail Sales
|
(0.3
|
)
|
1.9
|
2.1
|
||||||||
Comparable Retail Sales(4)(5)
|
(0.3
|
)
|
1.5
|
2.0
|
||||||||
Comparable Number of Prescriptions(2)(4)(5)
|
2.3
|
3.5
|
1.8
|
|||||||||
Comparable 30-Day Equivalent Prescriptions(2)(3)(4)(5)
|
4.0
|
4.6
|
3.9
|
Percent to Sales
|
||||||||||||
2016
|
2015
|
2014
|
||||||||||
Gross Margin
|
26.6
|
26.9
|
28.2
|
|||||||||
Selling, general and administrative expenses
|
21.4
|
22.5
|
23.6
|
(1) |
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure and related disclosures.
|
(2) |
Includes immunizations.
|
(3) |
Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
|
(4) |
The fiscal year ended August 31, 2016 figures include an adjustment to remove February 29, 2016 results due to the leap year.
|
(5) |
Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or subject to a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. The method of calculating comparable sales varies across the retail industry. As a result, our method of calculating comparable sales may not be the same as other retailers’ methods.
|
(in millions, except location amounts)
|
||||||||||
2016
|
2015
|
2014
|
||||||||
Sales
|
$
|
13,256
|
$
|
8,657
|
NA
|
|||||
Gross Profit
|
5,432
|
3,452
|
NA
|
|||||||
Selling, general and administrative expenses
|
4,403
|
3,043
|
NA
|
|||||||
Operating Income
|
1,029
|
409
|
NA
|
|||||||
Adjusted Operating Income (Non-GAAP measure)(1)
|
1,155
|
616
|
NA
|
|||||||
Number of Locations at period end
|
4,673
|
4,582
|
NA
|
Percentage Increases
(Decreases)
|
||||||
2016
|
2015
|
|||||
Sales
|
53.1
|
NA
|
||||
Gross Profit
|
57.4
|
NA
|
||||
Selling, general and administrative expenses
|
44.7
|
NA
|
||||
Operating Income
|
151.6
|
NA
|
||||
Adjusted Operating Income (Non-GAAP measure)(1)
|
87.5
|
NA
|
||||
Comparable Store Sales(2)
|
|
NA
|
NA
|
|||
Comparable Store Sales in constant currency(2)(3)
|
|
NA
|
NA
|
|||
Pharmacy Sales
|
46.2
|
NA
|
||||
Comparable Pharmacy Sales(2)
|
|
NA
|
NA
|
|||
Comparable Pharmacy Sales in constant currency(2)(3)
|
|
NA
|
NA
|
|||
Retail Sales
|
57.1
|
NA
|
||||
Comparable Retail Sales(2)
|
NA
|
NA
|
||||
Comparable Retail Sales in constant currency(2)(3)
|
NA
|
NA
|
Percent to Sales
|
||||||||||
2016
|
2015
|
2014
|
||||||||
Gross Margin
|
41.0
|
39.9
|
NA
|
|||||||
Selling, general and administrative expenses
|
33.2
|
35.1
|
NA
|
NA |
Not Applicable
|
(1) |
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure and related disclosures.
|
(2) |
Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. The method of calculating comparable sales varies across the retail industry. As a result, our method of calculating comparable sales may not be the same as other retailers’ methods.
|
(3) |
Operating results reported in U.S. dollars are affected by foreign currency exchange rate fluctuations. We use the term “constant currency” to represent results that have been adjusted to exclude foreign currency impact. Foreign currency impact represents the difference in results that are attributable to fluctuations in the currency exchange rates used to convert the results for businesses where the functional currency is not the U.S. dollar. This impact is calculated by translating current period results at the currency exchange rates used in the comparable period in the prior year, rather than the exchange rates in effect during the current period. See “--Non-GAAP Measures” below.
|
(in millions)
|
||||||||||
2016
|
2015
|
2014
|
||||||||
Sales
|
$
|
22,571
|
$
|
15,327
|
NA
|
|||||
Gross Profit
|
2,131
|
1,486
|
NA
|
|||||||
Selling, general and administrative expenses
|
1,589
|
1,110
|
NA
|
|||||||
Operating Income
|
579
|
376
|
NA
|
|||||||
Adjusted Operating Income (Non-GAAP measure)(1)
|
708
|
450
|
NA
|
Percentage Increases
(Decreases)
|
||||||
2016
|
2015
|
|||||
Sales
|
47.3
|
NA
|
||||
Gross Profit
|
43.4
|
NA
|
||||
Selling, general and administrative expenses
|
43.2
|
NA
|
||||
Operating Income
|
54.0
|
NA
|
||||
Adjusted Operating Income (Non-GAAP measure)(1)
|
57.3
|
NA
|
||||
Comparable Sales(2)
|
NA
|
NA
|
||||
Comparable Sales in constant currency(2)(3)
|
NA
|
NA
|
Percent to Sales
|
||||||||||
2016
|
2015
|
2014
|
||||||||
Gross Margin
|
9.4
|
9.7
|
NA
|
|||||||
Selling, general and administrative expenses
|
7.0
|
7.2
|
NA
|
NA |
Not applicable
|
(1) |
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure and related disclosures.
|
(2) |
Comparable Sales are defined as sales excluding acquisitions and dispositions.
|
(3) |
Operating results reported in U.S. dollars are affected by foreign currency exchange rate fluctuations. We use the term “constant currency” to represent results that have been adjusted to exclude foreign currency impact. Foreign currency impact represents the difference in results that are attributable to fluctuations in the currency exchange rates used to convert the results for businesses where the functional currency is not the U.S. dollar. This impact is calculated by translating current period results at the currency exchange rates used in the comparable period in the prior year, rather than the exchange rates in effect during the current period. See “--Non-GAAP Measures” below.
|
(in millions)
|
||||||||||||||||||||
2016
|
||||||||||||||||||||
Retail
Pharmacy
USA
|
Retail
Pharmacy
International
|
Pharmaceutical
Wholesale
|
Eliminations
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||||||||
Operating Income (GAAP)
|
$
|
4,405
|
$
|
1,029
|
$
|
579
|
$
|
(12
|
)
|
$
|
6,001
|
|||||||||
Cost transformation
|
374
|
29
|
21
|
-
|
424
|
|||||||||||||||
Acquisition-related amortization
|
185
|
97
|
87
|
-
|
369
|
|||||||||||||||
LIFO provision
|
214
|
-
|
-
|
-
|
214
|
|||||||||||||||
Acquisition-related costs
|
102
|
-
|
-
|
-
|
102
|
|||||||||||||||
Legal settlement
|
47
|
-
|
-
|
-
|
47
|
|||||||||||||||
Asset impairment
|
30
|
-
|
-
|
-
|
30
|
|||||||||||||||
Adjustments to equity earnings in AmerisourceBergen
|
-
|
-
|
21
|
-
|
21
|
|||||||||||||||
Adjusted Operating Income (Non-GAAP measure)
|
$
|
5,357
|
$
|
1,155
|
$
|
708
|
$
|
(12
|
)
|
$
|
7,208
|
(in millions)
|
||||||||||||||||||||
2015
|
||||||||||||||||||||
Retail
Pharmacy
USA
|
Retail
Pharmacy
International
|
Pharmaceutical
Wholesale
|
Eliminations
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||||||||
Operating Income (GAAP)
|
$
|
3,890
|
$
|
409
|
$
|
376
|
$
|
(7
|
)
|
$
|
4,668
|
|||||||||
Cost transformation
|
523
|
19
|
-
|
-
|
542
|
|||||||||||||||
Acquisition-related amortization
|
230
|
188
|
67
|
-
|
485
|
|||||||||||||||
LIFO provision
|
285
|
-
|
-
|
-
|
285
|
|||||||||||||||
Acquisition-related costs
|
80
|
-
|
7
|
-
|
87
|
|||||||||||||||
Asset impairment
|
110
|
-
|
-
|
-
|
110
|
|||||||||||||||
Store closures and other optimization costs
|
56
|
-
|
-
|
-
|
56
|
|||||||||||||||
Loss on sale of business
|
17
|
-
|
-
|
-
|
17
|
|||||||||||||||
Adjustments to equity earnings in Alliance Boots
|
(93
|
)
|
-
|
-
|
-
|
(93
|
)
|
|||||||||||||
Adjusted Operating Income (Non-GAAP measure)
|
$
|
5,098
|
$
|
616
|
$
|
450
|
$
|
(7
|
)
|
$
|
6,157
|
(in millions)
|
||||||||||||||||||||
2014
|
||||||||||||||||||||
Retail
Pharmacy
USA
|
Retail
Pharmacy
International
|
Pharmaceutical
Wholesale
|
Eliminations
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||||||||
Operating Income (GAAP)
|
$
|
4,194
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
4,194
|
||||||||||
Acquisition-related amortization
|
282
|
-
|
-
|
-
|
282
|
|||||||||||||||
LIFO provision
|
132
|
-
|
-
|
-
|
132
|
|||||||||||||||
Acquisition-related costs
|
82
|
-
|
-
|
-
|
82
|
|||||||||||||||
Store closures and other optimization costs
|
271
|
-
|
-
|
-
|
271
|
|||||||||||||||
Gain on sale of business
|
(9
|
)
|
-
|
-
|
-
|
(9
|
)
|
|||||||||||||
Adjustments to equity earnings in Alliance Boots
|
(86
|
) |
-
|
-
|
-
|
(86
|
) | |||||||||||||
Adjusted Operating Income (Non-GAAP measure)
|
$
|
4,866
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
4,866
|
(in millions)
|
||||||||||||
2016
|
2015
|
2014
|
||||||||||
Net earnings attributable to Walgreens Boots Alliance, Inc. (GAAP)
|
$
|
4,173
|
$
|
4,220
|
$
|
1,932
|
||||||
Adjustments to Operating Income:
|
||||||||||||
Cost transformation(1)
|
424
|
542
|
-
|
|||||||||
Acquisition-related amortization(1)
|
369
|
485
|
282
|
|||||||||
LIFO provision(1)
|
214
|
285
|
132
|
|||||||||
Acquisition-related costs(1)
|
102
|
87
|
82
|
|||||||||
Legal settlement(1)
|
47
|
-
|
-
|
|||||||||
Asset impairment(1)
|
30
|
110
|
-
|
|||||||||
Adjustments to equity earnings in AmerisourceBergen(1)
|
21
|
-
|
-
|
|||||||||
Store closures and other optimization costs(1)
|
-
|
56
|
271
|
|||||||||
Loss (gain) on sale of business(1)
|
-
|
17
|
(9
|
)
|
||||||||
Adjustments to equity earnings in Alliance Boots(1)
|
-
|
(93
|
)
|
(86
|
)
|
|||||||
Total Adjustments to Operating Income
|
1,207
|
1,489
|
672
|
|||||||||
Adjustments to Other income (expense):
|
||||||||||||
Change in fair market value of AmerisourceBergen warrants(1)
|
517
|
(779
|
)
|
(385
|
)
|
|||||||
Net investment hedging (gain) loss(1)
|
12
|
111
|
-
|
|||||||||
Impact of change in accounting method for AmerisourceBergen equity investment(1)
|
(268
|
)
|
-
|
-
|
||||||||
Gain on previously held equity interest(1)
|
-
|
(563
|
)
|
-
|
||||||||
Alliance Boots call option loss(1)
|
-
|
-
|
866
|
|||||||||
Total Adjustments to Other income (expense)
|
261
|
(1,231
|
)
|
481
|
||||||||
Adjustments to Interest expense, net:
|
||||||||||||
Early debt extinguishment(1)
|
-
|
99
|
-
|
|||||||||
Prefunded interest expenses(1)
|
46
|
42
|
-
|
|||||||||
Total Adjustments to Interest expense, net
|
46
|
141
|
-
|
|||||||||
Adjustments to Income tax provision:
|
||||||||||||
Equity method non-cash tax(2)
|
10
|
71
|
180
|
|||||||||
United Kingdom tax rate change(2)
|
(178
|
)
|
-
|
-
|
||||||||
Release of capital loss valuation allowance(2)
|
-
|
(220
|
)
|
-
|
||||||||
Tax impact of adjustments(3)
|
(510
|
)
|
(385
|
)
|
(95
|
)
|
||||||
Total Adjustments to Income tax provision
|
(678
|
)
|
(534
|
)
|
85
|
|||||||
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)
|
$
|
5,009
|
$
|
4,085
|
$
|
3,170
|
2016(1)
|
2015(1)
|
2014(1)
|
||||||||||
Diluted net earnings per common share (GAAP)
|
$
|
3.82
|
$
|
4.00
|
$
|
2.00
|
||||||
Adjustments to Operating Income
|
1.11
|
1.41
|
0.69
|
|||||||||
Adjustments to Other income (expense)
|
0.24
|
(1.17
|
)
|
0.50
|
||||||||
Adjustments to Interest expense, net
|
0.04
|
0.14
|
-
|
|||||||||
Adjustments to Income tax provision
|
(0.62
|
)
|
(0.50
|
)
|
0.09
|
|||||||
Adjusted diluted net earnings per common share (Non-GAAP measure)
|
$
|
4.59
|
$
|
3.88
|
$
|
3.28
|
||||||
Weighted average common shares outstanding, diluted (in millions)
|
1,091.1
|
1,053.9
|
965.2
|
(1) |
Presented on a pre-tax basis. The comparable prior periods have been recast accordingly to reflect the tax impact of adjustments as a single adjustment. There has been no change in Net earnings attributable to Walgreens Boots Alliance, Inc., diluted net earnings per share, adjusted net earnings attributable to Walgreens Boots Alliance, Inc. or adjusted net earnings per share from those previously reported.
|
(2) |
Discrete tax-only items.
|
(3) |
Represents the adjustment to the GAAP basis tax provision commensurate with non-GAAP adjustments.
|
2016
|
2015
|
2014
|
||||||||||
Retail Pharmacy USA
|
$
|
777
|
$
|
951
|
$
|
1,106
|
||||||
Retail Pharmacy International(1)
|
444
|
249
|
-
|
|||||||||
Pharmaceutical Wholesale(1)
|
104
|
51
|
-
|
|||||||||
Total
|
$
|
1,325
|
$
|
1,251
|
$
|
1,106
|
(1) |
Our Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which we acquired the 55% of Alliance Boots that we did not already own on December 31, 2014. As a result of the timing of the acquisition, only eight months of capital expenditures (January through August 2015) have been reported for these divisions in fiscal 2015.
|
Rating Agency
|
Long-Term Debt Rating
|
Commercial
Paper Rating
|
Outlook
|
Fitch
|
BBB
|
F2
|
Stable
|
Moody’s
|
Baa2
|
P-2
|
On review for downgrade
|
Standard & Poor’s
|
BBB
|
A-2
|
Negative
|
Payments Due by Period
|
||||||||||||||||||||
Total
|
Less Than
1 Year
|
1-3 Years
|
3-5 Years
|
Over 5
Years
|
||||||||||||||||
Operating leases(1)
|
$
|
34,089
|
$
|
3,066
|
$
|
5,798
|
$
|
5,035
|
$
|
20,190
|
||||||||||
Purchase obligations(2):
|
3,108
|
2,922
|
176
|
10
|
-
|
|||||||||||||||
Open inventory purchase orders
|
2,077
|
2,077
|
-
|
-
|
-
|
|||||||||||||||
Real estate development
|
401
|
351
|
50
|
-
|
-
|
|||||||||||||||
Other corporate obligations
|
630
|
494
|
126
|
10
|
-
|
|||||||||||||||
Short-term borrowings and long-term debt*(3)
|
19,150
|
323
|
2,553
|
4,832
|
11,442
|
|||||||||||||||
Interest payment on short term borrowings and long-term debt(3)
|
6,723
|
590
|
1,121
|
1,049
|
3,963
|
|||||||||||||||
Insurance*
|
612
|
201
|
168
|
67
|
176
|
|||||||||||||||
Retirement benefit obligations
|
1,180
|
73
|
127
|
103
|
877
|
|||||||||||||||
Closed location obligations*
|
467
|
81
|
95
|
68
|
223
|
|||||||||||||||
Capital lease obligations*(1)
|
1,270
|
68
|
122
|
114
|
966
|
|||||||||||||||
Finance lease obligations
|
1,357
|
18
|
35
|
35
|
1,269
|
|||||||||||||||
Other liabilities reflected on the balance sheet*(4)
|
1,121
|
147
|
292
|
193
|
489
|
|||||||||||||||
Total
|
$
|
69,077
|
$
|
7,489
|
$
|
10,487
|
$
|
11,506
|
$
|
39,595
|
* |
Recorded on balance sheet.
|
(1) |
Amounts for operating leases and capital leases do not include certain operating expenses under these leases such as common area maintenance, insurance and real estate taxes. These expenses were $460 million for the fiscal year ended August 31, 2016.
|
(2) |
Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including open purchase orders.
|
(3) |
In addition, in the event that the merger contemplated by the Merger Agreement with Rite Aid is not consummated on or prior to June 1, 2017 or if the Merger Agreement is terminated at any time on or prior to June 1, 2017, then Walgreens Boots Alliance will be required to redeem the certain series of notes issued on June 1, 2016 on the date described in the applicable note at a redemption price equal to 101% of the aggregate principal amount of the notes to be redeemed, plus accrued and unpaid interest from and including the date of initial issuance, or the most recent date to which interest has been paid, whichever is later, to, but excluding, the date of redemption. In addition, pursuant to the Merger Agreement, if the Merger Agreement is terminated by us or Rite Aid (i) due to the entry of a final order enjoining or prohibiting the merger by any antitrust authority, or (ii) following January 27, 2017 because required antitrust approvals have not been obtained or an antitrust authority has issued an injunction or order preventing the merger, we could be required to pay Rite Aid a termination fee of up to $650 million in certain circumstances. See “Liquidity and Capital Resources” above.
|
(4)
|
Includes $302 million ($59 million in less than 1 year, $168 million in 1-3 years, $75 million in 3-5 years and none over 5 years) of unrecognized tax benefits recorded under Accounting Standards Codification Topic 740, Income Taxes.
|
2016
|
2015
|
|||||||
Assets
|
||||||||
Current Assets:
|
||||||||
Cash and cash equivalents
|
$
|
9,807
|
$
|
3,000
|
||||
Accounts receivable, net
|
6,260
|
6,849
|
||||||
Inventories
|
8,956
|
8,678
|
||||||
Other current assets
|
860
|
1,130
|
||||||
Total Current Assets
|
25,883
|
19,657
|
||||||
Non-Current Assets:
|
||||||||
Property, plant and equipment, at cost, less accumulated depreciation and amortization
|
14,335
|
15,068
|
||||||
Goodwill
|
15,527
|
16,372
|
||||||
Intangible assets, net
|
10,302
|
12,351
|
||||||
Equity method investments
|
6,174
|
1,242
|
||||||
Other non-current assets
|
467
|
4,092
|
||||||
Total Non-Current Assets
|
46,805
|
49,125
|
||||||
Total Assets
|
$
|
72,688
|
$
|
68,782
|
||||
Liabilities and Equity
|
||||||||
Current Liabilities:
|
||||||||
Short-term borrowings
|
$
|
323
|
$
|
1,068
|
||||
Trade accounts payable (see Note 19)
|
11,000
|
10,088
|
||||||
Accrued expenses and other liabilities
|
5,484
|
5,225
|
||||||
Income taxes
|
206
|
176
|
||||||
Total Current Liabilities
|
17,013
|
16,557
|
||||||
Non-Current Liabilities:
|
||||||||
Long-term debt
|
18,705
|
13,315
|
||||||
Deferred income taxes
|
2,644
|
3,538
|
||||||
Other non-current liabilities
|
4,045
|
4,072
|
||||||
Total Non-Current Liabilities
|
25,394
|
20,925
|
||||||
Commitments and Contingencies (see Note 12)
|
||||||||
Equity:
|
||||||||
Preferred stock $.01 par value; authorized 32 million shares, none issued
|
-
|
-
|
||||||
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at August 31, 2016 and 2015
|
12
|
12
|
||||||
Paid-in capital
|
10,111
|
9,953
|
||||||
Employee stock loan receivable
|
(1
|
)
|
(2
|
)
|
||||
Retained earnings
|
27,684
|
25,089
|
||||||
Accumulated other comprehensive (loss) income
|
(2,992
|
)
|
(214
|
)
|
||||
Treasury stock, at cost; 89,527,027 shares at August 31, 2016 and 82,603,274 at August 31, 2015
|
(4,934
|
)
|
(3,977
|
)
|
||||
Total Walgreens Boots Alliance, Inc. Shareholders’ Equity
|
29,880
|
30,861
|
||||||
Noncontrolling interests
|
401
|
439
|
||||||
Total Equity
|
30,281
|
31,300
|
||||||
Total Liabilities and Equity
|
$
|
72,688
|
$
|
68,782
|
Equity attributable to Walgreens Boots Alliance, Inc.
|
||||||||||||||||||||||||||||||||||||
Common Stock
Shares
|
Common
Stock
Amount
|
Treasury
Stock
Amount
|
Paid-In
Capital
|
Employee
Stock
Loan
Receivable
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Retained
Earnings
|
Noncontrolling
Interests
|
Total
Equity
|
||||||||||||||||||||||||||||
August 31, 2013
|
946,595,578
|
$
|
80
|
$
|
(3,114
|
)
|
$
|
1,074
|
$
|
(11
|
)
|
$
|
(92
|
)
|
$
|
21,621
|
$
|
-
|
$
|
19,558
|
||||||||||||||||
Net earnings
|
-
|
-
|
-
|
-
|
-
|
-
|
1,932
|
99
|
2,031
|
|||||||||||||||||||||||||||
Other comprehensive income, net of tax
|
-
|
-
|
-
|
-
|
-
|
228
|
-
|
-
|
228
|
|||||||||||||||||||||||||||
Dividends declared ($1.28 per share)
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,226
|
)
|
-
|
(1,226
|
)
|
|||||||||||||||||||||||||
Treasury stock purchases
|
(11,810,351
|
)
|
-
|
(705
|
)
|
-
|
-
|
-
|
-
|
-
|
(705
|
)
|
||||||||||||||||||||||||
Employee stock purchase and option plans
|
15,601,662
|
-
|
622
|
(16
|
)
|
-
|
-
|
-
|
-
|
606
|
||||||||||||||||||||||||||
Stock-based compensation
|
-
|
-
|
-
|
114
|
-
|
-
|
-
|
-
|
114
|
|||||||||||||||||||||||||||
Employee stock loan receivable
|
-
|
-
|
-
|
-
|
6
|
-
|
-
|
-
|
6
|
|||||||||||||||||||||||||||
Other
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
5
|
5
|
|||||||||||||||||||||||||||
August 31, 2014
|
950,386,889
|
$
|
80
|
$
|
(3,197
|
)
|
$
|
1,172
|
$
|
(5
|
)
|
$
|
136
|
$
|
22,327
|
$
|
104
|
$
|
20,617
|
|||||||||||||||||
Net earnings
|
-
|
-
|
-
|
-
|
-
|
-
|
4,220
|
59
|
4,279
|
|||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax
|
-
|
-
|
-
|
-
|
-
|
(350
|
)
|
-
|
(6
|
)
|
(356
|
)
|
||||||||||||||||||||||||
Dividends declared ($1.37 per share)
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,458
|
)
|
-
|
(1,458
|
)
|
|||||||||||||||||||||||||
Exchange of Walgreen Co. shares for Walgreens Boots Alliance, Inc. shares
|
-
|
(69
|
)
|
-
|
69
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||||
Issuance of shares for Alliance Boots acquisition
|
144,333,468
|
1
|
-
|
10,976
|
-
|
-
|
-
|
-
|
10,977
|
|||||||||||||||||||||||||||
Treasury stock purchases
|
(16,250,190
|
)
|
-
|
(1,226
|
)
|
-
|
-
|
-
|
-
|
-
|
(1,226
|
)
|
||||||||||||||||||||||||
Employee stock purchase and option plans
|
11,440,177
|
-
|
446
|
56
|
-
|
-
|
-
|
-
|
502
|
|||||||||||||||||||||||||||
Stock-based compensation
|
-
|
-
|
-
|
109
|
-
|
-
|
-
|
-
|
109
|
|||||||||||||||||||||||||||
Acquisition of noncontrolling interest
|
-
|
-
|
-
|
(2,429
|
)
|
-
|
-
|
-
|
(130
|
)
|
(2,559
|
)
|
||||||||||||||||||||||||
Employee stock loan receivable
|
-
|
-
|
-
|
-
|
3
|
-
|
-
|
-
|
3
|
|||||||||||||||||||||||||||
Noncontrolling interests in businesses acquired
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
412
|
412
|
|||||||||||||||||||||||||||
August 31, 2015
|
1,089,910,344
|
$
|
12
|
$
|
(3,977
|
)
|
$
|
9,953
|
$
|
(2
|
)
|
$
|
(214
|
)
|
$
|
25,089
|
$
|
439
|
$
|
31,300
|
||||||||||||||||
Net earnings
|
-
|
-
|
-
|
-
|
-
|
-
|
4,173
|
18
|
4,191
|
|||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax
|
-
|
-
|
-
|
-
|
-
|
(2,778
|
)
|
-
|
(56
|
)
|
(2,834
|
)
|
||||||||||||||||||||||||
Dividends declared ($1.46 per share)
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,578
|
)
|
-
|
(1,578
|
)
|
|||||||||||||||||||||||||
Treasury stock purchases
|
(13,815,558
|
)
|
-
|
(1,152
|
)
|
-
|
-
|
-
|
-
|
-
|
(1,152
|
)
|
||||||||||||||||||||||||
Employee stock purchase and option plans
|
6,891,805
|
-
|
195
|
43
|
-
|
-
|
-
|
-
|
238
|
|||||||||||||||||||||||||||
Stock-based compensation
|
-
|
-
|
-
|
115
|
-
|
-
|
-
|
-
|
115
|
|||||||||||||||||||||||||||
Employee stock loan receivable
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
-
|
1
|
|||||||||||||||||||||||||||
August 31, 2016
|
1,082,986,591
|
$
|
12
|
$
|
(4,934
|
)
|
$
|
10,111
|
$
|
(1
|
)
|
$
|
(2,992
|
)
|
$
|
27,684
|
$
|
401
|
$
|
30,281
|
2016
|
2015
|
2014
|
||||||||||
Sales
|
$
|
117,351
|
$
|
103,444
|
$
|
76,392
|
||||||
Cost of sales
|
87,477
|
76,691
|
54,823
|
|||||||||
Gross Profit
|
29,874
|
26,753
|
21,569
|
|||||||||
Selling, general and administrative expenses
|
23,910
|
22,400
|
17,992
|
|||||||||
Equity earnings in AmerisourceBergen
|
37
|
-
|
-
|
|||||||||
Equity earnings in Alliance Boots
|
-
|
315
|
617
|
|||||||||
Operating Income
|
6,001
|
4,668
|
4,194
|
|||||||||
Gain on previously held equity interest
|
-
|
563
|
-
|
|||||||||
Other income (expense)
|
(261
|
)
|
685
|
(481
|
)
|
|||||||
Earnings Before Interest and Income Tax Provision
|
5,740
|
5,916
|
3,713
|
|||||||||
Interest expense, net
|
596
|
605
|
156
|
|||||||||
Earnings Before Income Tax Provision
|
5,144
|
5,311
|
3,557
|
|||||||||
Income tax provision
|
997
|
1,056
|
1,526
|
|||||||||
Post tax earnings from other equity method investments
|
44
|
24
|
-
|
|||||||||
Net Earnings
|
4,191
|
4,279
|
2,031
|
|||||||||
Net earnings attributable to noncontrolling interests
|
18
|
59
|
99
|
|||||||||
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
|
$
|
4,173
|
$
|
4,220
|
$
|
1,932
|
||||||
Net earnings per common share:
|
||||||||||||
Basic
|
$
|
3.85
|
$
|
4.05
|
$
|
2.03
|
||||||
Diluted
|
$
|
3.82
|
$
|
4.00
|
$
|
2.00
|
||||||
Weighted average common shares outstanding:
|
||||||||||||
Basic
|
1,083.1
|
1,043.2
|
953.1
|
|||||||||
Diluted
|
1,091.1
|
1,053.9
|
965.2
|
2016
|
2015
|
2014
|
||||||||||
Net Earnings
|
$
|
4,191
|
$
|
4,279
|
$
|
2,031
|
||||||
Other comprehensive income (loss), net of tax:
|
||||||||||||
Pension/postretirement obligations
|
(241
|
)
|
14
|
(48
|
)
|
|||||||
Unrealized gain (loss) on cash flow hedges
|
3
|
(13
|
)
|
(27
|
)
|
|||||||
Unrecognized gain (loss) on available-for-sale investments
|
(257
|
)
|
152
|
106
|
||||||||
Share of other comprehensive income (loss) of equity method investments
|
(1
|
)
|
113
|
(18
|
)
|
|||||||
Currency translation adjustments
|
(2,338
|
)
|
(622
|
)
|
215
|
|||||||
Total Other Comprehensive Income (Loss)
|
(2,834
|
)
|
(356
|
)
|
228
|
|||||||
Total Comprehensive Income
|
1,357
|
3,923
|
2,259
|
|||||||||
Comprehensive income (loss) attributable to noncontrolling interests
|
(39
|
)
|
53
|
99
|
||||||||
Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.
|
$
|
1,396
|
$
|
3,870
|
$
|
2,160
|
2016
|
2015
|
2014
|
||||||||||
Cash Flows from Operating Activities:
|
||||||||||||
Net earnings
|
$
|
4,191
|
$
|
4,279
|
$
|
2,031
|
||||||
Adjustments to reconcile net earnings to net cash provided by operating activities:
|
||||||||||||
Depreciation and amortization
|
1,718
|
1,742
|
1,316
|
|||||||||
Change in fair value of warrants and related amortization
|
516
|
(779
|
)
|
(385
|
)
|
|||||||
Loss on exercise of call option
|
-
|
-
|
866
|
|||||||||
Gain on previously held equity interest
|
-
|
(563
|
)
|
-
|
||||||||
Deferred income taxes
|
(442
|
)
|
(32
|
)
|
177
|
|||||||
Stock compensation expense
|
115
|
109
|
114
|
|||||||||
Equity earnings from equity method investments
|
(81
|
)
|
(339
|
)
|
(619
|
)
|
||||||
Other
|
148
|
752
|
183
|
|||||||||
Changes in operating assets and liabilities:
|
||||||||||||
Accounts receivable, net
|
115
|
(338
|
)
|
(616
|
)
|
|||||||
Inventories
|
(644
|
)
|
719
|
860
|
||||||||
Other current assets
|
66
|
22
|
(10
|
)
|
||||||||
Trade accounts payable
|
1,572
|
268
|
(339
|
)
|
||||||||
Accrued expenses and other liabilities
|
313
|
170
|
195
|
|||||||||
Income taxes
|
202
|
(335
|
)
|
17
|
||||||||
Other non-current assets and liabilities
|
58
|
(11
|
)
|
103
|
||||||||
Net cash provided by operating activities
|
7,847
|
5,664
|
3,893
|
|||||||||
Cash Flows from Investing Activities:
|
||||||||||||
Additions to property, plant and equipment
|
(1,325
|
)
|
(1,251
|
)
|
(1,106
|
)
|
||||||
Proceeds from sale leaseback transactions
|
60
|
867
|
67
|
|||||||||
Proceeds related to the sale of businesses
|
74
|
814
|
93
|
|||||||||
Proceeds from sale of other assets
|
155
|
184
|
139
|
|||||||||
Alliance Boots acquisition, net of cash acquired
|
-
|
(4,461
|
)
|
-
|
||||||||
Other business and intangible asset acquisitions, net of cash acquired
|
(126
|
)
|
(371
|
)
|
(344
|
)
|
||||||
Investment in AmerisourceBergen
|
(2,360
|
)
|
-
|
(493
|
)
|
|||||||
Other
|
5
|
(58
|
)
|
(87
|
)
|
|||||||
Net cash used for investing activities
|
(3,517
|
)
|
(4,276
|
)
|
(1,731
|
)
|
||||||
Cash Flows from Financing Activities:
|
||||||||||||
Proceeds and payments of short-term borrowings, net
|
29
|
(226
|
)
|
-
|
||||||||
Proceeds from issuance of long-term debt
|
5,991
|
12,285
|
-
|
|||||||||
Payments of long-term debt
|
(791
|
)
|
(10,472
|
)
|
(550
|
)
|
||||||
Proceeds from finance leases
|
-
|
-
|
268
|
|||||||||
Stock purchases
|
(1,152
|
)
|
(1,226
|
)
|
(705
|
)
|
||||||
Proceeds related to employee stock plans
|
235
|
503
|
612
|
|||||||||
Cash dividends paid
|
(1,563
|
)
|
(1,384
|
)
|
(1,199
|
)
|
||||||
Other
|
(143
|
)
|
(395
|
)
|
(48
|
)
|
||||||
Net cash provided by (used for) financing activities
|
2,606
|
(915
|
)
|
(1,622
|
)
|
|||||||
Effect of exchange rate changes on cash and cash equivalents
|
(129
|
)
|
(119
|
)
|
-
|
|||||||
Changes in Cash and Cash Equivalents:
|
||||||||||||
Net increase in cash and cash equivalents
|
6,807
|
354
|
540
|
|||||||||
Cash and cash equivalents at beginning of period
|
3,000
|
2,646
|
2,106
|
|||||||||
Cash and cash equivalents at end of period
|
$
|
9,807
|
$
|
3,000
|
$
|
2,646
|
2016
|
2015
|
|||||||
Land and land improvements
|
$
|
3,738
|
$
|
3,687
|
||||
Buildings and building improvements
|
7,557
|
7,705
|
||||||
Fixtures and equipment
|
9,064
|
8,904
|
||||||
Capitalized system development costs and software
|
1,787
|
1,491
|
||||||
Capital lease properties
|
789
|
821
|
||||||
22,935
|
22,608
|
|||||||
Less: accumulated depreciation and amortization
|
8,600
|
7,540
|
||||||
Balance at end of year
|
$
|
14,335
|
$
|
15,068
|
· |
Changes in the fair value of a derivative designated as a fair value hedge, along with the gain or loss on the hedged asset or liability attributable to the hedged risk, are recorded in the Consolidated Statements of Earnings.
|
· |
The effective portion of changes in the fair value of a derivative designated as a cash flow hedge is recorded in accumulated other comprehensive income (loss) in the Consolidated Statements of Comprehensive Income and reclassified into earnings in the period or periods during which the hedged item affects earnings.
|
· |
The effective portion of changes in the fair value of a derivative designated as a hedge of a net investment in a foreign operation is recorded in cumulative translation adjustments within accumulated other comprehensive income (loss) in the Consolidated Statements of Comprehensive Income. Recognition in earnings of amounts previously recorded in cumulative translation adjustments is limited to circumstances such as complete or substantially complete liquidation of the net investment in the hedged investments in foreign operations.
|
· |
Changes in the fair value of a derivative not designated in a hedging relationship are recognized in the Consolidated Statements of Earnings along with the ineffective portions of changes in the fair value of derivatives designated in hedging relationships.
|
Retail Pharmacy
|
||||||||||||||||
Fiscal 2016
|
USA
|
International
|
Pharmaceutical Wholesale
|
Consolidated
|
||||||||||||
Asset impairments
|
215
|
10
|
-
|
225
|
||||||||||||
Real estate costs
|
89
|
1
|
1
|
91
|
||||||||||||
Severance and other business transition and exit costs
|
70
|
18
|
20
|
108
|
||||||||||||
Total restructuring costs
|
$
|
374
|
$
|
29
|
$
|
21
|
$
|
424
|
||||||||
Fiscal 2015
|
||||||||||||||||
Asset impairments
|
216
|
7
|
-
|
223
|
||||||||||||
Real estate costs
|
219
|
-
|
-
|
219
|
||||||||||||
Severance and other business transition and exit costs
|
105
|
12
|
-
|
117
|
||||||||||||
Total restructuring costs
|
$
|
540
|
$
|
19
|
$
|
-
|
$
|
559
|
||||||||
Fiscal 2014
|
||||||||||||||||
Asset impairments
|
137
|
-
|
-
|
137
|
||||||||||||
Real estate costs
|
71
|
-
|
-
|
71
|
||||||||||||
Severance and other business transition and exit costs
|
1
|
-
|
-
|
1
|
||||||||||||
Total restructuring costs
|
$
|
209
|
$
|
-
|
$
|
-
|
$
|
209
|
Financing
Obligation
|
Capital
Lease
|
Operating
Lease
|
||||||||||
2017
|
$
|
18
|
$
|
68
|
$
|
3,066
|
||||||
2018
|
18
|
62
|
2,972
|
|||||||||
2019
|
18
|
59
|
2,826
|
|||||||||
2020
|
18
|
58
|
2,632
|
|||||||||
2021
|
18
|
57
|
2,403
|
|||||||||
Later
|
1,267
|
966
|
20,190
|
|||||||||
Total Minimum Lease Payments
|
$
|
1,357
|
$
|
1,270
|
$
|
34,089
|
2016
|
2015
|
|||||||
Balance at beginning of period
|
$
|
446
|
$
|
257
|
||||
Provision for present value of non-cancellable lease payments on closed facilities
|
134
|
231
|
||||||
Assumptions about future sublease income, terminations and changes in interest rates
|
(34
|
)
|
(6
|
)
|
||||
Interest accretion
|
27
|
27
|
||||||
Liability assumed through acquisition of Alliance Boots
|
-
|
13
|
||||||
Cash payments, net of sublease income
|
(107
|
)
|
(76
|
)
|
||||
Balance at end of period
|
$
|
466
|
$
|
446
|
2016
|
2015
|
2014
|
||||||||||
Minimum rentals
|
$
|
3,355
|
$
|
3,176
|
$
|
2,687
|
||||||
Contingent rentals
|
60
|
38
|
5
|
|||||||||
Less: Sublease rental income
|
(49
|
)
|
(46
|
)
|
(22
|
)
|
||||||
$
|
3,366
|
$
|
3,168
|
$
|
2,670
|
2016
|
2015
|
|||||||||||||||
Carrying
Value
|
Ownership
Percentage
|
Carrying
Value
|
Ownership
Percentage
|
|||||||||||||
AmerisourceBergen
|
$
|
4,964
|
24
|
%
|
$
|
NA |
NA
|
|||||||||
Others
|
1,210
|
12% - 50
|
%
|
1,242
|
12% - 50
|
%
|
||||||||||
Total
|
$
|
6,174
|
$
|
1,242
|
Statements of Earnings (in millions)
|
||||||||||
Year Ended August 31,
|
||||||||||
2016
|
2015(1)
|
2014(l)
|
||||||||
Net sales
|
NA
|
$
|
13.071
|
$
|
37.579
|
|||||
Gross Profit
|
NA
|
3.050
|
8.096
|
|||||||
Net Earnings
|
NA
|
723
|
1.444
|
|||||||
Share of earnings from equity method investments(1)
|
NA
|
315
|
617
|
(l)
|
Earnings in foreign equity method investments are translated at their respective average exchange rates.
|
August 31, 2016
|
||||||||||||||||
Amortized
cost basis
|
Gross
unrealized
gains
|
Gross
unrealized
(losses)
|
Fair value
|
|||||||||||||
Corporate bonds and Treasury Bills
|
$
|
30
|
$
|
2
|
$
|
-
|
$
|
32
|
August 31, 2015
|
||||||||||||||||
Amortized
cost basis
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
(losses)
|
Fair value
|
|||||||||||
AmerisourceBergen common stock
|
$
|
717
|
$
|
430
|
$
|
-
|
$
|
1,147
|
||||||||
Corporate bonds and Treasury Bills
|
37
|
-
|
(1
|
)
|
36
|
|||||||||||
Total available-for-sale investments
|
$
|
754
|
$
|
430
|
$
|
(1
|
)
|
$
|
1,183
|
Amount
|
||||
Consideration attributed to WBAD
|
$
|
2,559
|
||
Less: Carrying value of the Company’s pre-existing noncontrolling interest
|
130
|
|||
Impact to additional paid in capital
|
$
|
2,429
|
Consideration paid
|
||||
Cash
|
$
|
4,874
|
||
Common stock
|
10,977
|
|||
Total consideration transferred
|
15,851
|
|||
Less: consideration attributed to WBAD
|
(2,559
|
)
|
||
13,292
|
||||
Fair value of the investment in Alliance Boots held before the Second Step Transaction
|
8,149
|
|||
Total consideration
|
$
|
21,441
|
Identifiable assets acquired and liabilities assumed including noncontrolling interests
|
||||
Cash and cash equivalents
|
$
|
413
|
||
Accounts receivable
|
3,799
|
|||
Inventories
|
3,713
|
|||
Other current assets
|
894
|
|||
Property, plant and equipment
|
3,806
|
|||
Intangible assets
|
11,691
|
|||
Other non-current assets
|
2,217
|
|||
Trade accounts payable, accrued expenses and other liabilities
|
(7,696
|
)
|
||
Borrowings
|
(9,010
|
)
|
||
Deferred income taxes
|
(2,452
|
)
|
||
Other non-current liabilities
|
(383
|
)
|
||
Noncontrolling interests
|
(412
|
)
|
||
Total identifiable net assets and noncontrolling interests
|
6,580
|
|||
Goodwill
|
$
|
14,861
|
Definite-Lived Intangible Assets
|
Weighted-Average Useful
Life (in years)
|
Amount (in millions)
|
||||||
Customer relationships
|
12
|
$
|
1,311
|
|||||
Loyalty card holders
|
20
|
742
|
||||||
Trade names and trademarks
|
9
|
399
|
||||||
Favorable lease interests
|
7
|
93
|
||||||
Total
|
$
|
2,545
|
Indefinite-Lived Intangible Assets
|
Amount (in millions)
|
|||
Trade names and trademarks
|
$
|
6,657
|
||
Pharmacy licenses
|
2,489
|
|||
Total
|
$
|
9,146
|
Year Ended
August 31,
2015
|
Year Ended
August 31,
2014
|
|||||||
(in millions, except per share amounts)
|
||||||||
Sales
|
$
|
116,491
|
$
|
113,896
|
||||
Net earnings
|
4,278
|
3,884
|
||||||
Net earnings per common share:
|
||||||||
Basic
|
$
|
4.10
|
$
|
3.54
|
||||
Diluted
|
4.06
|
3.50
|
Year Ended
August 31, |
||||
(in millions, except per share amounts)
|
||||
Sales
|
$
|
22,470
|
||
Net earnings
|
853
|
|||
Net earnings per common share:
|
||||
Basic
|
$
|
0.82
|
||
Diluted
|
0.81
|
Retail Pharmacy
USA
|
Retail Pharmacy
International
|
Pharmaceutical
Wholesale
|
Walgreens
Boots
Alliance, Inc.
|
|||||||||||||
August 31, 2014
|
$
|
2,359
|
$
|
-
|
$
|
-
|
$
|
2,359
|
||||||||
Acquisitions
|
7,290
|
4,036
|
3,646
|
14,972
|
||||||||||||
Sale of business(1)
|
(706
|
)
|
-
|
-
|
(706
|
)
|
||||||||||
Other(2)
|
(3
|
)
|
-
|
-
|
(3
|
)
|
||||||||||
Currency translation adjustments
|
-
|
(138
|
)
|
(112
|
)
|
(250
|
)
|
|||||||||
August 31, 2015
|
$
|
8,940
|
$
|
3,898
|
$
|
3,534
|
$
|
16,372
|
||||||||
Acquisitions
|
-
|
23
|
-
|
23
|
||||||||||||
Sale of business
|
(4
|
)
|
-
|
-
|
(4
|
)
|
||||||||||
Other(2)
|
100
|
(113
|
)
|
13
|
-
|
|||||||||||
Currency translation adjustments
|
-
|
(439
|
)
|
(425
|
)
|
(864
|
)
|
|||||||||
August 31, 2016
|
$
|
9,036
|
$
|
3,369
|
$
|
3,122
|
$
|
15,527
|
(1) |
Represents goodwill associated with Walgreens Infusion Services business which was sold in April 2015.
|
(2) |
Other primarily represents the reallocation of goodwill between reporting units and purchase accounting adjustments for prior year acquisitions.
|
August 31, 2016
|
August 31, 2015
|
|||||||
Gross Amortizable Intangible Assets
|
||||||||
Customer relationships and loyalty card holders
|
$
|
1,867
|
$
|
2,139
|
||||
Purchased prescription files
|
932
|
885
|
||||||
Favorable lease interests and non-compete agreements
|
619
|
594
|
||||||
Trade names and trademarks
|
532
|
675
|
||||||
Purchasing and payer contracts
|
94
|
94
|
||||||
Total gross amortizable intangible assets
|
4,044
|
4,387
|
||||||
Accumulated amortization
|
||||||||
Customer relationships and loyalty card holders
|
$
|
275
|
$
|
173
|
||||
Purchased prescription files
|
600
|
470
|
||||||
Favorable lease interests and non-compete agreements
|
388
|
299
|
||||||
Trade names and trademarks
|
105
|
83
|
||||||
Purchasing and payer contracts
|
71
|
65
|
||||||
Total accumulated amortization
|
1,439
|
1,090
|
||||||
Total amortizable intangible assets, net
|
$
|
2,605
|
$
|
3,297
|
||||
Indefinite-Lived Intangible Assets
|
||||||||
Trade names and trademarks
|
$
|
5,604
|
$
|
6,590
|
||||
Pharmacy licenses
|
2,093
|
2,464
|
||||||
Total Indefinite-Lived intangible assets
|
$
|
7,697
|
$
|
9,054
|
||||
Total intangible assets, net
|
$
|
10,302
|
$
|
12,351
|
2017
|
2018
|
2019
|
2020
|
2021
|
||||||||||||||||
Estimated annual amortization expense
|
$
|
357
|
$
|
319
|
$
|
293
|
$
|
243
|
$
|
199
|
August 31, 2016
|
August 31, 2015
|
|||||||
Short-Term Borrowings(1)
|
||||||||
Unsecured Pound Sterling variable rate term loan due 2019
|
$
|
63
|
$
|
-
|
||||
Unsecured variable rate notes due 2016
|
-
|
747
|
||||||
Other(2)
|
260
|
321
|
||||||
Total short-term borrowings
|
$
|
323
|
$
|
1,068
|
||||
Long-Term Debt(1)
|
||||||||
Unsecured Pound Sterling variable rate term loan due 2019
|
$
|
1,833
|
$
|
2,229
|
||||
$6 Billion Note Issuance(7)(9)
|
||||||||
1.750% unsecured notes due 2018
|
1,246
|
-
|
||||||
2.600% unsecured notes due 2021
|
1,493
|
-
|
||||||
3.100% unsecured notes due 2023
|
744
|
-
|
||||||
3.450% unsecured notes due 2026
|
1,885
|
-
|
||||||
4.650% unsecured notes due 2046
|
590
|
-
|
||||||
$8 Billion Note Issuance(7)(9)
|
||||||||
1.750% unsecured notes due 2017
|
746
|
746
|
||||||
2.700% unsecured notes due 2019
|
1,244
|
1,243
|
||||||
3.300% unsecured notes due 2021
|
1,242
|
1,241
|
||||||
3.800% unsecured notes due 2024
|
1,987
|
1,985
|
||||||
4.500% unsecured notes due 2034
|
494
|
494
|
||||||
4.800% unsecured notes due 2044
|
1,492
|
1,491
|
||||||
£700 Million Note Issuance(3)(7)(9)
|
||||||||
2.875% unsecured Pound Sterling notes due 2020
|
521
|
612
|
||||||
3.600% unsecured Pound Sterling notes due 2025
|
391
|
459
|
||||||
€750 Million Note Issuance(5)(7)(9)
|
||||||||
2.125% unsecured Euro notes due 2026
|
830
|
836
|
||||||
$4 Billion Note Issuance(7)(8)(9)
|
||||||||
3.100% unsecured notes due 2022
|
1,194
|
1,193
|
||||||
4.400% unsecured notes due 2042
|
492
|
492
|
||||||
$1 Billion Note Issuance(8)(9)
|
||||||||
5.250% unsecured notes due 2019(4)
|
249
|
250
|
||||||
Other(6)
|
32
|
44
|
||||||
Total long-term debt, less current portion
|
$
|
18,705
|
$
|
13,315
|
(1) |
All notes are presented net of unamortized discount and debt issuance costs, where applicable.
|
(2) |
Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
|
(3) |
Pound Sterling denominated notes are translated at the spot rates at August 31, 2016 and 2015, respectively.
|
(4) |
Includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
|
(5) |
Euro denominated notes are translated at the spot rate at August 31, 2016 and 2015.
|
(6) |
Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
|
(7) |
Notes are unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding.
|
(8) |
Notes are senior debt obligations of Walgreens and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance.
|
(9) |
The fair value of the $6 billion, $8 billion, £0.7 billion, €0.75 billion, $4 billion and $1 billion note issuances as of August 31, 2016 was $6.2 billion, $7.7 billion, $1.0 billion, $0.9 billion, $1.8 billion and $0.3 billion, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market price and translated at the August 31, 2016 spot rate, as applicable.
|
Year ended August 31,
|
Amount
|
|||
2017
|
$
|
323
|
||
2018
|
2,137
|
|||
2019
|
416
|
|||
2020
|
2,808
|
|||
2021
|
2,024
|
|||
Later
|
11,442
|
|||
Total estimated future maturities
|
$
|
19,150
|
2016
|
Notional(1)
|
Fair Value
|
Location in Consolidated
Balance Sheets
|
||||||
Derivatives designated as fair value hedges:
|
|||||||||
Interest rate swaps
|
$
|
250
|
$
|
3
|
Other non-current assets
|
||||
Derivatives not designated as hedges:
|
|||||||||
Foreign currency forwards
|
1,177
|
16
|
Other current assets
|
||||||
Foreign currency forwards
|
41
|
-
|
Other current liabilities
|
||||||
Basis swap
|
2
|
1
|
Other current liabilities
|
(1) |
Amounts are presented in U.S. dollar equivalents, as applicable.
|
2015
|
Notional(1)
|
Fair Value
|
Location in Consolidated
Balance Sheets
|
||||||
Derivatives designated as fair value hedges:
|
|||||||||
Interest rate swaps
|
$
|
250
|
$
|
2
|
Other non-current assets
|
||||
Derivatives designated as cash flow hedges:
|
|||||||||
Foreign Currency Forwards
|
1,205
|
34
|
Other current assets
|
||||||
Foreign Currency Forwards
|
495
|
9
|
Other current liabilities
|
||||||
Basis Swap
|
1
|
-
|
Other current assets
|
(1) |
Amounts are presented in U.S. dollar equivalents, as applicable.
|
Location in Consolidated
Statements of Earnings
|
2016
|
2015
|
2014
|
||||||||||
Interest rate swaps
|
Interest expense, net
|
$
|
-
|
$
|
1
|
$
|
-
|
||||||
Foreign currency forwards
|
Selling, general and administrative expense
|
19
|
78
|
-
|
|||||||||
Second Step Transaction foreign currency forwards
|
Other income (expense)
|
-
|
(166
|
)
|
-
|
||||||||
Foreign currency forwards
|
Other income (expense)
|
(12
|
)
|
72
|
-
|
Location in Consolidated
Balance Sheets
|
August 31,
2016
|
August 31,
2015
|
|||||||
Asset derivatives not designated as hedges:
|
|||||||||
Warrants
|
Other non-current assets
|
$
|
-
|
$
|
2,140
|
Location in Consolidated Statements of Earnings
|
2016
|
2015
|
2014
|
||||||||||
Warrants
|
Other income (expense)
|
$
|
(546
|
)
|
$
|
759
|
$
|
366
|
Level 1 - |
Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
|
Level 2 - |
Observable inputs other than quoted prices in active markets.
|
Level 3 - |
Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
|
August 31, 2016
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
Assets:
|
||||||||||||||||
Restricted cash (1)
|
$
|
185
|
$
|
185
|
$
|
-
|
$
|
-
|
||||||||
Money market funds (2)
|
9,133
|
9,133
|
-
|
-
|
||||||||||||
Available-for-sale investments (3)
|
32
|
32
|
-
|
-
|
||||||||||||
Interest rate swaps (4)
|
3
|
-
|
3
|
-
|
||||||||||||
Foreign currency forwards (5)
|
16
|
-
|
16
|
-
|
||||||||||||
Liabilities:
|
||||||||||||||||
Basis swaps (5)
|
1
|
-
|
1
|
-
|
August 31, 2015
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
Assets:
|
||||||||||||||||
Restricted cash (1)
|
$
|
184
|
$
|
184
|
$
|
-
|
$
|
-
|
||||||||
Money market funds (2)
|
2,043
|
2,043
|
-
|
-
|
||||||||||||
Available-for-sale investments (3)
|
1,183
|
1,183
|
-
|
-
|
||||||||||||
Interest rate swaps (4)
|
2
|
-
|
2
|
-
|
||||||||||||
Foreign currency forwards (5)
|
34
|
-
|
34
|
-
|
||||||||||||
Warrants (6)
|
2,140
|
-
|
2,140
|
-
|
||||||||||||
Liabilities:
|
||||||||||||||||
Foreign currency forwards (5)
|
9
|
-
|
9
|
-
|
(1) |
Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
|
(2) |
Money market funds are valued at the closing price reported by the fund sponsor.
|
(3) |
Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information.
|
(4) |
The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
|
(5) |
The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
|
(6) |
Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.
|
2016
|
2015
|
2014
|
||||||||||
U.S.
|
$
|
2,577
|
$
|
2,725
|
$
|
3,386
|
||||||
Non – U.S.
|
2,567
|
2,586
|
171
|
|||||||||
Total
|
$
|
5,144
|
$
|
5,311
|
$
|
3,557
|
2016
|
2015
|
2014
|
||||||||||
Current provision
|
||||||||||||
Federal
|
$
|
999
|
$
|
846
|
$
|
1,207
|
||||||
State
|
56
|
121
|
109
|
|||||||||
Non – U.S.
|
371
|
128
|
35
|
|||||||||
1,426
|
1,095
|
1,351
|
||||||||||
Deferred provision
|
||||||||||||
Federal
|
(183
|
)
|
(23
|
)
|
183
|
|||||||
State
|
6
|
(16
|
)
|
(3
|
)
|
|||||||
Non – U.S. – Tax Law Change
|
(182
|
)
|
-
|
-
|
||||||||
Non – U.S. – Excluding Tax Law Change
|
(70
|
)
|
-
|
(5
|
)
|
|||||||
(429
|
)
|
(39
|
)
|
175
|
||||||||
Income tax provision
|
$
|
997
|
$
|
1,056
|
$
|
1,526
|
2016
|
2015
|
2014
|
||||||||||
Federal statutory rate
|
35.0
|
%
|
35.0
|
%
|
35.0
|
%
|
||||||
State income taxes, net of federal benefit
|
0.8
|
1.3
|
1.9
|
|||||||||
Loss on Alliance Boots call option(1)
|
-
|
-
|
8.5
|
|||||||||
Deferred tax asset recognition(1)
|
-
|
(4.1
|
)
|
-
|
||||||||
Gain on previously held equity interest
|
-
|
(5.8
|
)
|
-
|
||||||||
Foreign income taxed at non-U.S. rates
|
(7.8
|
)
|
(6.2
|
)
|
(3.1
|
)
|
||||||
Non-taxable income
|
(4.4
|
)
|
(2.6
|
)
|
-
|
|||||||
Non-deductible expenses
|
1.1
|
2.3
|
0.3
|
|||||||||
Tax Law changes
|
(3.5
|
)
|
-
|
-
|
||||||||
Tax Credits
|
(1.5
|
)
|
-
|
-
|
||||||||
Other
|
(0.3
|
)
|
-
|
0.3
|
||||||||
Effective income tax rate
|
19.4
|
%
|
19.9
|
%
|
42.9
|
%
|
(1) |
Upon the amendment and immediate exercise of the call option to acquire the remaining 55% ownership of Alliance Boots, the Company was required to compare the fair value of the amended option with the book value of the original option with a gain or loss recognized for the difference. The fair value of the amended option resulted in a financial statement loss of $866 million. The loss on the Alliance Boots call option was, in part, a capital loss and available to be carried forward and offset future capital gains through fiscal 2020. In 2015, the deferred tax asset related to the loss was recognized, resulting in the 4.1% effective tax rate benefit reported in the table above.
|
2016
|
2015
|
|||||||
Deferred tax assets
|
||||||||
Postretirement benefits
|
$
|
190
|
$
|
130
|
||||
Compensation and benefits
|
205
|
224
|
||||||
Insurance
|
75
|
68
|
||||||
Accrued rent
|
169
|
167
|
||||||
Outside basis difference
|
134
|
73
|
||||||
Bad debts
|
65
|
67
|
||||||
Tax attributes
|
373
|
341
|
||||||
Stock compensation
|
97
|
119
|
||||||
Deferred income
|
150
|
-
|
||||||
Other
|
195
|
93
|
||||||
1,653
|
1,282
|
|||||||
Less: Valuation allowance
|
305
|
125
|
||||||
Total deferred tax assets
|
1,348
|
1,157
|
||||||
Deferred tax liabilities
|
||||||||
Accelerated depreciation
|
1,205
|
1,234
|
||||||
Inventory
|
388
|
420
|
||||||
Intangible assets
|
1,418
|
1,822
|
||||||
Equity method investment
|
978
|
333
|
||||||
Deferred income
|
-
|
889
|
||||||
3,989
|
4,698
|
|||||||
Net deferred tax liabilities
|
$
|
2,641
|
$
|
3,541
|
2016
|
2015
|
2014
|
||||||||||
Balance at beginning of year
|
$
|
261
|
$
|
193
|
$
|
208
|
||||||
Gross increases related to business combination
|
-
|
84
|
-
|
|||||||||
Gross increases related to tax positions in a prior period
|
21
|
45
|
55
|
|||||||||
Gross decreases related to tax positions in a prior period
|
(47
|
)
|
(75
|
)
|
(82
|
)
|
||||||
Gross increases related to tax positions in the current period
|
68
|
63
|
46
|
|||||||||
Settlements with taxing authorities
|
(17
|
)
|
(45
|
)
|
(22
|
)
|
||||||
Currency
|
(11
|
)
|
-
|
-
|
||||||||
Lapse of statute of limitations
|
(6
|
)
|
(4
|
)
|
(12
|
)
|
||||||
Balance at end of year
|
$
|
269
|
$
|
261
|
$
|
193
|
Percentage of Fair Market Value
|
2016
|
2015
|
||||||
Equity securities
|
8.9%
|
|
9.5%
|
|
||||
Debt securities
|
78.8%
|
|
81.5%
|
|
||||
Real estate
|
4.3%
|
|
5.6%
|
|
||||
Other
|
8.0%
|
|
3.4%
|
|
August 31, 2016
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
Equity securities:
|
||||||||||||||||
Equity securities (1)
|
$
|
834
|
$
|
-
|
$
|
834
|
$
|
-
|
||||||||
Debt securities:
|
||||||||||||||||
Fixed interest government bonds (2)
|
265
|
-
|
265
|
-
|
||||||||||||
Index linked government bonds (2)
|
3,502
|
-
|
3,502
|
-
|
||||||||||||
Corporate bonds (3)
|
3,663
|
-
|
3,663
|
-
|
||||||||||||
Real estate:
|
|
|
||||||||||||||
Real estate (4)
|
411
|
-
|
-
|
411
|
||||||||||||
Other:
|
||||||||||||||||
Other investments (5)
|
753
|
38
|
713
|
2
|
||||||||||||
Total
|
$
|
9,428
|
$
|
38
|
$
|
8,977
|
$
|
413
|
August 31, 2015
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
Equity securities:
|
||||||||||||||||
Equity securities (1)
|
$
|
852
|
$
|
-
|
$
|
852
|
$
|
-
|
||||||||
Debt securities:
|
||||||||||||||||
Fixed interest government bonds (2)
|
267
|
-
|
267
|
-
|
||||||||||||
Index linked government bonds (2)
|
1,006
|
-
|
1,006
|
-
|
||||||||||||
Corporate bonds (3)
|
5,535
|
-
|
5,535
|
-
|
||||||||||||
Other bonds (6)
|
472
|
-
|
472
|
-
|
||||||||||||
Real estate:
|
||||||||||||||||
Real estate (4)
|
502
|
-
|
-
|
502
|
||||||||||||
Other:
|
||||||||||||||||
Other investments (5)
|
302
|
25
|
275
|
2
|
||||||||||||
Total
|
$
|
8,936
|
$
|
25
|
$
|
8,407
|
$
|
504
|
(1) |
Equity securities, which mainly comprise investments in comingled funds, are valued based on quoted prices and are primarily exchange-traded. Securities for which official close or last trade pricing on an active exchange is available are classified as Level 1 investments. If closing prices are not available, securities are valued at the last quoted bid price and typically are categorized as Level 2 investments.
|
(2) |
Debt securities: government bonds comprise fixed interest and index linked bonds issued by central governments, and are valued based on quotes received from independent pricing services or from dealers who make markets in such securities. Pricing services utilize pricing which considers readily available inputs such as the yield or price of bonds of comparable quality, coupon, maturity, and type, as well as dealer-supplied prices. Debt securities: government bonds are categorized as Level 2 investments.
|
(3) |
Debt securities: corporate bonds comprise bonds issued by corporations and are valued using recently executed transactions, or quoted market prices for similar assets and liabilities in active markets, or for identical assets and liabilities in markets that are not active. If there have been no market transactions in a particular fixed income security, its fair value is calculated by pricing models that benchmark the security against other securities with actual market prices. Debt securities: corporate bonds are categorized as Level 2 investments.
|
(4) |
Real estate comprises investments in certain property funds which themselves are valued based on the value of the underlying properties. These properties are valued using a number of standard industry techniques such as cost, discounted cash flows, independent appraisals and market based comparable data. Real estate investments are categorized as Level 3 investments. Change in Level 3 investments driven primarily by currency fluctuations.
|
(5) |
Other investments mainly comprise cash and cash equivalents and derivatives. Cash is categorized as a Level 1 investment. Cash equivalents are valued using observable yield curves, discounting and interest rates and are categorized as Level 2 investments. Derivatives which are exchange-traded and for which market quotations are readily available are valued at the last reported sale price or official closing price as reported by an independent pricing service on the primary market, or exchange on which they are traded, and are categorized as Level 1 investments. Over-the-counter derivatives typically are valued by independent pricing services and are categorized as Level 2 investments.
|
(6) |
Debt securities: other bonds comprise agency and mortgage-backed securities. These are valued using recently executed transactions and quoted market prices for similar assets and liabilities in active markets, or for identical assets and liabilities in markets that are not active. If there have been no market transactions in a particular fixed income security, its fair value is calculated by pricing models that benchmark the security against other securities with actual market prices. Debt securities: other bonds are categorized as Level 2 investments.
|
Boots and Other
Pension Plans
|
||||||||
2016
|
2015(1)
|
|||||||
Service costs
|
$
|
4
|
$
|
3
|
||||
Interest costs
|
308
|
214
|
||||||
Expected returns on plan assets
|
(247
|
)
|
(173
|
)
|
||||
Curtailments
|
(2
|
)
|
(2
|
)
|
||||
Total net periodic pension costs
|
$
|
63
|
$
|
42
|
2016
|
2015(1)
|
|||||||
Benefit obligation at beginning of year
|
$
|
8,635
|
$
|
8,827
|
||||
Service costs
|
4
|
3
|
||||||
Interest costs
|
308
|
214
|
||||||
Amendments
|
(2
|
)
|
(2
|
)
|
||||
Net actuarial (gain) loss
|
2,272
|
(103
|
)
|
|||||
Benefits paid
|
(277
|
)
|
(186
|
)
|
||||
Currency translation adjustments
|
(1,477
|
)
|
(118
|
)
|
||||
Benefit obligation at end of year
|
$
|
9,463
|
$
|
8,635
|
2016
|
2015(1)
|
|||||||
Plan assets at fair value at beginning of year
|
$
|
8,936
|
$
|
8,987
|
||||
Employer contributions
|
75
|
152
|
||||||
Benefits paid
|
(277
|
)
|
(186
|
)
|
||||
Return on assets
|
2,216
|
91
|
||||||
Currency translation adjustments
|
(1,522
|
)
|
(108
|
)
|
||||
Plan assets at fair value at end of year
|
$
|
9,428
|
$
|
8,936
|
2016
|
2015
|
|||||||
Other non-current assets
|
$
|
155
|
$
|
468
|
||||
Accrued expenses and other liabilities
|
(6
|
)
|
(1
|
)
|
||||
Other non-current liabilities
|
(184
|
)
|
(166
|
)
|
||||
Net (liability) asset recognized at end of year
|
$
|
(35
|
)
|
$
|
301
|
2016
|
2015 (1)
|
|||||||
Net actuarial (gain) loss
|
(258
|
)
|
21
|
(1) |
Fiscal 2015 represents change in pension benefit obligation and plan assets from December 31, 2014 to August 31, 2015.
|
2016
|
2015
|
|||||||
Projected benefit obligation
|
$
|
9,463
|
$
|
8,635
|
||||
Accumulated benefit obligation
|
9,457
|
8,624
|
||||||
Fair value of plan assets
|
9,428
|
8,936
|
Estimated Future
Benefit Payments
|
||||
2017
|
$
|
264
|
||
2018
|
237
|
|||
2019
|
248
|
|||
2020
|
266
|
|||
2021
|
279
|
|||
2022-2026
|
1,641
|
2016
|
2015
|
|||||||
Weighted-average assumptions used to determine benefit obligations
|
||||||||
Discount rate
|
2.17
|
%
|
3.87
|
%
|
||||
Rate of compensation increase
|
2.44
|
%
|
2.55
|
%
|
||||
Weighted-average assumptions used to determine net periodic benefit cost
|
||||||||
Discount rate
|
3.87
|
%
|
3.77
|
%
|
||||
Expected long-term return on plan assets
|
3.05
|
%
|
2.99
|
%
|
||||
Rate of compensation increase
|
2.55
|
%
|
2.66
|
%
|
Pension/post
-retirement
obligations
|
Unrecognized
gain (loss) on
available-for-
sale
investments
|
Unrealized
gain (loss)
on cash
flow hedges
|
Share of
OCI of
equity
method
investments
|
Cumulative
translation
adjustments
|
Total
|
|||||||||||||||||||
Balance at August 31, 2013
|
$
|
63
|
$
|
1
|
$
|
-
|
$
|
(95
|
)
|
$
|
(61
|
)
|
$
|
(92
|
)
|
|||||||||
Other comprehensive income (loss) before reclassification adjustments
|
(77
|
)
|
170
|
(43
|
)
|
(27
|
)
|
330
|
353
|
|||||||||||||||
Tax benefit (provision)
|
29
|
(64
|
)
|
16
|
9
|
(115
|
)
|
(125
|
)
|
|||||||||||||||
Net other comprehensive income (loss)
|
(48
|
)
|
106
|
(27
|
)
|
(18
|
)
|
215
|
228
|
|||||||||||||||
Balance at August 31, 2014
|
$
|
15
|
$
|
107
|
$
|
(27
|
)
|
$
|
(113
|
)
|
$
|
154
|
$
|
136
|
||||||||||
Other comprehensive income (loss) before reclassification adjustments
|
23
|
247
|
(14
|
)
|
(57
|
)
|
(779
|
)
|
(580
|
)
|
||||||||||||||
Amounts reclassified from accumulated OCI
|
-
|
-
|
(5
|
)
|
230
|
80
|
305
|
|||||||||||||||||
Tax benefit (provision)
|
(9
|
)
|
(95
|
)
|
6
|
(60
|
)
|
83
|
(75
|
)
|
||||||||||||||
Net other comprehensive income (loss)
|
14
|
152
|
(13
|
)
|
113
|
(616
|
)
|
(350
|
)
|
|||||||||||||||
Balance at August 31, 2015
|
$
|
29
|
$
|
259
|
$
|
(40
|
)
|
$
|
-
|
$
|
(462
|
)
|
$
|
(214
|
)
|
|||||||||
Other comprehensive income (loss) before reclassification adjustments
|
(303
|
)
|
(148
|
)
|
-
|
(1
|
)
|
(2,279
|
)
|
(2,731
|
)
|
|||||||||||||
Amounts reclassified from accumulated OCI
|
-
|
(268
|
)
|
5
|
-
|
(3
|
)
|
(266
|
)
|
|||||||||||||||
Tax benefit (provision)
|
62
|
159
|
(2
|
)
|
-
|
-
|
219
|
|||||||||||||||||
Net other comprehensive income (loss)
|
(241
|
)
|
(257
|
)
|
3
|
(1
|
)
|
$
|
(2,282
|
)
|
(2,778
|
)
|
||||||||||||
Balance at August 31, 2016
|
$
|
(212
|
)
|
$
|
2
|
$
|
(37
|
)
|
$
|
(1
|
)
|
$
|
(2,744
|
)
|
$
|
(2,992
|
)
|
· |
The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.
|
· |
The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.
|
· |
The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses and an equity method investment in AmerisourceBergen reported on a two-month lag. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.
|
Retail Pharmacy
|
||||||||||||||||||||
USA
|
International(1)
|
Pharmaceutical
Wholesale
|
Eliminations(1)
|
Walgreens
Boots Alliance,
Inc.
|
||||||||||||||||
For the Year Ended August 31, 2016
|
||||||||||||||||||||
Sales to external customers
|
$
|
83,802
|
$
|
13,256
|
$
|
20,293
|
$
|
-
|
$
|
117,351
|
||||||||||
Intersegment sales
|
-
|
-
|
2,278
|
(2,278
|
)
|
-
|
||||||||||||||
Sales
|
$
|
83,802
|
$
|
13,256
|
$
|
22,571
|
$
|
(2,278
|
)
|
$
|
117,351
|
|||||||||
Adjusted Operating Income
|
$
|
5,357
|
$
|
1,155
|
$
|
708
|
$
|
(12
|
)
|
$
|
7,208
|
|||||||||
Depreciation and amortization
|
$
|
1,134
|
$
|
401
|
$
|
166
|
$
|
17
|
$
|
1,718
|
||||||||||
Additions to property, plant and equipment
|
777
|
444
|
104
|
-
|
1,325
|
|||||||||||||||
For the Year Ended August 31, 2015
|
||||||||||||||||||||
Sales to external customers
|
$
|
80,974
|
$
|
8,657
|
$
|
13,813
|
$
|
-
|
$
|
103,444
|
||||||||||
Intersegment sales
|
-
|
-
|
1,514
|
(1,514
|
)
|
-
|
||||||||||||||
Sales
|
$
|
80,974
|
$
|
8,657
|
$
|
15,327
|
$
|
(1,514
|
)
|
$
|
103,444
|
|||||||||
Adjusted Operating Income
|
$
|
5,098
|
$
|
616
|
$
|
450
|
$
|
(7
|
)
|
$
|
6,157
|
|||||||||
Depreciation and amortization
|
$
|
1,217
|
$
|
393
|
$
|
120
|
$
|
12
|
$
|
1,742
|
||||||||||
Additions to property, plant and equipment
|
951
|
249
|
51
|
-
|
1,251
|
|||||||||||||||
For the Year Ended August 31, 2014
|
||||||||||||||||||||
Sales to external customers
|
$
|
76,392
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
76,392
|
||||||||||
Intersegment sales
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Sales
|
$
|
76,392
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
76,392
|
||||||||||
Adjusted Operating Income
|
$
|
4,866
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
4,866
|
||||||||||
Depreciation and amortization
|
$
|
1,316
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
1,316
|
||||||||||
Additions to property, plant and equipment
|
1,106
|
-
|
-
|
-
|
1,106
|
(1) |
To improve comparability, certain classification changes have been made to fiscal 2015 Sales, Cost of sales and Selling, general and administrative expenses. This change has no impact on Operating Income.
|
Retail Pharmacy
|
||||||||||||||||||||
USA
|
International
|
Pharmaceutical
Wholesale
|
Eliminations
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||||||||
For the Year Ended August 31, 2016
|
||||||||||||||||||||
Adjusted Operating Income
|
$
|
5,357
|
$
|
1,155
|
$
|
708
|
$
|
(12
|
)
|
$
|
7,208
|
|||||||||
Cost transformation
|
(424
|
)
|
||||||||||||||||||
Acquisition-related amortization
|
(369
|
)
|
||||||||||||||||||
LIFO provision
|
(214
|
)
|
||||||||||||||||||
Acquisition-related costs
|
(102
|
)
|
||||||||||||||||||
Legal settlement
|
(47
|
)
|
||||||||||||||||||
Asset impairment
|
(30
|
)
|
||||||||||||||||||
Adjustments to equity earnings in AmerisourceBergen
|
(21
|
)
|
||||||||||||||||||
Operating Income
|
$
|
6,001
|
||||||||||||||||||
For the Year Ended August 31, 2015
|
||||||||||||||||||||
Adjusted Operating Income
|
$
|
5,098
|
$
|
616
|
$
|
450
|
$
|
(7
|
)
|
$
|
6,157
|
|||||||||
Cost transformation
|
(542
|
)
|
||||||||||||||||||
Acquisition-related amortization
|
(485
|
)
|
||||||||||||||||||
LIFO provision
|
(285
|
)
|
||||||||||||||||||
Acquisition-related costs
|
(87
|
)
|
||||||||||||||||||
Asset impairment
|
(110
|
)
|
||||||||||||||||||
Store closures and other optimization costs
|
(56
|
)
|
||||||||||||||||||
(Loss) on sale of business
|
(17
|
)
|
||||||||||||||||||
Adjustments to equity earnings in Alliance Boots
|
93
|
|||||||||||||||||||
Operating Income
|
$
|
4,668
|
||||||||||||||||||
For the Year Ended August 31, 2014
|
||||||||||||||||||||
Adjusted Operating Income
|
$
|
4,866
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
4,866
|
||||||||||
Acquisition-related amortization
|
(282
|
)
|
||||||||||||||||||
Acquisition-related costs
|
(82
|
) | ||||||||||||||||||
LIFO provision
|
(132
|
)
|
||||||||||||||||||
Store closures and other optimization costs
|
(271
|
)
|
||||||||||||||||||
Gain on sale of business
|
9
|
|||||||||||||||||||
Adjustments to equity earnings in Alliance Boots
|
86
|
|||||||||||||||||||
Operating Income
|
$
|
4,194
|
2016
|
2015
|
2014
|
||||||||||
United States
|
$
|
83,802
|
$
|
80,974
|
$
|
76,392
|
||||||
United Kingdom
|
14,081
|
9,235
|
-
|
|||||||||
Europe (excluding the United Kingdom)
|
16,793
|
11,402
|
-
|
|||||||||
Other
|
2,675
|
1,833
|
-
|
|||||||||
Sales
|
$
|
117,351
|
$
|
103,444
|
$
|
76,392
|
2016
|
2015
|
|||||||
United States
|
$
|
10,924
|
$
|
11,327
|
||||
United Kingdom
|
2,611
|
2,835
|
||||||
Europe (excluding the United Kingdom)
|
625
|
725
|
||||||
Other
|
175
|
181
|
||||||
Total long-lived assets
|
$
|
14,335
|
$
|
15,068
|
2016
|
2015
|
2014
|
||||||||||
Purchases, net
|
$
|
41,889
|
$
|
39,360
|
$
|
31,439
|
||||||
Trade accounts payable, net
|
3,456
|
2,867
|
2,360
|
2016
|
2015
|
|||||||
Accounts receivable
|
||||||||
Accounts receivable
|
$
|
6,426
|
$
|
7,021
|
||||
Allowance for doubtful accounts
|
(166
|
)
|
(172
|
)
|
||||
$
|
6,260
|
$
|
6,849
|
|||||
Other non-current assets
|
||||||||
Investment in AmerisourceBergen
|
$
|
-
|
$
|
1,147
|
||||
Warrants
|
-
|
2,140
|
||||||
Other
|
467
|
805
|
||||||
$
|
467
|
$
|
4,092
|
|||||
Accrued expenses and other liabilities
|
||||||||
Accrued salaries and wages
|
$
|
1,398
|
$
|
1,357
|
||||
Other
|
4,086
|
3,868
|
||||||
$
|
5,484
|
$
|
5,225
|
Quarter Ended
|
||||||||||||||||||||
November
|
February
|
May
|
August
|
Fiscal Year
|
||||||||||||||||
Fiscal 2016(1)
|
||||||||||||||||||||
Sales
|
$
|
29,033
|
$
|
30,184
|
$
|
29,498
|
$
|
28,636
|
$
|
117,351
|
||||||||||
Gross Profit
|
7,419
|
7,867
|
7,433
|
7,155
|
29,874
|
|||||||||||||||
Net Earnings attributable to Walgreens Boots Alliance, Inc.
|
1,110
|
930
|
1,103
|
1,030
|
4,173
|
|||||||||||||||
Net earnings per common share:
|
||||||||||||||||||||
Basic
|
$
|
1.02
|
$
|
0.86
|
$
|
1.02
|
$
|
0.95
|
$
|
3.85
|
||||||||||
Diluted
|
1.01
|
0.85
|
1.01
|
0.95
|
3.82
|
|||||||||||||||
Cash Dividends Declared Per Common Share
|
$
|
0.3600
|
$
|
0.3600
|
$
|
0.3600
|
$
|
0.3750
|
$
|
1.4550
|
||||||||||
Fiscal 2015(1)
|
||||||||||||||||||||
Sales
|
$
|
19,554
|
$
|
26,573
|
$
|
28,795
|
$
|
28,522
|
$
|
103,444
|
||||||||||
Gross Profit
|
5,296
|
6,842
|
7,420
|
7,195
|
26,753
|
|||||||||||||||
Net Earnings attributable to Walgreens Boots Alliance, Inc.
|
850
|
2,042
|
1,302
|
26
|
4,220
|
|||||||||||||||
Net earnings per common:
|
||||||||||||||||||||
Basic
|
$
|
0.90
|
$
|
1.96
|
$
|
1.19
|
$
|
0.02
|
$
|
4.05
|
||||||||||
Diluted
|
0.89
|
1.93
|
1.18
|
0.02
|
4.00
|
|||||||||||||||
Cash Dividends Declared Per Common Share
|
$
|
0.3375
|
$
|
0.3375
|
$
|
0.3375
|
$
|
0.3600
|
$
|
1.3725
|
(1) |
To improve comparability, certain classification changes have been made to fiscal 2016 for the quarterly periods ended November 30, 2015, February 29, 2016, and May 31, 2016 and to fiscal 2015 for the quarterly periods ended February 29, 2015, May 31, 2015, and August 31, 2015 to Sales, Cost of sales and Selling, general and administrative expenses. This change has no impact on Operating Income.
|
/s/
|
Stefano Pessina
|
/s/
|
George R. Fairweather
|
||
Stefano Pessina
|
George R. Fairweather
|
||||
Executive Vice Chairman and Chief
Executive Officer
|
Executive Vice President and Global Chief
Financial Officer
|
(a) |
Documents filed as part of this report:
|
(1) |
Financial statements. The following financial statements, supplementary data, and reports of independent public accountants appear in Part II, Item 8 of this Form 10-K and are incorporated herein by reference.
|
(2) |
Financial statement schedules and supplementary information
|
(3) |
Exhibits. Exhibits 10.1 through 10.66 constitute management contracts or compensatory plans or arrangements required to be filed as exhibits pursuant to Item 15(b) of this Form 10-K.
|
• |
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
|
• |
may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
|
• |
may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
|
• |
were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.
|
(b)
|
Exhibits
|
Exhibit
No.
|
Description
|
SEC Document Reference
|
|
2.1*
|
Purchase and Option Agreement by and among Walgreen Co., Alliance Boots GmbH and AB Acquisitions Holdings Limited dated June 18, 2012 and related annexes.
|
Incorporated by reference to Annex B-1 to the proxy statement/prospectus forming a part of the Registration Statement on Form S-4 (File No. 333-198768) filed with the SEC pursuant to Rule 424(b)(3) on November 24, 2014.
|
|
2.2*
|
Amendment No. 1, dated August 5, 2014, to the Purchase and Option Agreement and Walgreen Co. Shareholders Agreement, by and among Walgreen Co., Alliance Boots GmbH, AB Acquisitions Holdings Limited, Walgreen Scotland Investments LP, KKR Sprint (European II) Limited, KKR Sprint (2006) Limited and KKR Sprint (KPE) Limited, Alliance Santé Participations S.A., Stefano Pessina and Kohlberg Kravis Roberts & Co. L.P.
|
Incorporated by reference to Annex B-2 to the proxy statement/prospectus forming a part of the Registration Statement on Form S-4 (File No. 333-198768) filed with the SEC pursuant to Rule 424(b)(3) on November 24, 2014.
|
|
2.3
|
Reorganization Agreement and Plan of Merger, dated October 17, 2014, by and among Walgreen Co., Walgreens Boots Alliance, Inc. and Ontario Merger Sub, Inc.
|
Incorporated by reference to Annex A to the proxy statement/prospectus forming a part of the Registration Statement on Form S-4 (File No. 333-198768) filed with the SEC pursuant to Rule 424(b)(3) on November 24, 2014.
|
|
2.4
|
Amendment No. 1, dated December 23, 2014, to the Reorganization Agreement and Plan of Merger, dated October 17, 2014, by and among Walgreen Co., Walgreens Boots Alliance, Inc. and Ontario Merger Sub, Inc.
|
Incorporated by reference to Exhibit 2.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on December 24, 2014.
|
|
2.5
|
Amendment No. 2, dated December 29, 2014, to the Reorganization Agreement and Plan of Merger, dated October 17, 2014, as amended December 23, 2014, by and among Walgreen Co., Walgreens Boots Alliance, Inc. and Ontario Merger Sub, Inc.
|
Incorporated by reference to Exhibit 2.3 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended November 30, 2014 (File No. 1-36759) filed with the SEC on December 30, 2014.
|
|
2.6*
|
Agreement and Plan of Merger, dated as of October 27, 2015, by and among Walgreens Boots Alliance, Inc., Victoria Merger Sub, Inc. and Rite Aid Corporation.
|
Incorporated by reference to Exhibit 2.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on October 29, 2015.
|
|
3.1
|
Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance, Inc.
|
Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
|
|
3.2
|
Amended and Restated Bylaws of Walgreens Boots Alliance, Inc.
|
Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 10, 2016.
|
4.1**
|
Indenture, dated as of July 17, 2008, between Walgreen Co. and Wells Fargo Bank, National Association, as trustee.
|
Incorporated by reference to Exhibit 4.1 to Walgreen Co.’s registration statement on Form S-3ASR (File No. 333-198443) filed with the SEC on September 16, 2014.
|
|
4.2
|
Form of Walgreen Co. 5.25% Note due 2019.
|
Incorporated by reference to Exhibit 4.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on January 13, 2009.
|
|
4.3
|
Form of Walgreen Co. 3.100% Note due 2022.
|
Incorporated by reference to Exhibit 4.4 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on September 13, 2012.
|
|
4.4
|
Form of Walgreen Co. 4.400% Note due 2042.
|
Incorporated by reference to Exhibit 4.5 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on September 13, 2012.
|
|
4.5
|
Form of Guarantee of Walgreens Boots Alliance, Inc.
|
Incorporated by reference to Exhibit 4.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
|
|
4.6
|
Indenture dated November 18, 2014 among Walgreens Boots Alliance, Inc. and Wells Fargo Bank, National Association, as trustee.
|
Incorporated by reference to Exhibit 4.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.7
|
Form of 1.750% Notes due 2017.
|
Incorporated by reference to Exhibit 4.3 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.8
|
Form of 2.700% Notes due 2019.
|
Incorporated by reference to Exhibit 4.4 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.9
|
Form of 3.300% Notes due 2021.
|
Incorporated by reference to Exhibit 4.5 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.10
|
Form of 3.800% Notes due 2024.
|
Incorporated by reference to Exhibit 4.6 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.11
|
Form of 4.500% Notes due 2034.
|
Incorporated by reference to Exhibit 4.7 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.12
|
Form of 4.800% Notes due 2044.
|
Incorporated by reference to Exhibit 4.8 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 18, 2014.
|
|
4.13
|
Form of 2.875% Notes due 2020 (£).
|
Incorporated by reference to Exhibit 4.2 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 20, 2014.
|
|
4.14
|
Form of 3.600% Notes due 2025 (£).
|
Incorporated by reference to Exhibit 4.3 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 20, 2014.
|
|
4.15
|
Form of 2.125% Notes due 2026 (€).
|
Incorporated by reference to Exhibit 4.4 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 20, 2014.
|
|
4.16
|
Indenture, dated as of December 17, 2015, between Walgreens Boots Alliance, Inc. and Wells Fargo Bank, National Association, as trustee
|
Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-3 (File No. 333-208587) filed with the SEC on December 17, 2015.
|
4.17
|
Form of 1.750% Notes due 2018
|
Incorporated by reference to Exhibit 4.2 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 1, 2016.
|
|
4.18
|
Form of 2.600% Notes due 2021
|
Incorporated by reference to Exhibit 4.3 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 1, 2016.
|
|
4.19
|
Form of 3.100% Notes due 2023
|
Incorporated by reference to Exhibit 4.4 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 1, 2016.
|
|
4.20
|
Form of 3.450% Notes due 2026
|
Incorporated by reference to Exhibit 4.5 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 1, 2016.
|
|
4.21
|
Form of 4.650% Notes due 2046
|
Incorporated by reference to Exhibit 4.6 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 1, 2016.
|
|
4.22
|
Shareholders Agreement, dated as of August 2, 2012, among Walgreen Co., Stefano Pessina, KKR Sprint (European II) Limited, KKR Sprint (2006) Limited and KKR Sprint (KPE) Limited, Alliance Santé Participations S.A., Kohlberg Kravis Roberts & Co. L.P. and certain other investors party thereto.
|
Incorporated by reference to Exhibit 4.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on August 6, 2012.
|
|
4.23
|
Amendment No. 1, dated August 5, 2014, to the Purchase and Option Agreement and Walgreen Co. Shareholders Agreement, by and among Walgreen Co., Alliance Boots GmbH, AB Acquisitions Holdings Limited, Walgreen Scotland Investments LP, KKR Sprint (European II) Limited, KKR Sprint (2006) Limited and KKR Sprint (KPE) Limited, Alliance Santé Participations S.A., Stefano Pessina and Kohlberg Kravis Roberts & Co. L.P.
|
Incorporated by reference to Annex B-2 to the proxy statement/prospectus forming a part of the Registration Statement on Form S-4 (File No. 333-198768) filed with the SEC pursuant to Rule 424(b)(3) on November 24, 2014.
|
|
4.24
|
Amendment No. 2, dated December 31, 2014, to the Purchase and Option Agreement and Walgreen Co. Shareholders Agreement, as Amended by Amendment No. 1, dated as of August 5, 2014, by and among Walgreen Co., Alliance Boots GmbH, AB Acquisitions Holdings Limited, Ontario Holdings WBS Limited, KKR Sprint (European II) Limited, KKR Sprint (2006) Limited and KKR Sprint (KPE) Limited, Alliance Santé Participations S.A., Stefano Pessina and Kohlberg Kravis Roberts & Co. L.P.
|
Incorporated by reference to Exhibit E to the Schedule 13D filed by Alliance Santé Participations S.A. (File No. 005-88481) filed with the SEC on December 31, 2014).
|
|
10.1
|
Walgreens Boots Alliance, Inc. Management Incentive Plan (as amended and restated effective December 31, 2014).
|
Incorporated by reference to Exhibit 10.6 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
|
|
10.2
|
Walgreens Boots Alliance, Inc. Management Incentive Plan (as amended and restated effective July 1, 2016).
|
Filed herewith.
|
|
10.3
|
Walgreens Boots Alliance, Inc. 2011 Cash-Based Incentive Plan (as amended and restated effective December 31, 2014).
|
Incorporated by reference to Exhibit 10.5 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
|
10.4
|
Walgreens Boots Alliance, Inc. 2011 Cash-Based Incentive Plan (as amended and restated effective July 1, 2016).
|
Filed herewith.
|
|
10.5
|
Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (as amended and restated effective July 8, 2015).
|
Incorporated by reference to Exhibit 10.3 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.6
|
Form of Restricted Stock Unit Award agreement (effective January 2015).
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on January 21, 2015.
|
|
10.7
|
Form of Performance Share Award agreement (effective October 2015).
|
Incorporated by reference to Exhibit 10.5 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.8
|
Form of Stock Option Award agreement (effective July 2016).
|
Filed herewith.
|
|
10.9
|
Form of Stock Option Award agreement (effective October 2015).
|
Incorporated by reference to Exhibit 10.6 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.10
|
Form of Performance Share Award agreement for CEO (February 2016).
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 29, 2016 (File No. 1-36759) filed with the SEC on April 5, 2016.
|
|
10.11
|
Form of Stock Option Award agreement for CEO (February 2016).
|
Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 29, 2016 (File No. 1-36759) filed with the SEC on April 5, 2016.
|
|
10.12
|
Form of Restricted Stock Unit Award agreement for Executive Chairman (February 2016).
|
Incorporated by reference to Exhibit 10.3 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 29, 2016 (File No. 1-36759) filed with the SEC on April 5, 2016.
|
|
10.13
|
Form of Restricted Stock Unit Agreement (Messrs. Skinner and Pessina).
|
Incorporated by reference to Exhibit 10.6 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.14
|
Form of Restricted Stock Unit Award agreement (effective July 2014).
|
Incorporated by reference to Exhibit 10.3 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on August 8, 2014.
|
|
10.15
|
Form of Performance Share Award agreement (effective July 2014).
|
Incorporated by reference to Exhibit 10.4 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on August 8, 2014.
|
|
10.16
|
Form of Stock Option Award agreement (effective July 2014).
|
Incorporated by reference to Exhibit 10.5 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on August 8, 2014.
|
10.17
|
Forms of Restricted Stock Unit Award agreement (effective October 2013).
|
Incorporated by reference to Exhibit 10.4 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2013 (File No. 1-00604).
|
|
10.18
|
Form of Performance Share Award agreement (effective January 10, 2013).
|
Incorporated by reference to Exhibit 10.3 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on January 14, 2013.
|
|
10.19
|
Form of Stock Option Award agreement (effective January 10, 2013).
|
Incorporated by reference to Exhibit 10.4 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on January 14, 2013.
|
|
10.20
|
Form of Amendment to Stock Option Award agreements.
|
Incorporated by reference to Exhibit 10.11 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2014 (File No. 1-00604) filed with the SEC on October 20, 2014.
|
|
10.21
|
UK Sub-Plan under the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan.
|
Incorporated by reference to Exhibit 10.16 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.22
|
Form of Stock Option Award agreement under UK Sub-plan (effective October 2015).
|
Incorporated by reference to Exhibit 10.17 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.23
|
Form of Stock Option Award agreement under UK Sub-plan (effective July 2016).
|
Filed herewith.
|
|
10.24
|
Walgreen Co. Long-Term Performance Incentive Plan (amendment and restatement of the Walgreen Co. Restricted Performance Share Plan).
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on January 11, 2007.
|
|
10.25
|
Walgreen Co. Long-Term Performance Incentive Plan Amendment No. 1 (effective January 10, 2007).
|
Incorporated by reference to Exhibit 10.2 to Walgreen Co.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2007 (File No. 1-00604).
|
|
10.26
|
Walgreen Co. Long-Term Performance Incentive Plan Amendment No. 2.
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on April 14, 2011.
|
|
10.27
|
Form of Restricted Stock Unit Award Agreement (August 15, 2011 grants).
|
Incorporated by reference to Exhibit 10.5 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2011 (File No. 1-00604).
|
|
10.28
|
Walgreen Co. Executive Stock Option Plan (as amended and restated effective January 13, 2010).
|
Incorporated by reference to Exhibit 99.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on January 20, 2010.
|
|
10.29
|
Form of Stock Option Agreement (Benefit Indicator 512—515) (effective September 1, 2011).
|
Incorporated by reference to Exhibit 10.11 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2011 (File No. 1-00604).
|
|
10.30
|
Form of Stock Option Agreement (Benefit Indicator 516 and above) (effective September 1, 2011).
|
Incorporated by reference to Exhibit 10.12 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2011 (File No. 1-00604).
|
|
10.31
|
Walgreen Co. 2002 Executive Deferred Compensation/Capital Accumulation Plan.
|
Incorporated by reference to Exhibit 10(g) to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2002 (File No. 1-00604).
|
10.32
|
Amendment to the Walgreen Co. 2002 et. al. Executive Deferred Compensation/ Capital Accumulation Plans.
|
Incorporated by reference to Exhibit 10.3 to Walgreen Co.’s Quarterly Report on Form 10-Q for the fiscal quarter ended February 28, 2009 (File No. 1-00604).
|
|
10.33
|
Walgreen Co. 2006 Executive Deferred Compensation/Capital Accumulation Plan (effective January 1, 2006).
|
Incorporated by reference to Exhibit 10(b) to Walgreen Co.’s Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2005 (File No. 1-00604).
|
|
10.34
|
Walgreen Co. 2011 Executive Deferred Compensation Plan.
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 12, 2010.
|
|
10.35
|
Amendment No. 1 to the Walgreen Co. 2011 Executive Deferred Compensation Plan.
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on January 19, 2011.
|
|
10.36
|
Walgreens Boots Alliance, Inc. Executive Deferred Profit-Sharing Plan (as amended and restated effective December 31, 2014).
|
Incorporated by reference to Exhibit 10.3 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
|
|
10.37
|
Share Walgreens Stock Purchase/Option Plan (effective October 1, 1992), as amended.
|
Incorporated by reference to Exhibit 10(d) to Walgreen Co.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2003 (File No. 1-00604).
|
|
10.38
|
Share Walgreens Stock Purchase/Option Plan Amendment No. 4 (effective July 15, 2005), as amended.
|
Incorporated by reference to Exhibit 10(h)(ii) to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2005 (File No. 1-00604).
|
|
10.39
|
Share Walgreens Stock Purchase/Option Plan Amendment No. 5 (effective October 11, 2006).
|
Incorporated by reference to Exhibit 10(b) to Walgreen Co.’s Quarterly Report on Form 10-Q for the quarter ended November 30, 2006 (File No. 1-00604).
|
|
10.40
|
Walgreen Select Senior Executive Retiree Medical Expense Plan.
|
Incorporated by reference to Exhibit 10(j) to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 1996 (File No. 1-00604).
|
|
10.41
|
Walgreen Select Senior Executive Retiree Medical Expense Plan Amendment No. 1 (effective August 1, 2002).
|
Incorporated by reference to Exhibit 10(a) to Walgreen Co.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2003 (File No. 1-00604).
|
|
10.42
|
Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan (as amended and restated effective December 31, 2014).
|
Incorporated by reference to Exhibit 10.4 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
|
|
10.43
|
Rules of the Alliance Boots 2012 Long Term Incentive Plan, as amended.
|
Incorporated by reference to Exhibit 10.11 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.44
|
Form of Award Agreement for Alliance Boots 2012 Long Term Incentive Plan.
|
Incorporated by reference to Exhibit 10.12 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.45
|
Offer Letter agreement between Stefano Pessina and Walgreens Boots Alliance, Inc.
|
Incorporated by reference to Exhibit 10.29 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
10.46
|
Employment Agreement between Alliance UniChem Plc and George Fairweather, dated March 28, 2002.
|
Incorporated by reference to Exhibit 10.14 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.47
|
Agreement between Alliance Boots plc and George Fairweather, dated July 31, 2006.
|
Incorporated by reference to Exhibit 10.15 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.48
|
Corporate Travel and Expense Support letter Agreement between Walgreens Boots Alliance, Inc. and George Fairweather, dated October 28, 2015.
|
Incorporated by reference to Exhibit 10.54 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.49
|
Employment Agreement between Alliance UniChem Services Limited and Marco Pagni, dated June 1, 2005.
|
Incorporated by reference to Exhibit 10.16 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.50
|
Letter Agreement with Marco Pagni, dated May 14, 2012.
|
Incorporated by reference to Exhibit 10.17 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.51
|
Corporate Travel and Expense Support letter Agreement between Walgreens Boots Alliance, Inc. and Marco Pagni, dated October 28, 2015.
|
Incorporated by reference to Exhibit 10.57 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.52
|
Service Agreement between Boots UK Limited and Alex Gourlay, dated January 29, 2009.
|
Incorporated by reference to Exhibit 10.18 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.53
|
Letter Agreement between Alliance Boots Management Services Limited and Alex Gourlay, dated June 28, 2010.
|
Incorporated by reference to Exhibit 10.19 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.54
|
Employment Agreement between Alliance UniChem Plc and Ornella Barra dated December 10, 2002.
|
Incorporated by reference to Exhibit 10.20 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.55
|
Agreement among Alliance Boots plc, Alliance UniChem Plc and Ornella Barra, dated July 31, 2006.
|
Incorporated by reference to Exhibit 10.21 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.56
|
Novation of Services Agreement among Alliance Boots Holdings Limited, Alliance Boots Management Services MC S.A.M and Ornella Barra, dated June 1, 2013.
|
Incorporated by reference to Exhibit 10.22 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.57
|
Service Agreement between Boots Management Services Limited and Simon Roberts, dated July 11, 2013.
|
Incorporated by reference to Exhibit 10.23 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
10.58
|
Services Agreement between Boots Management Services Limited and Ken Murphy, dated October 1, 2013.
|
Incorporated by reference to Exhibit 10.24 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2015 (File No. 1-36759) filed with the SEC on April 9, 2015.
|
|
10.59
|
drugstore.com, inc., 1998 Stock Plan, as amended.
|
Incorporated by reference to Exhibit 99.1 to Walgreen Co.’s Registration Statement on Form S-8
(File No. 333-174811) filed with the SEC on June 9, 2011.
|
|
10.60
|
drugstore.com, inc., 2008 Equity Incentive Plan, as amended.
|
Incorporated by reference to Exhibit 99.2 to Walgreen Co.’s Registration Statement on Form S-8
(File No. 333-174811) filed with the SEC on June 9, 2011.
|
|
10.61
|
Walgreens Boots Alliance, Inc. Long-Term Global Assignment Relocation Policy
|
Incorporated by reference to Exhibit 10.68 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
10.62
|
Secondment Agreement dated September 27, 2013 between Alliance Boots Management Services Limited and Walgreen Co.
|
Incorporated by reference to Exhibit 10.52 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2013 (File No. 1-00604).
|
|
10.63
|
Assignment Letter dated September 27, 2013 between Alexander Gourlay and Alliance Boots Management Services Ltd.
|
Incorporated by reference to Exhibit 10.53 to Walgreen Co.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2013 (File No. 1-00604).
|
|
10.64
|
Extension, dated January 27, 2016, to Assignment Letter between Alexander Gourlay and Walgreens Boots Alliance Services Limited (formerly Alliance Boots Management Services Ltd.).
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on February 1, 2016.
|
|
10.65
|
Offer letter agreement between Kimberly R. Scardino and Walgreens Boots Alliance, Inc.
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on August 4, 2015.
|
|
10.66
|
Letter agreement dated September 23, 2016 between Simon Roberts and Walgreens Boots Alliance, Inc.
|
Filed herewith.
|
|
10.67
|
Shareholders’ Agreement, dated as of August 2, 2012, by and among Alliance Boots GmbH, AB Acquisition Holdings Limited and Walgreen Co.
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on August 6, 2012.
|
|
10.68
|
Framework Agreement, dated as of March 18, 2013, by and among Walgreen Co., Alliance Boots GmbH and AmerisourceBergen Corporation, including as Annex B-1 thereto, the form of Warrant 1 and, as Annex B-2 thereto, the form of Warrant 2.
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on March 20, 2013.
|
|
10.69
|
Amendment No. 1 dated August 25, 2016 to Warrant 2 issued on March 18, 2013.
|
Incorporated by reference to Exhibits 4.1 and 4.2 to AmerisourceBergen Corporation’s Current Report on Form 8-K (File No. 001-16671), filed on August 25, 2016 and incorporated by reference herein.
|
|
10.70
|
Shareholders Agreement, dated as of March 18, 2013, by and among Walgreen Co., Alliance Boots GmbH and AmerisourceBergen Corporation.
|
Incorporated by reference to Exhibit 10.2 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on March 20, 2013.
|
|
10.71
|
Term Loan Credit Agreement, dated as of November 10, 2014, among Walgreen Co., Walgreens Boots Alliance, Inc., the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent.
|
Incorporated by reference to Exhibit 10.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 12, 2014.
|
10.72
|
Revolving Credit Agreement, dated as of November 10, 2014, among Walgreen Co., Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Bank of America, N.A., as administrative agent.
|
Incorporated by reference to Exhibit 10.2 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on November 12, 2014.
|
|
10.73
|
Bridge Term Loan Credit Agreement, dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and UBS AG, Stamford Branch, as administrative agent.
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on December 21, 2015.
|
|
10.74
|
Amendment, dated as of January 20, 2016, to the Bridge Term Loan Credit Agreement dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and UBS AG, Stamford Branch, as administrative agent.
|
Incorporated by reference to Exhibit 10.7 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 29, 2016 (File No. 1-36759) filed with the SEC on April 5, 2016.
|
|
10.75
|
Term Loan Credit Agreement, dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Bank of America, N.A., as administrative agent.
|
Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on December 21, 2015.
|
|
10.76
|
Amendment, dated as of January 20, 2016, to the Term Loan Credit Agreement, dated as of December 18, 2015, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Bank of America, N.A., as administrative agent.
|
Incorporated by reference to Exhibit 10.9 to Walgreens Boots Alliance, Inc.’s Quarterly Report on Form 10-Q for the quarter ended February 29, 2016 (File No. 1-36759) filed with the SEC on April 5, 2016.
|
|
10.77
|
Term Loan Credit Agreement, dated August 30, 2016, by and between Walgreens Boots Alliance, Inc. and Sumitomo Mitsui Banking Corporation, as lender and administrative agent.
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on August 31, 2016.
|
|
12.
|
Computation of Ratio of Earnings to Fixed Charges.
|
Filed herewith.
|
|
21.
|
Subsidiaries of the Registrant.
|
Filed herewith.
|
|
23.1
|
Consent of Deloitte & Touche LLP.
|
Filed herewith.
|
|
23.2
|
Consent of KPMG LLP.
|
Filed herewith.
|
|
23.3
|
Consent of KPMG LLP.
|
Filed herewith.
|
|
31.1
|
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
Filed herewith.
|
|
31.2
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
Filed herewith.
|
|
32.1
|
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
|
Furnished herewith.
|
|
32.2
|
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
|
Furnished herewith.
|
|
99.1
|
Alliance Boots GmbH audited consolidated financial statements comprised of the Group statements of financial position at March 31, 2014 and 2013, and the related Group income statements, Group statements of comprehensive income, Group statements of changes in equity and Group statements of cash flows for each of the years in the three-year period ended March 31, 2014.
|
Incorporated by reference to Exhibit 99.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604) filed with the SEC on May 15, 2014.
|
99.2
|
Alliance Boots GmbH interim condensed consolidated financial statements comprised of the Group interim consolidated condensed statement of financial position at December 31, 2014 and 2013, and the related Group interim consolidated condensed income statement, Group interim consolidated condensed statement of comprehensive income, Group interim consolidated condensed statement of changes in equity and Group interim consolidated condensed statement of cash flows for each of the nine month periods then ended.
|
Incorporated by reference to Exhibit 99.2 to Walgreens Boots Alliance, Inc.’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015 (File No. 1-36759) filed with the SEC on October 28, 2015.
|
|
101.INS
|
XBRL Instance Document
|
Filed herewith.
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
Filed herewith.
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
Filed herewith.
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
Filed herewith.
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
Filed herewith.
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
Filed herewith.
|
* |
Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Copies of any omitted schedule or exhibit will be furnished supplementally to the SEC upon request.
|
** |
Other instruments defining the rights of holders of long-term debt of the registrant and its consolidated subsidiaries may be omitted from Exhibit 4 in accordance with Item 601(b)(4)(iii)(A) of Regulation S-K. Copies of any such agreements will be furnished supplementally to the SEC upon request.
|
WALGREENS BOOTS ALLIANCE, INC.
|
|||
October 20, 2016
|
By:
|
/s/ George R. Fairweather
|
|
George R. Fairweather
|
|||
Executive Vice President and Global Chief Financial Officer
|
Name
|
Title
|
Date
|
||
/s/ Stefano Pessina
|
Executive Vice Chairman and Chief
|
October 20, 2016
|
||
Stefano Pessina
|
Executive Officer (Principal Executive Officer) and Director
|
|||
/s/ George R. Fairweather
|
Executive Vice President and Global
|
October 20, 2016
|
||
George R. Fairweather
|
Chief Financial Officer (Principal Financial Officer)
|
|||
/s/ Kimberly R. Scardino
|
Senior Vice President, Global Controller
|
October 20, 2016
|
||
Kimberly R. Scardino
|
and Chief Accounting Officer (Principal Accounting Officer)
|
|||
/s/ James A. Skinner
|
Executive Chairman
|
October 20, 2016
|
||
James A. Skinner
|
||||
/s/ Janice M. Babiak
|
Director
|
October 20, 2016
|
||
Janice M. Babiak
|
||||
/s/ David J. Brailer
|
Director
|
October 20, 2016
|
||
David J. Brailer
|
||||
/s/ William C. Foote
|
Director
|
October 20, 2016
|
||
William C. Foote
|
||||
/s/ Ginger L. Graham
|
Director
|
October 20, 2016
|
||
Ginger L. Graham
|
||||
/s/ John A. Lederer
|
Director
|
October 20, 2016
|
||
John A. Lederer
|
||||
/s/ Dominic P. Murphy
|
Director
|
October 20, 2016
|
||
Dominic P. Murphy
|
||||
/s/ Leonard D. Schaeffer
|
Director
|
October 20, 2016
|
||
Leonard D. Schaeffer
|
||||
/s/ Nancy M. Schlichting
|
Director
|
October 20, 2016
|
||
Nancy M. Schlichting
|
Exhibit
No.
|
Description
|
Walgreens Boots Alliance, Inc. Management Incentive Plan (as amended and restated effective July 1, 2016).
|
|
Walgreens Boots Alliance, Inc. 2011 Cash-Based Incentive Plan (as amended and restated effective July 1, 2016).
|
|
Form of Stock Option Award agreement (effective July 2016).
|
|
Form of Stock Option Award agreement under UK Sub-plan (effective July 2016).
|
|
Letter agreement dated September 23, 2016 between Simon Roberts and Walgreens Boots Alliance, Inc.
|
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
Subsidiaries of the Registrant.
|
|
Consent of Deloitte & Touche LLP.
|
|
Consent of KPMG LLP.
|
|
Consent of KPMG LLP.
|
|
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
|
|
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
|
|
101.INS
|
XBRL Instance Document
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
1. |
Purpose: The purpose of the Plan is to provide special incentive and motivation to eligible employees through annual bonuses.
|
2. |
Definitions: Whenever used in the Plan, the following terms shall have the meanings set forth below, unless the context clearly provides otherwise:
|
a. |
The term "Base Salary" shall mean, (i) for U.S. Participants the hourly or salaried base compensation paid during the fiscal year, and any such base salary earned but deferred or reduced pursuant to a Company Section 401(k) plan, or Section 125 plan, or another Company deferral plan, but excluding any incentive or other bonuses, stock purchase discounts, or other fringe benefits or supplementary remuneration; and (ii) for non-U.S. Participants, bonus-eligible base compensation, as defined by Local Rules.
|
b. |
The term "Committee" shall mean the Compensation Committee of the Board of Directors of the Company.
|
c. |
The term "Company" shall mean Walgreens Boots Alliance, Inc., a Delaware corporation, and, as applicable, subsidiaries and affiliates of Walgreens Boots Alliance, Inc. whose employees are eligible to participate in the Plan.
|
d. |
The term “Disability” shall mean total disability as determined by the Committee, consistent with how the Company determines whether termination of employment is upon disability for other benefit plan purposes, and such determination may vary based on Local Rules.
|
e. |
The term "Employee" shall mean any employee of the Company, including, but not limited to, the officers of Walgreens Boots Alliance, Inc. Employee shall not include any person who is not classified as an employee in the common law sense in the records of the Company, even if those records are subsequently determined to have been in error or the person is subsequently reclassified as an employee. For example, no person shall be considered to be an Employee for any period of time during which he or she: (1) is a leased employee; (2) is an independent contractor; or (3) is otherwise not classified as an employee in the records of the Company.
|
f. |
The term "Extraordinary Items" shall mean significant transactions that are different from the typical or customary business transactions and are not expected to occur frequently as determined by the informed professional judgment of the Chief Financial Officer of the Company after taking into consideration all the facts involved in a particular situation and the objectives of the Plan.
|
g. |
The term "Individual Adjustment" shall mean the amount of any increase or reduction in the bonus share that would otherwise be allocated to a Participant; or shall mean any separate individual performance bonus component, as applicable.
|
h. |
The term “Local Rules” shall mean terms and conditions of the Plan applied on a customized basis to all or portions of non-U.S. Participants based on country-specific rules and/or business unit specific rules or practices, as defined, documented and administered at the local business unit level.
|
i. |
The term "Participant" shall mean any Employee who participates in and is eligible to receive incentive compensation pursuant to paragraph 3 of the Plan.
|
j. |
The term "Plan Year" shall mean the fiscal year of Walgreens Boots Alliance, Inc., which runs from September 1 to the following August 31, or such other 12-month period as may be designated by the Committee.
|
k. |
The term “Retirement” shall mean termination of employment from the Company in good standing, as determined by the Committee or its delegates, and after having attained at least age 55 and at least 10 years of continuous service; or as may otherwise be defined based on Local Rules.
|
3. |
Eligibility and Participation: The Committee shall have the authority and discretion to determine the class or classes of Employees eligible to participate in the Plan for any Plan Year. As of the effective date of this amended and restated Plan, the following categories of Employees shall be eligible to participate in the Plan:
|
a. |
Any Walgreens U.S. Employee whose job position is within the Analysis pay band and above or its equivalent and is not covered by another Company management incentive plan;
|
b. |
Any non-U.S. Employee of the Company whose position is in the Company’s executive level 7 (or its equivalent) or above; and
|
c. |
Any other Employee who is approved for participation by the Committee, based on the recommendation of Company management that he or she is in a position to make a substantial contribution to the success of the Company by exceptional service in a supervisory or staff position.
|
4. |
Determination of Bonuses: Participant bonuses for each Plan Year shall be determined as follows:
|
a. |
Prior to the beginning of the Plan Year, or as early in the Plan Year as is practical considering the circumstances, management will recommend for Committee approval the bonus structure and accompanying details for that Plan Year. Such recommendation shall cover the following areas and any other pertinent bonus provisions:
|
(1) |
The class or class of employees eligible to participate in the Plan for such Plan Year.
|
(2) |
The performance measure or measures upon which bonuses shall be based, and the extent to which such measures shall be based on overall Company, division, or business unit performance, or some combination thereof. The application of such performance measures may vary among different categories of Participants.
|
(3) |
Target bonus levels (typically expressed as a percentage of Base Salary), threshold and maximum bonus levels (typically expressed as a percentage of the target bonus level), and the corresponding Company performance measure or measures. Such bonus levels may vary for different groups of Participants as determined by the Committee.
|
(4) |
Any Individual Adjustments that may be applied, whether based on pre-established individual performance measures or determined on a discretionary basis.
|
b. |
After the end of each Plan Year when the computations and accounting determinations required to determine Plan bonuses have been completed, the highest-ranking accounting officer of the Company will report to the Committee that in his or her opinion those computations and accounting determinations were made in reasonable accordance with the terms of the Plan, and generally accepted accounting principles, subject to any adjustments provided for under the terms of paragraph 4c of the Plan and the certifications provided for under the terms of this paragraph 4b.
|
c. |
In the event that the Company experiences any Extraordinary Items, the Chief Financial Officer, in consultation with the Chief Human Resources Officer, will recommend to the Committee, whether such Extraordinary Items will be included in or excluded from the determination of the Company’s financial performance measure or measures used in determining the bonus for the Plan Year.
|
d. |
The bonuses earned by Participants under the terms of the Plan will be paid to Participants after the first meeting of the Board of Directors which follows the end of the applicable Plan Year, but in no event later than the date by which such bonuses must be paid in order to be allowed as a Federal income tax deduction for the fiscal year coinciding with such Plan Year.
|
5. |
Participation for Partial Plan Years:
|
a. |
Any Plan Participant whose employment with the Company terminates during a Plan Year for reasons other than Retirement, Disability or death shall not be eligible for a bonus for that Plan Year. Notwithstanding the foregoing, Company management may recommend to the Committee for its approval a discretionary bonus for any terminated Participant if in the judgment of management such a discretionary bonus is warranted.
|
b. |
Any Plan Participant whose employment with the Company terminates during a Plan Year due to Retirement, Disability or death shall be eligible for a pro-rated bonus for such Plan Year, based on Base Salary earned while a Participant in the Plan prior to such termination of employment.
|
c. |
A Participant who is eligible for a bonus hereunder for a portion of a Plan Year (due to hire, promotion or transfer during that Plan Year), shall generally be eligible for a bonus under this Plan based on Base Salary earned during the eligible portion of the Plan Year. Notwithstanding the foregoing, the bonus amount payable to a Participant who is hired within the Plan Year, moves to a different target bonus level during the Plan Year, or receives payment under another Company incentive plan during the current or prior year, shall be subject to the discretion of the Committee and its delegates.
|
d. |
Subject to the end-of-year employment requirement set forth in paragraph 5a above, a Plan Participant who is on a Company-approved leave of absence (other than a Personal Leave of absence) for a portion of a Plan Year shall remain eligible for a bonus for up to the first six months of such leave of absence. Any short-term disability pay during any such leave of absence shall be included in such Participant’s bonusable Base Salary.
|
e. |
The foregoing provisions of this paragraph 5 are subject to any Local Rules as may apply in determining (i) bonus eligibility for Employees who are hired or transferred during the Plan Year, or for Participants who terminate employment during the Play Year or prior to the bonus payment date; and (ii) bonusable Base Salary determinations for those who are Participants for partial Plan Years due to hire, transfer or termination, and for Participants who are on Company-approved leaves of absence during the Plan Year.
|
6. |
Administration. Subject to the terms of the Plan and the powers granted to the full Board of Directors, the Committee has ultimate authority and responsibility for the administration of the Plan. The Committee shall have all powers necessary to administer the Plan, including, without limitation, the power to interpret the provisions of the Plan, to decide all questions of eligibility, to establish rules and forms for the administration of the Plan, and to delegate specific duties and responsibilities to officers or other employees of the Company. All determinations, interpretations, rules, and decisions of the Committee with respect to any question arising out of or in connection with the administration, interpretation and application of the Plan and the rules and regulations promulgated hereunder shall be final, conclusive and binding upon all persons having or claiming to have any interest or right under the Plan.
|
7. |
Indemnification. The Company shall indemnify the members of the Committee, the other members of the Board of Directors and all Company officers and other employees responsible for administering the Plan against any and all liabilities arising by reason of any act or failure to act made in good faith in accordance with the provisions of the Plan. For this purpose, liabilities include expenses reasonably incurred in the defense of any claim relating to the Plan.
|
8. |
Amendment and Termination. The Plan may be amended from time to time or terminated at any time by the Board of Directors of Walgreens Boots Alliance, Inc., or the Compensation Committee thereof to the extent so delegated by the Board of Directors.
|
9. |
General Plan Provisions:
|
a. |
In addition to bonuses determined and paid pursuant to paragraph 4 hereof, nothing in this Plan is intended to limit the authority of the Committee (i) to award additional discretionary bonuses to one or more senior executives of the Company as the Committee deems appropriate from time to time and/or to (ii) approve additional discretionary bonus pools to the to be allocated among Participants as determined by the Committee.
|
b. |
The impact of the payment of bonuses under the Plan on Participants’ other Company employee benefits shall be based on the governing terms of such other employee benefit plans and programs, or as determined by the Committee or its delegates, where necessary.
|
c. |
Neither the existence of the Plan nor any substantive aspect of the Plan shall give any Participant the right to continued employment with the Company for any period of time or shall interfere with the right of the Company to discipline or discharge a Participant at any time.
|
d. |
The Company shall withhold from any bonus payment made pursuant to the Plan any taxes required to be withheld from such payment under local, state or federal law.
|
e. |
Bonuses otherwise payable hereunder may be paid on a deferred basis pursuant to any deferred compensation program that may be implemented with Committee approval in compliance with the requirements of Internal Revenue Code Section 409A and the regulations thereunder.
|
f. |
The Company shall not be required to fund or otherwise segregate any cash or other assets for purposes of meeting its obligations under the Plan.
|
g. |
The provisions of the Plan shall be construed and interpreted according to the laws of the State of Illinois, except as preempted by federal law.
|
h. |
A Participant shall not have any right to pledge, hypothecate, anticipate or in any way create a lien upon any amounts provided under this Plan and no benefits payable hereunder shall be assignable in anticipation of payment either by voluntary or involuntary acts, or by operation of law.
|
i. |
The Plan shall be binding upon the Company and any successor of the Company, including without limitation any corporation or other entity acquiring directly or indirectly all or substantially all of the assets of the Company whether by merger, consolidation, sale or otherwise. Such successor shall thereafter be deemed the "Company" for the purposes of the Plan.
|
Article 1. Establishment, Purpose, and Duration
|
1
|
Article 2. Definitions
|
1
|
Article 3. Administration
|
6
|
Article 4. Eligibility and Participation
|
7
|
Article 5. Awards
|
7
|
Article 6. Awards Not Assignable or Transferable
|
8
|
Article 7. Performance Measures
|
9
|
Article 8. Beneficiary Designation
|
10
|
Article 9. Rights of Participants
|
10
|
Article 10. Change of Control
|
11
|
Article 11. Amendment and Termination
|
11
|
Article 12. Reporting and Withholding
|
12
|
Article 13. Successors
|
12
|
Article 14. General Provisions
|
12
|
Article 1.
|
Establishment, Purpose, and Duration
|
Article 2.
|
Definitions
|
2.1 |
“Affiliate” means any entity (a) which, directly or indirectly, is controlled by, controls, or is under common control with the Company, or (b) in which the Company has a significant entity interest, in either case as determined by the Committee, and which is designated by the Committee as such for purposes of the Plan.
|
2.2 |
Not used.
|
2.3 |
“Award” means, individually or collectively, a grant to a Participant under an Award Agreement of any Cash-Based Award, subject to the terms of this Plan.
|
2.4 |
“Award Agreement” means either: (a) a written or electronic agreement entered into by the Company and a Participant setting forth the terms and provisions applicable to an Award granted under this Plan, including any amendment or modification thereof, or (b) a written or electronic statement issued by the Company to a Participant describing the terms and provisions of such Award, including any amendment or modification thereof. The Committee may provide for the use of electronic, Internet, or other non-paper Award Agreements, and the use of electronic, Internet, or other non-paper means for the acceptance thereof and actions thereunder by a Participant.
|
2.5 |
“Beneficial Owner” or “Beneficial Ownership” shall have the meaning ascribed to such terms in Rule 13d-3 of the General Rules and Regulations under the Exchange Act.
|
2.6 |
“Board” or “Board of Directors” means the Board of Directors of the Company.
|
2.7 |
“Cash-Based Award” means a contractual right granted to an Employee under Article 5 entitling such Participant to receive a cash payment or payments, at such times, and subject to such conditions, as are set forth in this Plan and the applicable Award Agreement.
|
2.8 |
“Cause” means, unless otherwise specified in an Award Agreement or in an applicable employment agreement between the Company and a Participant, with respect to any Participant any of the following:
|
(a) |
Any act that would constitute a material violation of the Company’s material written policies;
|
(b) |
Willfully engaging in conduct materially and demonstrably injurious to the Company, provided, however, that no act or failure to act, on the Participant’s part, shall be considered “willful” unless done, or omitted to be done, by the Participant not in good faith and without reasonable belief that such action or omission was in the best interest of the Company;
|
(c) |
Being indicted for, or if charged with but not indicted for, being tried for (i) a crime of embezzlement or a crime involving moral turpitude, or (ii) a crime with respect to the Company involving a breach of trust or dishonesty, or (iii) in either case, a plea of guilty or no contest to such a crime;
|
(d) |
Abuse of alcohol in the workplace, use of any illegal drug in the workplace or a presence under the influence of alcohol or illegal drugs in the workplace;
|
(e) |
Failure to comply in any material respect with the Foreign Corrupt Practices Act, the Securities Act of 1933, the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, and the Truth in Negotiations Act, or any rules and regulations issued thereunder; and
|
(f) |
Failure to follow the lawful directives of the Company’s Chief Executive Officer, the President or the Board of Directors.
|
2.9 |
“Change of Control” means:
|
(a) |
An acquisition after the date hereof by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") of beneficial ownership (within the meaning of Rule 13d−3 promulgated under the Exchange Act) of twenty percent (20%) or more of either (a) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (b) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); excluding, however, the following: (1) any acquisition directly from the Company, other than an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from the Company or approved by the Incumbent Board (as defined below), (2) any acquisition by the Company, (3) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any entity controlled by the Company, (4) any acquisition by an underwriter temporarily holding Company securities pursuant to an offering of such securities, or (5) any acquisition pursuant to a transaction which complies with clauses (1), (2), and (3) of subsection (c) below; or
|
(b) |
A change in the composition of the Board such that the individuals who, as of the Effective Date of the Plan, constitute the Board (such Board shall be hereinafter referred to as the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, for purposes of this Section, that any individual who becomes a member of the Board subsequent to the effective date of the Plan, whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of those individuals who are members of the Board and who were also members of the Incumbent Board (or deemed to be such pursuant to this proviso), either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination shall be considered as though such individual were a member of the Incumbent Board; but, provided further, that any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board shall not be so considered as a member of the Incumbent Board; or
|
(c) |
Consummation of a reorganization, merger, or consolidation (or similar transaction), a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity ("Corporate Transaction"); in each case, unless immediately following such Corporate Transaction (i) all or substantially all of the individuals and entities who are the Beneficial Owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Corporate Transaction will beneficially own, directly or indirectly, more than fifty percent (50%) of, respectively, the outstanding shares of common stock, and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Corporate Transaction (including, without limitation, a corporation which, as a result of such transaction, owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Corporate Transaction, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (other than the Company, any employee benefit plan (or related trust) of the Company or such corporation resulting from such Corporate Transaction) will beneficially own, directly or indirectly, twenty percent (20%) or more of, respectively, the outstanding shares of common stock of the corporation resulting from such Corporate Transaction or the combined voting power of the outstanding voting securities of such corporation entitled to vote generally in the election of directors, except to the extent that such ownership existed prior to the Corporate Transaction, and (iii) individuals who were members of the Incumbent Board at the time of the Board's approval of the execution of the initial agreement providing for such Corporate Transaction will constitute at least a majority of the members of the board of directors of the corporation resulting from such Corporate Transaction; or
|
(d) |
The approval by the shareholders of the Company of a complete liquidation or dissolution of the Company;
|
2.10 |
“Code” means the U.S. Internal Revenue Code of 1986, as amended from time to time. For purposes of this Plan, references to sections of the Code shall be deemed to include references to any applicable regulations thereunder and any successor or similar provision.
|
2.11 |
“Committee” means the Compensation Committee of the Board or a subcommittee thereof, or any other committee designated by the Board to administer this Plan. The members of the Committee shall be appointed from time to time by and shall serve at the discretion of the Board and shall be composed of not less than two Directors, each of whom is a nonemployee director (within the meaning of Rule 16b-3) and an outside director (within the meaning of Code Section 162(m)) to the extent Rule 16b-3 and Section 162(m) of the Code, respectively, are applicable to the Company and the Plan. If the Committee does not exist or cannot function for any reason, the Board may take any action under the Plan that would otherwise be the responsibility of the Committee.
|
2.12 |
“Company” means Walgreens Boots Alliance, Inc., a Delaware corporation, and any successor thereto as provided in Article 13 herein.
|
2.13 |
“Covered Employee” means any Employee who is or may become a “Covered Employee,” as defined in Code Section 162(m), and who is designated, either as an individual Employee or class of Employees, by the Committee within the shorter of: (a) ninety (90) days after the beginning of the Performance Period provided the outcome for the Performance Period is substantially uncertain, or (b) twenty-five percent (25%) of the Performance Period has elapsed, as a “Covered Employee” under this Plan for such applicable Performance Period.
|
2.14 |
“Director” means any individual who is a member of the Board of Directors of the Company.
|
2.15 |
“Disability” shall mean disability as determined by the Committee in accordance with standards and procedures similar to those under the applicable Company long-term disability plan, if any. At any time that the Company does not maintain an applicable long-term disability plan, “Disability” shall mean any physical or mental disability which is determined to be total and permanent by a physician selected or relied upon in good faith by the Company.
|
2.16 |
“Effective Date” has the meaning set forth in Section 1.1.
|
2.17 |
“Employee” means any individual performing services for the Company, an Affiliate, or a Subsidiary, including but not limited to officers, and designated as an employee of the Company, an Affiliate, or a Subsidiary on the payroll records thereof. An Employee shall not include any individual during any period he or she is classified or treated by the Company, Affiliate, or Subsidiary as an independent contractor, a consultant, or any employee of an employment, consulting, or temporary agency or any other entity other than the Company, Affiliate, or Subsidiary, without regard to whether such individual is subsequently determined to have been, or is subsequently retroactively reclassified as a common-law employee of the Company, Affiliate, or Subsidiary during such period. An individual shall not cease to be an Employee in the case of: (a) any leave of absence approved by the Company, or (b) transfers between locations of the Company or between the Company, any Affiliates, or any Subsidiaries. A leave of absence may continue so long as the Employee is on military leave, sick leave, or other bona fide leave of absence if the period of such leave does not exceed six (6) months, or if longer, so long as the Participant retains a right to reemployment with the Company, a Subsidiary, or an Affiliate under an applicable statute or by contract. Neither service as a Director nor payment of a Director’s fee by the Company shall be sufficient to constitute "employment" by the Company.
|
2.18 |
“Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.
|
2.19 |
“Extraordinary Items” means (a) extraordinary, unusual, nonrecurring and/or infrequently occurring items of gain or loss; (b) gains or losses on the disposition of a business; (c) changes in tax or accounting regulations or laws; or (d) the effect of a merger or acquisition, all of which must be identified in the audited financial statements, including footnotes, or Management Discussion and Analysis section of the Company’s annual report.
|
2.20 |
“Grant Date” means the date an Award is granted to a Participant pursuant to the Plan.
|
2.21 |
“Participant” means any eligible individual as set forth in Article 4 to whom an Award is granted.
|
2.22 |
“Performance-Based Compensation” means compensation under an Award that is intended to satisfy the requirements of Code Section 162(m) for certain performance-based compensation paid to Covered Employees. Notwithstanding the foregoing, nothing in this Plan shall be construed to mean that an Award which does not satisfy the requirements for performance-based compensation under Code Section 162(m) does not constitute performance-based compensation for other purposes, including Code Section 409A.
|
2.23 |
“Performance Measures” mean measures as described in Article 7 on which the performance goals are based and which are approved by the Company’s shareholders pursuant to this Plan in order to qualify Awards as Performance-Based Compensation.
|
2.24 |
“Performance Period” means the period of time, as determined by the Committee, during which the performance goals must be met in order to determine the degree of payout with respect to an Award.
|
2.25 |
“Person” has the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including a “group” as defined in Section 13(d) thereof.
|
2.26 |
“Plan” means the Walgreens Boots Alliance, Inc. 2011 Cash-Based Incentive Plan (formerly the Walgreen Co. 2011 Cash-Based Incentive Plan).
|
2.27 |
“Plan Year” means the Company’s fiscal year, which begins September 1 and ends August 31.
|
2.28 |
“Service” means a Participant’s employment relationship with the Company, an Affiliate, or a Subsidiary.
|
2.29 |
“Share” means a share of common stock of the Company, $0.01 par value per share.
|
2.30 |
“Specified Employee” means a “specified employee” within the meaning of Code Section 409A and any specified employee identification policy or procedure of the Company.
|
2.31 |
“Subsidiary” means any corporation or other entity, whether domestic or foreign, in which the Company has or obtains, directly or indirectly, an interest of more than fifty percent (50%) by reason of stock ownership or otherwise.
|
2.32 |
“Termination of Employment” or “Terminates Employment” means a separation from Service of a Participant, within the meaning of Code Section 409A.
|
Article 3.
|
Administration
|
(a) |
To determine from time to time which of the persons eligible under the Plan shall be granted Awards, when and how each Award shall be granted, what type or combination of types of Awards shall be granted, the provisions of each Award granted (which need not be identical);
|
(b) |
To construe and interpret the Plan and Awards granted under it, and to establish, amend, and revoke rules and regulations for its administration. The Committee, in the exercise of this power, may correct any defect, omission, or inconsistency in the Plan or in an Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective;
|
(c) |
To approve forms of Award Agreements for use under the Plan;
|
(d) |
To amend the Plan or any Award Agreement as provided in the Plan;
|
(e) |
To adopt subplans and/or special provisions applicable to Awards regulated by the laws of a jurisdiction other than and outside of the United States. Such subplans and/or special provisions may take precedence over other provisions of the Plan, but unless otherwise superseded by the terms of such subplans and/or special provisions, the provisions of the Plan shall govern; and
|
(f) |
To authorize any person to execute on behalf of the Company any instrument required to effectuate any Award previously granted by the Committee.
|
Article 4.
|
Eligibility and Participation
|
Article 5.
|
Awards
|
Article 6.
|
Awards Not Assignable or Transferable
|
Article 7.
|
Performance Measures
|
(a) |
Net earnings, net income, or consolidated net income (before or after taxes);
|
(b) |
Earnings per Share;
|
(c) |
Net sales or revenue growth;
|
(d) |
Achievement of balance sheet or income statement objectives;
|
(e) |
Gross, pre-tax, post-tax, or net operating profit;
|
(f) |
Return measures (including, but not limited to, return on assets, capital, invested capital, equity, sales, or revenue);
|
(g) |
Cash flow (including, but not limited to, operating cash flow, discounted cash flow, cumulative cash flow, free cash flow, cash flow return on equity, and cash flow return on investment);
|
(h) |
Earnings (based on either LIFO or FIFO accounting for inventories), before or after taxes, interest, depreciation, and/or amortization;
|
(i) |
Gross, net or operating margins;
|
(j) |
Productivity ratios;
|
(k) |
Share price (including, but not limited to, growth measures and total shareholder return);
|
(l) |
Expense targets;
|
(m) |
Costs (including cost reduction or savings);
|
(n) |
Performance against operating budget goals;
|
(o) |
Operating profit or efficiency;
|
(p) |
Unit sales volume;
|
(q) |
Market or category share;
|
(r) |
Customer satisfaction;
|
(s) |
Working capital targets;
|
(t) |
Improvements in financial ratings;
|
(u) |
Regulatory compliance;
|
(v) |
Extent to which strategic and/or business goals are met;
|
(w) |
Total return to shareholders equity (including both the market value of the Company’s Shares and dividends thereon); and,
|
(x) |
Economic value added or EVA (net operating profit after tax minus the sum of capital multiplied by the cost of capital).
|
Article 8.
|
Beneficiary Designation
|
Article 9.
|
Rights of Participants
|
Article 10.
|
Change of Control
|
(a) |
Performance Goals. Upon a Change of Control, all then-outstanding Awards with performance goals yet to be achieved shall be considered to be earned at target values, or at such value otherwise determined by the terms and conditions set forth in the applicable Award Agreement, and payable at the time set forth in the applicable Award Agreement.
|
(b) |
Awards With Service Requirements. Upon a Participant’s involuntary termination for a reason other than Cause during the two (2) year period following a Change of Control, any Service requirement applicable to then-outstanding Awards shall be considered satisfied.
|
Article 11.
|
Amendment and Termination
|
(a) |
Subject to subparagraph (b) of this Section 11.1 and Section 11.3 of the Plan, the Board may at any time terminate the Plan or an outstanding Award Agreement and the Committee may, at any time and from time to time, amend the Plan or an outstanding Award Agreement.
|
(b) |
Notwithstanding the foregoing, no amendment of this Plan shall be made without shareholder approval if shareholder approval is required pursuant to rules promulgated by any stock exchange or quotation system on which Shares are listed or quoted or by applicable U.S. state corporate laws or regulations, applicable U.S. federal laws or regulations, and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.
|
Article 12.
|
Reporting and Withholding
|
Article 13.
|
Successors
|
Article 14.
|
General Provisions
|
(a) |
The Committee may specify in an Award Agreement that the Participant’s rights, payments, and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events may include, but shall not be limited to, termination of employment for Cause, termination of the Participant’s provision of services to the Company, Affiliate, or Subsidiary, violation of material Company, Affiliate, or Subsidiary policies, breach of noncompetition, confidentiality, or other restrictive covenants that may apply to the Participant, or other conduct by the Participant that is detrimental to the business or reputation of the Company, any Affiliate, or Subsidiary.
|
(b) |
If any of the Company’s financial statements are required to be restated resulting from errors, omissions, or fraud, the Committee may (in its sole discretion, but acting in good faith) direct that the Company recover all or a portion of any Award granted or paid to a Participant with respect to any fiscal year of the Company the financial results of which are negatively affected by such restatement. The amount to be recovered from the Participant shall be the amount by which the Award exceeded the amount that would have been payable to the Participant had the financial statements been initially filed as restated, or any greater or lesser amount (including, but not limited to, the entire Award) that the Committee shall determine. In no event shall the amount to be recovered by the Company be less than the amount required to be repaid or recovered as a matter of law (including but not limited to amounts that are required to be recovered or forfeited under Section 304 of the Sarbanes-Oxley Act of 2002 or Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010). The Committee shall determine whether the Company shall effect any such recovery: (i) by seeking repayment from the Participant, (ii) by reducing (subject to applicable law and the terms and conditions of the applicable plan, program or arrangement) the amount that would otherwise be payable to the Participant under any compensatory plan, program, or arrangement maintained by the Company, an Affiliate, or any Subsidiary, (iii) by withholding payment of future increases in compensation (including the payment of any discretionary bonus amount) or grants of compensatory awards that would otherwise have been made in accordance with the Company’s otherwise applicable compensation practices, or (iv) by any combination of the foregoing.
|
(a) |
Determine which Affiliates and Subsidiaries shall be covered by this Plan;
|
(b) |
Determine which Employees outside the United States are eligible to participate in this Plan;
|
(c) |
Modify the terms and conditions of any Award granted to Employees outside the United States to comply with applicable foreign laws;
|
(d) |
Establish sub-plans and modify any terms and procedures, to the extent such actions may be necessary or advisable. Any subplans and modifications to Plan terms and procedures established under this Section 14.5 by the Committee shall be attached to this Plan document as appendices; and
|
(e) |
Take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local government regulatory exemptions or approvals.
|
(a) |
The Committee may grant Awards under the Plan that provide for the deferral of compensation within the meaning of Code Section 409A. It is intended that such Awards comply with the requirements of Code Section 409A so that amounts deferred thereunder are not includible in income before actual payment and are not subject to an additional tax of twenty percent (20%) at the time the deferred amounts are no longer subject to a substantial risk of forfeiture.
|
(b) |
Notwithstanding any provision of the Plan or Award Agreement to the contrary, if one or more of the payments or benefits to be received by a Participant pursuant to an Award would constitute deferred compensation subject to Code Section 409A and would cause the Participant to incur any penalty tax or interest under Code Section 409A or any regulations or Treasury guidance promulgated thereunder, the Committee may reform the Plan and Award Agreement to comply with the requirements of Code Section 409A and to the extent practicable maintain the original intent of the Plan and Award Agreement. By accepting an Award under this Plan, a Participant agrees to any amendments to the Award made pursuant to this Section 14.8(b) without further consideration or action.
|
a. |
“Trade Secrets” are a form of intellectual property and may include all tangible and intangible forms and types of financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs or codes, and may in particular include such things as pricing information, business records, software programs, algorithms, inventions, patent applications, and designs and processes not known outside the Company. Trade Secrets may be stored, compiled, memorialized or contained in various forms or media, such as paper, electronic media or transmission (such as disc, email, file transfers, tape, or web site features), all other forms of audio and/or video transfer, or even oral communications.
|
b. |
“Confidential Information” shall include Trade Secrets and, more broadly, any information or material which is not generally known to the public, and which (i) is generated or collected by or utilized in the operations of the Company and relates to the actual or anticipated business of the Company or the Company’s actual or prospective vendors or clients; or (ii) is suggested by or results from any task assigned to me by the Company or work performed by me for or on behalf of the Company or any client of the Company. Confidential Information shall not be considered generally known to the public if revealed improperly to the public by me or others without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company. Confidential Information may take a variety of forms including but not limited to paper, electronic, media or transmission (such as email, file transfers, tape or web site features), and all other forms of audio and/or video transfer. Examples of confidential information include, but are not limited to, customer, referral source, supplier and contractor identification and contacts, confidential information about customers, business relationships, contract terms, pricing and margins, business, marketing and customer plans and strategies, financial data, techniques, formulations, technical know-how, formulae, research, development and production information, processes, designs, architectures, prototypes, models, software, patent applications and plans, projections, proposals, discussion guides, personal or performance information about employees, or legal advice related to the foregoing.
|
(a) |
I will not directly or indirectly, solicit any Restricted Customer for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer. For purposes of this Agreement, “Competing Products or Services” means products or services that are competitive with products or services offered by, developed by, designed by or distributed by the Company to any Restricted Customer, and “Restricted Customer” means any person, company or entity which was a customer, potential customer, vendor, supplier or referral source of the Company and with which I had direct contact or about which I learned confidential information at any time during the last two years of my employment with the Company; and
|
(b) |
I will not, nor will I assist any third party to, directly or indirectly (i) raid, hire, solicit, or attempt to persuade any employee of the Company with whom I currently work or with whom I worked at any point during the last two years preceding the termination of my employment with the Company, and who possesses or had access to confidential information of the Company, to leave the employ of the Company; (ii) interfere with the performance by any such employee of his/her duties for the Company; or (iii) communicate with any such employee for the purposes described in items (i) and (ii) in this paragraph.
|
a. |
Ownership. All Intellectual Property is, shall be and shall remain the exclusive property of the Company. Employee hereby assigns to the Company all right, title and interest, if any, in and to the Intellectual Property; provided, however, that, when applicable, the Company shall own the copyrights in all copyrightable works included in the Intellectual Property pursuant to the "work-made-for-hire" doctrine (rather than by assignment), as such term is defined in the 1976 Copyright Act. All Intellectual Property shall be owned by the Company irrespective of any copyright notices or confidentiality legends to the contrary which may be placed on such works by Employee or by others. Employee shall ensure that all copyright notices and confidentiality legends on all work product authored by Employee or anyone acting on his/her behalf shall conform to the Company's practices and shall specify the Company as the owner of the work. The Company hereby provides notice to Employee that the obligation to assign does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on the Employee's own time, unless (a) the invention relates (i) to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by Employee for the Company.
|
b. |
Keep Records. Employee shall keep and maintain, or cause to be kept and maintained by anyone acting on his/her behalf, adequate and current written records of all Intellectual Property in the form of notes, sketches, drawings, computer files, reports or other documents relating thereto. Such records shall be and shall remain the exclusive property of the Company and shall be available to the Company at all times during the term of this Agreement.
|
c. |
Assistance. Employee shall supply all assistance requested in securing for Company’s benefit any patent, copyright, trademark, service mark, license, right or other evidence of ownership of any such Intellectual Property, and will provide full information regarding any such item and execute all appropriate documentation prepared by Company in applying or otherwise registering, in Company’s name, all rights to any such item or the defense and protection of such Intellectual Property.
|
d. |
Prior Inventions. Employee has disclosed to the Company any continuing obligations to any third party with respect to Intellectual Property. Employee claims no rights to any inventions created prior to his/her employment for which a patent application has not previously been filed, unless he/she has described them in detail on a schedule attached to this Agreement.
|
e. |
Trade Secret Provisions. The provisions in Paragraph 1 with regard to Trade Secrets and the TSA shall apply as well in the context of the parties’ Intellectual Property rights and obligations.
|
(a) |
I agree that the restrictions contained in this Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me.
|
(b) |
Because the Company’s current base of operations is in Illinois and my connections thereto, (i) this Agreement shall be governed by and construed in accordance with the laws of the State of Illinois, where this Agreement is entered into, without giving effect to any conflict of law provisions, and (ii) I consent to personal jurisdiction and the exclusive jurisdiction of the state and federal courts of Illinois with respect to any claim, dispute or declaration arising out of this Agreement.
|
(c) |
In the event of a breach or a threatened breach of this Agreement, I acknowledge that the Company will face irreparable injury which may be difficult to calculate in dollar terms and that the Company shall be entitled, in addition to all remedies otherwise available in law or in equity, to temporary restraining orders and preliminary and final injunctions enjoining such breach or threatened breach in any court of competent jurisdiction without the necessity of posting a surety bond, as well as to obtain an equitable accounting of all profits or benefits arising out of any violation of this Agreement.
|
(d) |
I agree that if a court determines that any of the provisions in this Agreement is unenforceable or unreasonable in duration, territory, or scope, then that court shall modify those provisions so they are reasonable and enforceable, and enforce those provisions as modified.
|
(e) |
If any phrase or provision of this Agreement is declared invalid or unenforceable by a court of competent jurisdiction, that phrase, clause or provision shall be deemed severed from this Agreement, and will not affect the enforceability of any other provisions of this Agreement, which shall otherwise remain in full force and effect.
|
(f) |
Notwithstanding the foregoing provisions of this Agreement, the non-competition provisions of Paragraph 2 above shall not restrict Employee from performing legal services as a licensed attorney for a Competing Business to the extent that the attorney licensure requirements in the applicable jurisdiction do not permit Employee to agree to the otherwise applicable restrictions of Paragraph 2.
|
(g) |
Waiver of any of the provisions of this Agreement by the Company in any particular instance shall not be deemed to be a waiver of any provision in any other instance and/or of the Company’s other rights at law or under this Agreement.
|
(h) |
I agree that the Company may assign this Agreement to its successors and assigns and that any such successor or assign may stand in the Company’s shoes for purposes of enforcing this Agreement.
|
(i) |
I agree to reimburse the Company for all attorneys’ fees, costs, and expenses that it reasonably incurs in connection with enforcing its rights and remedies under this Agreement, but only to the extent the Company is ultimately the prevailing party in the applicable legal proceedings.
|
(j) |
If I violate this Agreement, then the restrictions set out in Paragraphs 2 - 6 shall be extended by the same period of time as the period of time during which the violation(s) occurred.
|
(k) |
I fully understand my obligations in this Agreement, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.
|
a) |
The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean superintendence of securities and insurance;
|
b) |
The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean superintendence of securities and insurance, and therefore such securities are not subject to its oversight;
|
c) |
The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean superintendence of securities and insurance; and
|
d) |
The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
|
a) |
La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la superintendencia de valores y seguros chilena;
|
b) |
La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la superintendencia de valores y seguros chilena, por lo que tales valores no están sujetos a la fiscalización de ésta;
|
c) |
Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
|
d) |
Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente.
|
a. |
“Trade Secrets” are a form of intellectual property and may include all tangible and intangible forms and types of financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs or codes, and may in particular include such things as pricing information, business records, software programs, algorithms, inventions, patent applications, and designs and processes not known outside the Company. Trade Secrets may be stored, compiled, memorialized or contained in various forms or media, such as paper, electronic media or transmission (such as disc, email, file transfers, tape, or web site features), all other forms of audio and/or video transfer, or even oral communications.
|
b. |
“Confidential Information” shall include Trade Secrets and, more broadly, any information or material which is not generally known to the public, and which (i) is generated or collected by or utilized in the operations of the Company and relates to the actual or anticipated business of the Company or the Company’s actual or prospective vendors or clients; or (ii) is suggested by or results from any task assigned to me by the Company or work performed by me for or on behalf of the Company or any client of the Company. Confidential Information shall not be considered generally known to the public if revealed improperly to the public by me or others without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company. Confidential Information may take a variety of forms including but not limited to paper, electronic, media or transmission (such as email, file transfers, tape or web site features), and all other forms of audio and/or video transfer. Examples of confidential information include, but are not limited to, customer, referral source, supplier and contractor identification and contacts, confidential information about customers, business relationships, contract terms, pricing and margins, business, marketing and customer plans and strategies, financial data, techniques, formulations, technical know-how, formulae, research, development and production information, processes, designs, architectures, prototypes, models, software, patent applications and plans, projections, proposals, discussion guides, personal or performance information about employees, or legal advice related to the foregoing.
|
(a) |
I will not directly or indirectly, solicit any Restricted Customer for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer. For purposes of this Agreement, “Competing Products or Services” means products or services that are competitive with products or services offered by, developed by, designed by or distributed by the Company to any Restricted Customer, and “Restricted Customer” means any person, company or entity which was a customer, potential customer, vendor, supplier or referral source of the Company and with which I had direct contact or about which I learned confidential information at any time during the last two years of my employment with the Company; and
|
(b) |
I will not, nor will I assist any third party to, directly or indirectly (i) raid, hire, solicit, or attempt to persuade any employee of the Company with whom I currently work or with whom I worked at any point during the last two years preceding the termination of my employment with the Company, and who possesses or had access to confidential information of the Company, to leave the employ of the Company; (ii) interfere with the performance by any such employee of his/her duties for the Company; or (iii) communicate with any such employee for the purposes described in items (i) and (ii) in this paragraph.
|
a. |
Ownership. All Intellectual Property is, shall be and shall remain the exclusive property of the Company. Employee hereby assigns to the Company all right, title and interest, if any, in and to the Intellectual Property; provided, however, that, when applicable, the Company shall own the copyrights in all copyrightable works included in the Intellectual Property pursuant to the "work-made-for-hire" doctrine (rather than by assignment), as such term is defined in the 1976 Copyright Act. All Intellectual Property shall be owned by the Company irrespective of any copyright notices or confidentiality legends to the contrary which may be placed on such works by Employee or by others. Employee shall ensure that all copyright notices and confidentiality legends on all work product authored by Employee or anyone acting on his/her behalf shall conform to the Company's practices and shall specify the Company as the owner of the work. The Company hereby provides notice to Employee that the obligation to assign does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on the Employee's own time, unless (a) the invention relates (i) to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by Employee for the Company.
|
b. |
Keep Records. Employee shall keep and maintain, or cause to be kept and maintained by anyone acting on his/her behalf, adequate and current written records of all Intellectual Property in the form of notes, sketches, drawings, computer files, reports or other documents relating thereto. Such records shall be and shall remain the exclusive property of the Company and shall be available to the Company at all times during the term of this Agreement.
|
c. |
Assistance. Employee shall supply all assistance requested in securing for Company’s benefit any patent, copyright, trademark, service mark, license, right or other evidence of ownership of any such Intellectual Property, and will provide full information regarding any such item and execute all appropriate documentation prepared by Company in applying or otherwise registering, in Company’s name, all rights to any such item or the defense and protection of such Intellectual Property.
|
d. |
Prior Inventions. Employee has disclosed to the Company any continuing obligations to any third party with respect to Intellectual Property. Employee claims no rights to any inventions created prior to his/her employment for which a patent application has not previously been filed, unless he/she has described them in detail on a schedule attached to this Agreement.
|
e. |
Trade Secret Provisions. The provisions in Paragraph 1 with regard to Trade Secrets and the TSA shall apply as well in the context of the parties’ Intellectual Property rights and obligations.
|
(a) |
I agree that the restrictions contained in this Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me.
|
(b) |
Because the Company’s current base of operations is in Illinois and my connections thereto, (i) this Agreement shall be governed by and construed in accordance with the laws of the State of Illinois, where this Agreement is entered into, without giving effect to any conflict of law provisions, and (ii) I consent to personal jurisdiction and the exclusive jurisdiction of the state and federal courts of Illinois with respect to any claim, dispute or declaration arising out of this Agreement.
|
(c) |
In the event of a breach or a threatened breach of this Agreement, I acknowledge that the Company will face irreparable injury which may be difficult to calculate in dollar terms and that the Company shall be entitled, in addition to all remedies otherwise available in law or in equity, to temporary restraining orders and preliminary and final injunctions enjoining such breach or threatened breach in any court of competent jurisdiction without the necessity of posting a surety bond, as well as to obtain an equitable accounting of all profits or benefits arising out of any violation of this Agreement.
|
(d) |
I agree that if a court determines that any of the provisions in this Agreement is unenforceable or unreasonable in duration, territory, or scope, then that court shall modify those provisions so they are reasonable and enforceable, and enforce those provisions as modified.
|
(e) |
If any phrase or provision of this Agreement is declared invalid or unenforceable by a court of competent jurisdiction, that phrase, clause or provision shall be deemed severed from this Agreement, and will not affect the enforceability of any other provisions of this Agreement, which shall otherwise remain in full force and effect.
|
(f) |
Notwithstanding the foregoing provisions of this Agreement, the non-competition provisions of Paragraph 2 above shall not restrict Employee from performing legal services as a licensed attorney for a Competing Business to the extent that the attorney licensure requirements in the applicable jurisdiction do not permit Employee to agree to the otherwise applicable restrictions of Paragraph 2.
|
(g) |
Waiver of any of the provisions of this Agreement by the Company in any particular instance shall not be deemed to be a waiver of any provision in any other instance and/or of the Company’s other rights at law or under this Agreement.
|
(h) |
I agree that the Company may assign this Agreement to its successors and assigns and that any such successor or assign may stand in the Company’s shoes for purposes of enforcing this Agreement.
|
(i) |
I agree to reimburse the Company for all attorneys’ fees, costs, and expenses that it reasonably incurs in connection with enforcing its rights and remedies under this Agreement, but only to the extent the Company is ultimately the prevailing party in the applicable legal proceedings.
|
(j) |
If I violate this Agreement, then the restrictions set out in Paragraphs 2 - 6 shall be extended by the same period of time as the period of time during which the violation(s) occurred.
|
(k) |
I fully understand my obligations in this Agreement, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.
|
a) |
The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean superintendence of securities and insurance;
|
b) |
The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean superintendence of securities and insurance, and therefore such securities are not subject to its oversight;
|
c) |
The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean superintendence of securities and insurance; and
|
d) |
The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
|
a) |
La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la superintendencia de valores y seguros chilena;
|
b) |
La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la superintendencia de valores y seguros chilena, por lo que tales valores no están sujetos a la fiscalización de ésta;
|
c) |
Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
|
d) |
Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente.
|
|
|
Boots Support Office
1 Thane Road
Beeston
Nottingham
NG90 1BS
|
1. |
As discussed, you have confirmed (and we have agreed) that your employment with Boots Management Services Limited (“the Company”) terminated on 15 July 2016 (“the Termination Date”). You acknowledge and accept that you were paid your contractual salary and benefits up to and including that date (less such deductions for tax and social security contributions as the Company was required to make by law) pursuant to your Executive Service Agreement with the Company (“your Executive Service Agreement”). There will be no further accrual, payments or payments in lieu of contractual salary or benefits after the Termination Date save as expressly stated below.
|
2. |
To the extent not already reimbursed, the Company shall reimburse any expenses reasonably incurred by you in the proper performance of your duties in accordance with the Company’s expenses policy.
|
3.
|
To the extent not already returned on or before the Termination Date, you will return all Company property in your possession or under your control including but not limited to all Company cars, laptops, mobile telephones, keys, security cards, credit cards, books, documents, papers, materials, computer discs and software and any copies thereof (whether in human readable or machine readable form).4.As your employment came to an end before the date of payment of any FY16 annual bonus, no bonus shall be payable to you under that scheme.
|
5. |
I confirm that you will also forfeit all awards under the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (“the Plan”) in accordance with the Plan rules.
|
6. |
Subject to paragraph 9 below, the Company hereby confirms that it has exercised its discretion pursuant to clause 12.5 of your Executive Service Agreement and shall make a payment to you in lieu of your basic salary under clause 3.2 thereof (less such deductions as the Company is required to make by law) (“the Notice Payment”) for the unexpired 12 months of the notice period.
|
7. |
Subject to paragraph 8 below and to any other written agreement that may be reached between us concerning the same, the post-termination obligations contained in clause 16 of your Executive Service Agreement shall remain in full force and effect and shall be immediately effective from the Termination Date.
|
8. |
In consideration of the Notice Payment it is agreed that those organisations listed below and their holding companies and subsidiaries and the subsidiaries of any such holding companies from time to time shall replace the list of organisations set out in Schedule 2 of your Executive Service Agreement:
|
· |
Ahold
|
· |
Asda
|
· |
A.S.Watson
|
· |
Celesio
|
· |
Cerp Rouen
|
· |
CVS
|
· |
John Lewis or Waitrose
|
· |
Marks & Spencer
|
· |
Mediq (formerly known as OPG)
|
· |
Morrisons
|
· |
Noweda
|
· |
Optical Express
|
· |
Phoenix Healthcare
|
· |
Sanacorp
|
· |
Specsavers
|
· |
Superdrug
|
· |
Tesco
|
· |
UK-based Co-operative Societies
|
· |
Vision Express
|
· |
WalMart
|
· |
Well+ Pharmacy
|
9. |
The Notice Payment will be paid to you in equal monthly instalments, commencing in the calendar month immediately after the Termination Date, until such time as you secure alternative employment or for a period of 12 months (whichever is earlier). For the purposes of this paragraph, “alternative employment” means any office, appointment, employment or self-employment under the terms of a contract of service or contract for services or otherwise.
|
10. |
Notwithstanding any other rights the Company may have against you, if you breach any provision of paragraph 8 above you acknowledge and agree to repay to the Company a sum equivalent to all gross payments made to you pursuant to paragraph 6 above and you agree that such sum is recoverable from you by the Company as a debt.
|
11.
|
You will resign (to the extent that you have not already done so) as an Officer of Walgreens Boots Alliance, Inc. from all and any directorships held in the Company and its Associated Companies in the form attached with immediate effect from the Termination Date.
|
12.
|
In this letter, “Associated Companies” means in relation to a company its holding companies and subsidiaries and the subsidiaries of any such holding companies from time to time.
|
13.
|
This letter together with any other written agreement between us following the Termination Date contains the entire agreement between the parties in relation to its subject matter and supersedes any prior arrangement, understanding written or oral agreements between the parties in relation to such subject matter.
|
14.
|
The existence, effect and interpretation of this letter shall be governed by the laws of England and the parties submit to the non-exclusive jurisdiction of the courts of England.
|
Signed |
/s/ Simon Roberts
|
Dated |
26th September 2016
|
Boots Management Services Limited. Registered office: 1 Thane Road West, Nottingham, NG2 3AA
Registered in England & Wales: Number 7073438
|
|
|
Member of Walgreens Boots Alliance
|
|
2016
|
2015
|
2014
|
2013
|
2012
|
2011
|
|||||||||||||||||||
Income before income tax provision
|
$
|
5,144
|
$
|
5,311
|
$
|
3,557
|
$
|
4,047
|
$
|
3,376
|
$
|
4,294
|
||||||||||||
Add:
|
||||||||||||||||||||||||
Minority Interests
|
-
|
-
|
-
|
5
|
-
|
-
|
||||||||||||||||||
Fixed charges
|
2,367
|
2,054
|
1,376
|
1,383
|
1,260
|
1,212
|
||||||||||||||||||
Amortization of capitalized interest
|
-
|
1
|
6
|
7
|
6
|
5
|
||||||||||||||||||
Less:
|
||||||||||||||||||||||||
Equity earnings
|
(37
|
)
|
(315
|
)
|
(617
|
)
|
(496
|
)
|
-
|
-
|
||||||||||||||
Capitalized interest
|
-
|
(1
|
)
|
(6
|
)
|
(7
|
)
|
(9
|
)
|
(10
|
)
|
|||||||||||||
Earnings as defined
|
$
|
7,474
|
$
|
7,050
|
$
|
4,316
|
$
|
4,939
|
$
|
4,633
|
$
|
5,501
|
||||||||||||
Interest expense, net of capitalized interest
|
$
|
628
|
$
|
632
|
$
|
168
|
$
|
193
|
$
|
94
|
$
|
77
|
||||||||||||
Capitalized interest
|
-
|
1
|
6
|
7
|
9
|
10
|
||||||||||||||||||
Portions of rentals representative of the interest factor
|
1,739
|
1,421
|
1,202
|
1,183
|
1,157
|
1,125
|
||||||||||||||||||
Fixed charges as defined
|
$
|
2,367
|
$
|
2,054
|
$
|
1,376
|
$
|
1,383
|
$
|
1,260
|
$
|
1,212
|
||||||||||||
Ratio of earnings to fixed charges
|
3.16
|
3.43
|
3.14
|
3.57
|
3.68
|
4.54
|
Name
|
State or Country
of Incorporation
|
Smart Insurance Company
|
Arizona
|
Walgreen Arizona Drug Co.
|
Arizona
|
Consolidated Stores, Inc.
|
Arkansas
|
Pharm-Mart Pharmacy of Warren, Inc.
|
Arkansas
|
S & W Pharmacy, Inc.
|
Arkansas
|
Stephen L. LaFrance Pharmacy, Inc.
|
Arkansas
|
Superior Bermuda GP
|
Bermuda
|
Casa Saba Brasil Holdings, Ltda
|
Brazil
|
Distrilife, Distribuidora Atacadista de Suplementos Alimenticios, Ltda
|
Brazil
|
Brandhandling International Limited
|
British Virgin Islands
|
Sunamerica Affordable Housing Partners XI, a California Limited Partnership
|
California
|
DS Distribution Canada Ltd.
|
Canada
|
Walgreen Drug (Ontario) Limited
|
Canada
|
AB Acquisitions FX Pref Limited
|
Cayman Islands
|
AB Property Holdings Limited
|
Cayman Islands
|
Ontario CI 1 Limited
|
Cayman Islands
|
Ontario CI 2 Limited
|
Cayman Islands
|
Ontario CI 3 Limited
|
Cayman Islands
|
Ontario CI 4 Limited
|
Cayman Islands
|
Walgreen Asia Holding Ltd.
|
Cayman Islands
|
WBAD CI 1 Limited
|
Cayman Islands
|
WBAD CI 2 Limited
|
Cayman Islands
|
ABF, Administradora de Beneficios Farmacéuticos S.A.
|
Chile
|
Administradora Fasa, S.A.
|
Chile
|
Comercial Farmacéutica S.A.
|
Chile
|
Comercializadora y Distribuidora BF S.A.
|
Chile
|
Compañía de Nutrición General S.A.
|
Chile
|
Droguería, Distribuidora y Logística DLI S.A.
|
Chile
|
Farmacias Ahumada S.A.
|
Chile
|
Fasa Investment Limitada
|
Chile
|
Inmobiliaria Gestión Punto Retail S.A.
|
Chile
|
Inversiones Internacionales Inverfar S.A.
|
Chile
|
Laboratorios MDK S.A.
|
Chile
|
Walgreen Asia Trading Ltd.
|
China
|
Walgreens China Business Trust
|
China
|
Alliance Healthcare s.r.o.
|
Czech Republic
|
Boots Retail Holdings (USA) Inc.
|
Delaware
|
Boots Retail USA Inc.
|
Delaware
|
CG Transportation, LLC
|
Delaware
|
Cystic Fibrosis Foundation Pharmacy, LLC
|
Delaware
|
DR Employee Services, LLC
|
Delaware
|
DRI I Inc.
|
Delaware
|
DS Pharmacy, Inc.
|
Delaware
|
Duane Reade Holdings, Inc.
|
Delaware
|
Duane Reade Inc.
|
Delaware
|
Duane Reade International, LLC
|
Delaware
|
East West Distributing Co., LLC
|
Delaware
|
Happy Harry's Discount Drug Stores, Inc.
|
Delaware
|
Happy Harry's, Inc.
|
Delaware
|
Healthcare Clinic Solutions, LLC
|
Delaware
|
Lake Cook Investments, LLC
|
Delaware
|
Pharma Dynamics, Inc.
|
Delaware
|
S&G US Holding LLC
|
Delaware
|
SIC Parent, LLC
|
Delaware
|
Smart Insurance Company Holdings, Inc.
|
Delaware
|
Smart Insurance Group Holdings, Inc
|
Delaware
|
Soap & Glory USA LLC
|
Delaware
|
Stephen L. LaFrance Holdings, Inc.
|
Delaware
|
Super D Drugs Acquisition Co.
|
Delaware
|
Take Care Health Systems, LLC
|
Delaware
|
WAGDCO, LLC
|
Delaware
|
WAGHID, LLC
|
Delaware
|
Walgreen International Investments LLC
|
Delaware
|
Walgreen Investments Co
|
Delaware
|
Walgreens Boots Alliance Holdings LLC
|
Delaware
|
Walgreens Boots Alliance, Inc.
|
Delaware
|
Walgreens Network Health Services, LLC
|
Delaware
|
Walgreens of North Carolina, Inc.
|
Delaware
|
Walgreens Sleep and Respiratory Services, LLC
|
Delaware
|
Walgreens Specialty Care Centers, LLC
|
Delaware
|
Walgreens Specialty Pharmacy Holdings, Inc.
|
Delaware
|
Walgreens Specialty Pharmacy, LLC
|
Delaware
|
Walgreens Venture Capital, LLC
|
Delaware
|
Waltrust Properties, Inc.
|
Delaware
|
WBA Financial, Inc
|
Delaware
|
WBA Investments, Inc.
|
Delaware
|
Well Ventures, LLC
|
Delaware
|
WRA Partners, LLC
|
Delaware
|
Alcura France SAS
|
France
|
Alliance Healthcare Formation SAS
|
France
|
Alliance Healthcare France SA (AHF)
|
France
|
Alliance Healthcare Group France SAS
|
France
|
Alliance Healthcare Répartition SAS
|
France
|
Alloga France SAS
|
France
|
Almus France SAS
|
France
|
Alphega SA
|
France
|
BCM Cosmetique SAS
|
France
|
Directlog SAS
|
France
|
Serex SAS
|
France
|
Skills in Healthcare France SAS
|
France
|
WBA France Finance SAS
|
France
|
acadicPharm GmbH
|
Germany
|
Alliance Healthcare Deutschland AG
|
Germany
|
Alliance Healthcare Deutschland Holdings 1 GmbH
|
Germany
|
ANZAG Rostock GmbH & Co. KG
|
Germany
|
ANZAG Rostock Grundstucks-Verwaltungsgesellschaft mbH
|
Germany
|
AS Logistik GmbH
|
Germany
|
BCM Kosmetik GmbH
|
Germany
|
CPL Pharma Lager und Vertrieb GmbH
|
Germany
|
GESDAT Gesellschaft fur Informationsmanagement mbH
|
Germany
|
Skills in Healthcare GmbH Deutschland
|
Germany
|
Soap & Glory GmbH
|
Germany
|
vitasco GmbH
|
Germany
|
Walgreen of Hawaii, LLC
|
Hawaii
|
Walgreen of Maui, Inc.
|
Hawaii
|
AA Asia Limited
|
Hong Kong
|
Alliance Boots Sourcing (Hong Kong) Limited
|
Hong Kong
|
Alliance Healthcare Asia Pacific Limited
|
Hong Kong
|
Alliance Healthcare Hong Kong Limited
|
Hong Kong
|
Walgreens (Hong Kong) Limited
|
Hong Kong
|
Bond Drug Company of Illinois, LLC
|
Illinois
|
Bowen Development Company
|
Illinois
|
Deerfield Funding Corporation
|
Illinois
|
Medication Adherence Solutions, LLC
|
Illinois
|
The 1901 Group, LLC
|
Illinois
|
The Patient Safety Research Foundation, Inc.
|
Illinois
|
Victoria Merger Sub, Inc.
|
Illinois
|
Walgreen Co.
|
Illinois
|
Walgreen Medical Supply, LLC
|
Illinois
|
Walgreen Mercantile Corporation
|
Illinois
|
Walgreen National Corporation
|
Illinois
|
Walgreen Pharmacy Services Midwest, LLC
|
Illinois
|
Walgreen Realty Resources LLC
|
Illinois
|
Walgreens Business Services, LLC
|
Illinois
|
Walgreens Community Development Corporation
|
Illinois
|
Walgreens Mail Service, Inc
|
Illinois
|
Walgreens Pharmacy Strategies, LLC
|
Illinois
|
Walgreens Store No. 7839, LLC
|
Illinois
|
Walgreens.com, Inc
|
Illinois
|
AB Acquisitions (Ireland) 2 Limited
|
Ireland
|
AB Acquisitions (Ireland) Limited
|
Ireland
|
Alliance Healthcare Limited
|
Ireland
|
Boots Retail (Ireland) Limited
|
Ireland
|
Woodglen Properties Limited
|
Ireland
|
Alliance Healthcare Italia (IT Services) Srl
|
Italy
|
Boots Contact Lenses Limited
|
Jersey
|
Armila UAB
|
Lithuania
|
Ramuneles Vaistine UAB
|
Lithuania
|
Walgreen Louisiana Co., Inc.
|
Louisiana
|
AB Acquisitions Luxco 1 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 2 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 2A S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 3 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 3A S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 4 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 5 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 5A S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 6 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 7 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 8 S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 8A S.à r.l.
|
Luxembourg
|
AB Acquisitions Luxco 9 S.à r.l.
|
Luxembourg
|
Alliance Boots Luxco Property Company S.à r.l.
|
Luxembourg
|
Alliance Boots Luxembourg S.à r.l.
|
Luxembourg
|
Alloga S.à r.l.
|
Luxembourg
|
Superior Luxco 1 S.à r.l.
|
Luxembourg
|
Superior Luxco 2 S.à r.l.
|
Luxembourg
|
Superior Luxco 3 S.à r.l.
|
Luxembourg
|
Walgreen Asia Services S.à r.l.
|
Luxembourg
|
Walgreen International S.à r.l.
|
Luxembourg
|
Walgreen Investments Luxembourg SCS
|
Luxembourg
|
Cystic Fibrosis Services, Inc.
|
Maryland
|
Eager Park Pharmacy and Health Services, LLC
|
Maryland
|
Walgreens of Massachusetts, LLC
|
Massachusetts
|
Benavides de Reynosa, S.A. de C.V.
|
Mexico
|
Comercializadora y Servicios Benavides, S.A. de C.V.
|
Mexico
|
Farmacias ABC de Mexico, S.A. de C.V.
|
Mexico
|
Farmacias Benavides S.A.B. de C.V.
|
Mexico
|
Servicios Generales Benavides, S.A. de C.V.
|
Mexico
|
Servicios Logisticos Benavides, S.A. de C.V.
|
Mexico
|
Servicios Operacionales Benavides, S.A. de C.V.
|
Mexico
|
Walgreens Boots Alliance Services MC S.A.M.
|
Monaco
|
Walgreen Hastings Co.
|
Nebraska
|
AB Acquisitions Nederland Holdco 1 B.V.
|
Netherlands
|
Alliance Boots B.V.
|
Netherlands
|
Alliance Healthcare Management Services (Nederland) B.V.
|
Netherlands
|
Alliance Healthcare Nederland B.V.
|
Netherlands
|
Alloga (Nederland) B.V.
|
Netherlands
|
Boots Nederland B.V.
|
Netherlands
|
Euro Registratie Collectief B.V.
|
Netherlands
|
Hedef International Holdings BV
|
Netherlands
|
Kring apotheek B.V.
|
Netherlands
|
Spits B.V.
|
Netherlands
|
Stephar B.V.
|
Netherlands
|
Duane Reade
|
New York
|
Walgreen Eastern Co., Inc.
|
New York
|
Walgreens Store No. 3288, LLC
|
New York
|
Alliance Healthcare Norge AS
|
Norway
|
Boots Norge AS
|
Norway
|
Snipetjernveien 10 AS
|
Norway
|
May's Drug Stores, Inc.
|
Oklahoma
|
Med-X Corporation
|
Oklahoma
|
M-X Corporation
|
Oklahoma
|
Alliance Santé - Distribuição Farmacêutica de Eulália Baeta Pereira e Ramalho Fernandes, S.A.
|
Portugal
|
Walgreen of Puerto Rico, Inc.
|
Puerto Rico
|
Walgreen of San Patricio, Inc.
|
Puerto Rico
|
FARMEXPERT D.C.I. SRL
|
Romania
|
Skills in Healthcare Romania S.r.l.
|
Romania
|
Boots Singapore Private Limited
|
Singapore
|
Alcura Health España, S.A.
|
Spain
|
Alliance Healthcare España Holdings, S.L.
|
Spain
|
Alliance Healthcare España S.A.
|
Spain
|
Alloga Logistica (España), S.L.
|
Spain
|
Almus Farmaceutica, S.A.
|
Spain
|
Centro Farmaceutico Asturiano, S.A.
|
Spain
|
Nexiapharma, S.L.
|
Spain
|
AH Schweiz GmbH
|
Switzerland
|
Alliance Boots GmbH
|
Switzerland
|
Alliance Boots Schweiz Investments GmbH
|
Switzerland
|
Alliance Boots Services GmbH
|
Switzerland
|
Walgreen Swiss International GmbH
|
Switzerland
|
Walgreens Boots Alliance Development GmbH
|
Switzerland
|
Aromatherapy Associates, Inc
|
Texas
|
Globe Stores, Inc.
|
Texas
|
Vision Direct Inc.
|
Texas
|
Boots Retail (Thailand) Limited
|
Thailand
|
Alliance Healthcare Ecza Deposu Anonim Şirketi (fka Hedef Ecza Deposu Ticaret A.S.)
|
Turkey
|
Alliance Healthcare Turkey Holding A.S.
|
Turkey
|
Alliance Healthcare Yatırım Holding Anonim Şirketi (fka Hedef - Alliance Holding A.S.)
|
Turkey
|
Esko Itriyat Sanayi ve Ticaret Anonim Sirketi
|
Turkey
|
Nareks Ecza Deposu Ticaret Anonim Şirketi
|
Turkey
|
Skills in Healthcare Pazarlama ve Tanıtım Hizmetleri Anonim Şirketi
|
Turkey
|
AB Acquisitions FX Inter Limited
|
United Kingdom
|
AB Acquisitions UK Holdco 2 Limited
|
United Kingdom
|
AB Acquisitions UK Holdco 5 Limited
|
United Kingdom
|
AB Acquisitions UK Holdco 6 Limited
|
United Kingdom
|
AB Acquisitions UK Holdco 7 Limited
|
United Kingdom
|
AB Acquisitions UK Topco Limited
|
United Kingdom
|
Alcura UK Limited
|
United Kingdom
|
Alliance BMP Limited
|
United Kingdom
|
Alliance Boots (Nominees) Limited
|
United Kingdom
|
Alliance Boots Group Limited
|
United Kingdom
|
Alliance Boots Holdings 1 Limited
|
United Kingdom
|
Alliance Boots Holdings 2
|
United Kingdom
|
Alliance Boots Holdings Limited
|
United Kingdom
|
Alliance Boots International Limited
|
United Kingdom
|
Alliance Boots Investments 2 Limited
|
United Kingdom
|
Alliance Boots Latin America Limited
|
United Kingdom
|
Alliance Boots Limited
|
United Kingdom
|
Alliance Boots PropCo A LLP
|
United Kingdom
|
Alliance Boots PropCo B LLP
|
United Kingdom
|
Alliance Boots PropCo Beeston LLP
|
United Kingdom
|
Alliance Boots PropCo C LLP
|
United Kingdom
|
Alliance Boots PropCo Retail Flex LLP
|
United Kingdom
|
Alliance Boots PropCo Unichem Flex LLP
|
United Kingdom
|
Alliance Boots PropCo Unichem LLP
|
United Kingdom
|
Alliance Boots Scottish Limited Partnership
|
United Kingdom
|
Alliance Healthcare (Distribution) Limited
|
United Kingdom
|
Alliance Healthcare (IT Services) Limited
|
United Kingdom
|
Alliance Healthcare Management Services Limited
|
United Kingdom
|
Alliance UniChem Investments 4 Limited
|
United Kingdom
|
Alliance UniChem IP Limited
|
United Kingdom
|
Alliance UniChem PWS JV Limited
|
United Kingdom
|
Alloga UK Limited
|
United Kingdom
|
Almus Pharmaceuticals Limited
|
United Kingdom
|
Aroma Actives Limited
|
United Kingdom
|
Aromatherapy Associates Limited
|
United Kingdom
|
Aromatherapy Investments Holding Limited
|
United Kingdom
|
Aromatherapy Investments Limited
|
United Kingdom
|
B&B Capital Partners (GP) Ltd
|
United Kingdom
|
B&B Capital Partners (SLP GP) Ltd
|
United Kingdom
|
B&B Capital Partners L.P.
|
United Kingdom
|
BCM Employment & Management Services Limited
|
United Kingdom
|
BCM Limited
|
United Kingdom
|
BCM Specials Limited
|
United Kingdom
|
Beachcourse Limited
|
United Kingdom
|
Beeston Site Services Limited
|
United Kingdom
|
Bellpharm Limited
|
United Kingdom
|
Blyth Pharmacy Limited
|
United Kingdom
|
Boots 2 Property Partnership
|
United Kingdom
|
Boots 2 Property Scottish Limited Partnership
|
United Kingdom
|
Boots Benevolent Fund
|
United Kingdom
|
Boots Charitable Trust
|
United Kingdom
|
Boots Delivery Services Limited
|
United Kingdom
|
Boots Development Properties Limited
|
United Kingdom
|
Boots Eyewear Limited
|
United Kingdom
|
Boots International Limited
|
United Kingdom
|
Boots International Management Services Limited
|
United Kingdom
|
Boots Korea Limited
|
United Kingdom
|
Boots Management Services Limited
|
United Kingdom
|
Boots Optical Investment Holdings Limited
|
United Kingdom
|
Boots Opticians Limited
|
United Kingdom
|
Boots Opticians Professional Services Limited
|
United Kingdom
|
Boots Pensions Limited
|
United Kingdom
|
Boots PropCo A Limited
|
United Kingdom
|
Boots PropCo B Limited
|
United Kingdom
|
Boots PropCo Beeston Limited
|
United Kingdom
|
Boots PropCo C Limited
|
United Kingdom
|
Boots Propco D Limited
|
United Kingdom
|
Boots Propco E Limited
|
United Kingdom
|
Boots Propco F Limited
|
United Kingdom
|
Boots PropCo Flex Limited
|
United Kingdom
|
Boots Propco G Limited
|
United Kingdom
|
Boots Propco H Limited
|
United Kingdom
|
Boots PropCo Limited
|
United Kingdom
|
Boots PropCo Retail Flex Limited
|
United Kingdom
|
Boots Properties Limited
|
United Kingdom
|
Boots Property HoldCo Limited
|
United Kingdom
|
Boots Property Partnership
|
United Kingdom
|
Boots Property Scottish Limited Partnership
|
United Kingdom
|
Boots Pure Drug Company Limited
|
United Kingdom
|
Boots The Chemists Limited
|
United Kingdom
|
Boots UK Limited
|
United Kingdom
|
Burrells Limited
|
United Kingdom
|
Burrows & Close Limited
|
United Kingdom
|
Caseview (P.L.) Limited
|
United Kingdom
|
Class Delta Limited
|
United Kingdom
|
D200 Energy Limited
|
United Kingdom
|
DDM Healthcare Limited
|
United Kingdom
|
Dollond & Aitchison Limited
|
United Kingdom
|
E. Moss, Limited
|
United Kingdom
|
Easterhouse Health Centre Pharmacy Limited
|
United Kingdom
|
Gordon's Chemist Limited
|
United Kingdom
|
Govanhill Pharmacy Limited
|
United Kingdom
|
Leamington Spa Properties (Two) Limited
|
United Kingdom
|
Liz Earle Beauty Co. (International) Limited
|
United Kingdom
|
Liz Earle Beauty Co. Limited
|
United Kingdom
|
Ontario Scottish Partnership
|
United Kingdom
|
Ontario UK 2 Limited
|
United Kingdom
|
OTC Direct Limited
|
United Kingdom
|
PhD Acquisition Bidco Limited
|
United Kingdom
|
PhD Acquisition Midco Limited
|
United Kingdom
|
PhD Nutrition Limited
|
United Kingdom
|
S and G Investments Limited
|
United Kingdom
|
Sleek Capital Limited
|
United Kingdom
|
Sleek International Limited
|
United Kingdom
|
Soap & Glory Limited
|
United Kingdom
|
Spa Strategy Limited
|
United Kingdom
|
SportsPlatform Holdco Limited
|
United Kingdom
|
SportsPlatform Midco Limited
|
United Kingdom
|
Sprint Investments 1 Limited
|
United Kingdom
|
Sprint Investments 5 Limited
|
United Kingdom
|
Superior Acquisitions Limited
|
United Kingdom
|
Superior Holdings Limited
|
United Kingdom
|
The Boots Company PLC
|
United Kingdom
|
The Refinery Limited
|
United Kingdom
|
TPW Acquisition Bidco Limited
|
United Kingdom
|
TPW Acquisition Midco Limited
|
United Kingdom
|
UniChem Limited
|
United Kingdom
|
W.H.C.P. (Dundee) Limited
|
United Kingdom
|
Walgreens Boots Alliance Scottish LP
|
United Kingdom
|
Walgreens Boots Alliance Services Limited
|
United Kingdom
|
WBA 1 Scottish LLP
|
United Kingdom
|
WBA 2 Scottish LLP
|
United Kingdom
|
WBA Finance 1 Limited
|
United Kingdom
|
WBA Finance 2 Limited
|
United Kingdom
|
WBA Financial Limited
|
United Kingdom
|
WBA Financial Services Limited
|
United Kingdom
|
WBA UK 1 LLP
|
United Kingdom
|
WBA UK 2 LLP
|
United Kingdom
|
WBA UK 3 LLP
|
United Kingdom
|
WBA UK 4 LLP
|
United Kingdom
|
WBA UK 5 LLP
|
United Kingdom
|
WBA UK 6 LLP
|
United Kingdom
|
WBA UK 7 LLP
|
United Kingdom
|
WBA UK 8 LLP
|
United Kingdom
|
WBA UK Finance Limited
|
United Kingdom
|
WBAD Holdings Limited
|
United Kingdom
|
Walgreen of US Virgin Islands, LLC
|
US Virgin Islands
|
LCA Insurance Co., Inc.
|
Vermont
|
drugstore.com, LLC
|
Washington
|
Walgreen Oshkosh, Inc.
|
Wisconsin
|
1. |
I have reviewed this annual report on Form 10-K of Walgreens Boots Alliance, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c) |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
/s/
|
Stefano Pessina
|
Chief Executive Officer
|
Date: October 20, 2016
|
|
Stefano Pessina
|
1. |
I have reviewed this annual report on Form 10-K of Walgreens Boots Alliance, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c) |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
/s/
|
George Fairweather
|
Global Chief Financial Officer
|
Date: October 20, 2016
|
|
George Fairweather
|
0,Y_@9O
M+?\ [YD",3] :Y94JD/BBU^)JIQ>S.H#5@:#J8!0 4 % 3B@#S_ ,6_$33O
M"F87)N;S&1;Q$9&>AE;I$#UYRY'1".:Z:5"=9W6D>_\ D8RJ*&F[['SSX@^)
M>MZ\2GFFS@/'E6Y*[4G^L;W^95_P!D5[%/#4Z?2[[O_(XY5)2\D>?DC.YC
MR>I)Y/XGDUV)6V_#_(P D+UX^O%'DA["^A['D>X]1[?2F&P=*+ '% "$ ]:
M.KT7QCK/AO:;2>01'I%*#)"P]E?H/>-E/O7-*C3JW32OU<=&O4M3E#9_(][\
M)_%NQUEEM=246-TV K%LP2$]E<\QD]E?CL')XKR*N%E3UA[T?Q.R%52TEHSU
M_(K@N=(M, Z4 >,_$SXAMH _LO36 OI%S))U^SHW3 Z>
Document and Entity Information - USD ($) $ in Billions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Sep. 30, 2016 |
Feb. 29, 2016 |
|
Document and Entity Information [Abstract] | |||
Entity Registrant Name | Walgreens Boots Alliance, Inc. | ||
Entity Central Index Key | 0001618921 | ||
Current Fiscal Year End Date | --08-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Public Float | $ 73.0 | ||
Entity Common Stock, Shares Outstanding | 1,083,282,661 | ||
Document Fiscal Year Focus | 2016 | ||
Document Fiscal Period Focus | FY | ||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Aug. 31, 2016 |
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares |
Aug. 31, 2016 |
Aug. 31, 2015 |
---|---|---|
Shareholders' Equity | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized (in shares) | 32,000,000 | 32,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, authorized (in shares) | 3,200,000,000 | 3,200,000,000 |
Common stock, issued (in shares) | 1,172,513,618 | 1,172,513,618 |
Treasury stock, issued (in shares) | 89,527,027 | 82,603,274 |
CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Millions |
Common Stock [Member] |
Treasury Stock Amount [Member] |
Pain-In Capital [Member] |
Employee Stock Loan Receivable [Member] |
Accumulated Other Comprehensive Income (Loss) [Member] |
Retained Earnings [Member] |
Noncontrolling Interests [Member] |
Total |
---|---|---|---|---|---|---|---|---|
Beginning Balance at Aug. 31, 2013 | $ 80 | $ (3,114) | $ 1,074 | $ (11) | $ (92) | $ 21,621 | $ 0 | $ 19,558 |
Beginning Balance (in shares) at Aug. 31, 2013 | 946,595,578 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | $ 0 | 0 | 0 | 0 | 0 | 1,932 | 99 | 2,031 |
Other comprehensive income (loss), net of tax | 0 | 0 | 0 | 0 | 228 | 0 | 0 | 228 |
Dividends declared | 0 | 0 | 0 | 0 | 0 | (1,226) | 0 | (1,226) |
Treasury stock purchases | $ 0 | (705) | 0 | 0 | 0 | 0 | 0 | (705) |
Treasury stock purchases (in shares) | (11,810,351) | |||||||
Employee stock purchase and option plans | $ 0 | 622 | (16) | 0 | 0 | 0 | 0 | 606 |
Employee stock purchase and option plans (in shares) | 15,601,662 | |||||||
Stock-based compensation | $ 0 | 0 | 114 | 0 | 0 | 0 | 0 | 114 |
Employee stock loan receivable | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 6 |
Other | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
Ending Balance at Aug. 31, 2014 | $ 80 | (3,197) | 1,172 | (5) | 136 | 22,327 | 104 | 20,617 |
Ending Balance (in shares) at Aug. 31, 2014 | 950,386,889 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | $ 0 | 0 | 0 | 0 | 0 | 4,220 | 59 | 4,279 |
Other comprehensive income (loss), net of tax | 0 | 0 | 0 | 0 | (350) | 0 | (6) | (356) |
Dividends declared | 0 | 0 | 0 | 0 | 0 | (1,458) | 0 | (1,458) |
Exchange of Walgreen Co. shares for Walgreens Boots Alliance, Inc. shares | (69) | 0 | 69 | 0 | 0 | 0 | 0 | 0 |
Issuance of shares for Alliance Boots acquisition | $ 1 | 0 | 10,976 | 0 | 0 | 0 | 0 | 10,977 |
Issuance of shares for Alliance Boots acquisition (in shares) | 144,333,468 | |||||||
Treasury stock purchases | $ 0 | (1,226) | 0 | 0 | 0 | 0 | 0 | (1,226) |
Treasury stock purchases (in shares) | (16,250,190) | |||||||
Employee stock purchase and option plans | $ 0 | 446 | 56 | 0 | 0 | 0 | 0 | 502 |
Employee stock purchase and option plans (in shares) | 11,440,177 | |||||||
Stock-based compensation | $ 0 | 0 | 109 | 0 | 0 | 0 | 0 | 109 |
Acquisition of noncontrolling interest | 0 | 0 | (2,429) | 0 | 0 | 0 | (130) | (2,559) |
Employee stock loan receivable | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
Noncontrolling interests in businesses acquired | 0 | 0 | 0 | 0 | 0 | 0 | 412 | 412 |
Ending Balance at Aug. 31, 2015 | $ 12 | (3,977) | 9,953 | (2) | (214) | 25,089 | 439 | 31,300 |
Ending Balance (in shares) at Aug. 31, 2015 | 1,089,910,344 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | $ 0 | 0 | 0 | 0 | 0 | 4,173 | 18 | 4,191 |
Other comprehensive income (loss), net of tax | 0 | 0 | 0 | 0 | (2,778) | 0 | (56) | (2,834) |
Dividends declared | 0 | 0 | 0 | 0 | 0 | (1,578) | 0 | (1,578) |
Treasury stock purchases | $ 0 | (1,152) | 0 | 0 | 0 | 0 | 0 | (1,152) |
Treasury stock purchases (in shares) | (13,815,558) | |||||||
Employee stock purchase and option plans | $ 0 | 195 | 43 | 0 | 0 | 0 | 0 | 238 |
Employee stock purchase and option plans (in shares) | 6,891,805 | |||||||
Stock-based compensation | $ 0 | 0 | 115 | 0 | 0 | 0 | 0 | 115 |
Employee stock loan receivable | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Ending Balance at Aug. 31, 2016 | $ 12 | $ (4,934) | $ 10,111 | $ (1) | $ (2,992) | $ 27,684 | $ 401 | $ 30,281 |
Ending Balance (in shares) at Aug. 31, 2016 | 1,082,986,591 |
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares |
3 Months Ended | 12 Months Ended | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
May 31, 2016 |
Feb. 29, 2016 |
Nov. 30, 2015 |
Aug. 31, 2015 |
May 31, 2015 |
Feb. 28, 2015 |
Nov. 30, 2014 |
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|||||||||||||
CONSOLIDATED STATEMENTS OF EQUITY [Abstract] | |||||||||||||||||||||||
Cash dividends declared (in dollars per share) | $ 0.3750 | [1] | $ 0.3600 | [1] | $ 0.3600 | [1] | $ 0.3600 | [1] | $ 0.3600 | [1] | $ 0.3375 | [1] | $ 0.3375 | [1] | $ 0.3375 | [1] | $ 1.4550 | [1] | $ 1.3725 | [1] | $ 1.28 | ||
|
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) shares in Millions, $ in Millions |
12 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
||||||||
CONSOLIDATED STATEMENTS OF EARNINGS [Abstract] | ||||||||||
Sales | $ 117,351 | [1] | $ 103,444 | [1] | $ 76,392 | |||||
Cost of sales | 87,477 | 76,691 | 54,823 | |||||||
Gross Profit | 29,874 | [1] | 26,753 | [1] | 21,569 | |||||
Selling, general and administrative expense | 23,910 | 22,400 | 17,992 | |||||||
Equity earnings in AmerisourceBergen | 37 | 0 | 0 | |||||||
Equity earnings in Alliance Boots | 0 | 315 | [2] | 617 | [2] | |||||
Operating Income | 6,001 | 4,668 | 4,194 | |||||||
Gain on previously held equity interest | 0 | 563 | 0 | |||||||
Other income (expense) | (261) | 685 | (481) | |||||||
Earnings Before Interest and Income Tax Provision | 5,740 | 5,916 | 3,713 | |||||||
Interest expense, net | 596 | 605 | 156 | |||||||
Earnings Before Income Tax Provision | 5,144 | 5,311 | 3,557 | |||||||
Income tax provision | 997 | 1,056 | 1,526 | |||||||
Post tax earnings from other equity method investments | 44 | 24 | 0 | |||||||
Net Earnings | 4,191 | 4,279 | 2,031 | |||||||
Net earnings attributable to noncontrolling interests | 18 | 59 | 99 | |||||||
Net Earnings Attributable to Walgreens Boots Alliance, Inc. | $ 4,173 | [1] | $ 4,220 | [1] | $ 1,932 | |||||
Net earnings per common share: | ||||||||||
Basic (in dollars per share) | $ 3.85 | $ 4.05 | $ 2.03 | |||||||
Diluted (in dollars per share) | $ 3.82 | $ 4.00 | $ 2.00 | |||||||
Weighted average common shares outstanding: | ||||||||||
Basic (in shares) | 1,083.1 | 1,043.2 | 953.1 | |||||||
Diluted (in shares) | 1,091.1 | 1,053.9 | 965.2 | |||||||
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract] | |||
Net Earnings | $ 4,191 | $ 4,279 | $ 2,031 |
Other comprehensive income (loss), net of tax: | |||
Pension/postretirement obligations | (241) | 14 | (48) |
Unrealized gain (loss) on cash flow hedges | 3 | (13) | (27) |
Unrecognized gain (loss) on available-for-sale investments | (257) | 152 | 106 |
Share of other comprehensive income (loss) of equity method investments | (1) | 113 | (18) |
Currency translation adjustments | (2,338) | (622) | 215 |
Total Other Comprehensive Income (Loss) | (2,834) | (356) | 228 |
Total Comprehensive Income | 1,357 | 3,923 | 2,259 |
Comprehensive income (loss) attributable to noncontrolling interests | (39) | 53 | 99 |
Comprehensive Income Attributable to Walgreens Boots Alliance, Inc. | $ 1,396 | $ 3,870 | $ 2,160 |
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Cash Flows from Operating Activities | |||
Net Earnings | $ 4,191 | $ 4,279 | $ 2,031 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
Depreciation and amortization | 1,718 | 1,742 | 1,316 |
Change in fair value of warrants and related amortization | 516 | (779) | (385) |
Loss on exercise of call option | 0 | 0 | 866 |
Gain on previously held equity interest | 0 | (563) | 0 |
Deferred income taxes | (442) | (32) | 177 |
Stock compensation expense | 115 | 109 | 114 |
Equity earnings from equity method investments | (81) | (339) | (619) |
Other | 148 | 752 | 183 |
Changes in operating assets and liabilities: | |||
Accounts receivable, net | 115 | (338) | (616) |
Inventories | (644) | 719 | 860 |
Other current assets | 66 | 22 | (10) |
Trade accounts payable | 1,572 | 268 | (339) |
Accrued expenses and other liabilities | 313 | 170 | 195 |
Income taxes | 202 | (335) | 17 |
Other non-current assets and liabilities | 58 | (11) | 103 |
Net cash provided by operating activities | 7,847 | 5,664 | 3,893 |
Cash Flows from Investing Activities | |||
Additions to property, plant and equipment | (1,325) | (1,251) | (1,106) |
Proceeds from sale leaseback transactions | 60 | 867 | 67 |
Proceeds related to the sale of business | 74 | 814 | 93 |
Proceeds from sale of other assets | 155 | 184 | 139 |
Alliance Boots acquisition, net of cash received | 0 | (4,461) | 0 |
Other business and intangible asset acquisitions, net of cash acquired | (126) | (371) | (344) |
Investment in AmerisourceBergen | (2,360) | 0 | (493) |
Other | 5 | (58) | (87) |
Net cash used for investing activities | (3,517) | (4,276) | (1,731) |
Cash Flows from Financing Activities | |||
Proceeds and payments of short-term borrowings, net | 29 | (226) | 0 |
Proceeds from issuance of long-term debt | 5,991 | 12,285 | 0 |
Payments of long-term debt | (791) | (10,472) | (550) |
Proceeds from financing leases | 0 | 0 | 268 |
Stock purchases | (1,152) | (1,226) | (705) |
Proceeds related to employee stock plans | 235 | 503 | 612 |
Cash dividends paid | (1,563) | (1,384) | (1,199) |
Other | (143) | (395) | (48) |
Net cash provided by (used for) financing activities | 2,606 | (915) | (1,622) |
Effect of exchange rate changes on cash and cash equivalents | (129) | (119) | 0 |
Changes in Cash and Cash Equivalents: | |||
Net increase in cash and cash equivalents | 6,807 | 354 | 540 |
Cash and cash equivalents at beginning of period | 3,000 | 2,646 | 2,106 |
Cash and cash equivalents at end of period | $ 9,807 | $ 3,000 | $ 2,646 |
Organization |
12 Months Ended |
---|---|
Aug. 31, 2016 | |
Organization [Abstract] | |
Organization | 1. Organization Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) and its subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale). See Note 18, Segment Reporting for further information. On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. (“Walgreens”) pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the “Reorganization”). Pursuant to the Reorganization, Walgreens became a wholly-owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of the Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. References to the “Company” refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires. On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (“Alliance Boots”) that Walgreens did not previously own (the “Second Step Transaction”) in exchange for £3.133 billion in cash and approximately 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014. |
Summary of Major Accounting Policies |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Major Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Major Accounting Policies | 2. Summary of Major Accounting Policies Basis of Presentation The consolidated financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned companies in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and on various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any period may not be comparable to the same period in previous years. In addition, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion”. In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on the Company’s Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars. To improve comparability, certain classification changes have been made to prior periods to conform to current year classifications. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and all highly liquid investments with an original maturity of three months or less. Credit and debit card receivables from banks, which generally settle within two to seven business days, of $114 million and $165 million were included in cash and cash equivalents at August 31, 2016 and 2015, respectively. Restricted Cash The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. As of August 31, 2016 and 2015, the amount of such restricted cash was $185 million, and $184 million respectively and is reported in Other current assets on the Consolidated Balance Sheets. Accounts Receivable Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily include amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies), clients and members, as well as vendors and manufacturers. Charges to bad debt are based on estimates of recoverability using both historical write-offs and specifically identified receivables. The allowance for doubtful accounts for fiscal 2016, 2015 and 2014 was $166 million, $172 million and $173 million, respectively. Inventory The Company values inventories on a lower of cost or market basis. Inventory includes product costs, inbound freight, direct labor, warehousing costs, overhead costs relating to the manufacture and distribution of products and vendor allowances not classified as a reduction of advertising expense. The Company’s Retail Pharmacy USA segment inventory is accounted for using the last-in-first-out (“LIFO”) method. At August 31, 2016 and 2015, Retail Pharmacy USA segment inventories would have been greater by $2.8 billion and $2.5 billion, respectively, if they had been valued on a lower of first-in-first-out (“FIFO”) cost or market basis. The total carrying value of the segment inventory accounted for under the LIFO method is $6.1 billion and $5.6 billion at August 31, 2016 and 2015, respectively. The Company’s Retail Pharmacy International and Pharmaceutical Wholesale segments’ inventory is accounted for using the FIFO method, except for retail inventory in the Retail Pharmacy International segment, which is primarily determined using the retail inventory method. Under the retail inventory method, cost is determined by applying a calculated cost-to-retail ratio across groupings of similar items. The cost-to-retail ratio is applied to ending inventory at its current owned retail valuation to determine the cost of ending inventory across groupings of similar items. Current owned retail valuation represents the retail price for which merchandise is offered for sale on a regular basis. Inherent in the retail method calculation are certain management judgments and estimates which can impact the owned retail valuation and, therefore, the ending inventory valuation at cost. The total carrying value of the inventory for Retail Pharmacy International and Pharmaceutical Wholesale segments is $2.9 billion and $3.1 billion at August 31, 2016 and 2015, respectively. Equity Method Investments The Company uses the equity method to account for investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company’s proportionate share of the net income or loss of these companies is included in consolidated net earnings. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. See Note 5, Equity Method Investments for further information relating to the Company’s equity method investments. Investments The Company’s investments consist principally of corporate debt, other debt securities, and equity securities of publicly-traded companies. The Company classifies its investments in securities at the time of purchase as held-to-maturity or available-for-sale, and re-evaluates such classifications on a quarterly basis. Held-to-maturity investments consist of debt securities that the Company has the intent and ability to hold until maturity. These securities are recorded at cost, adjusted for the amortization of premiums and discounts, which approximates fair value. Available-for-sale debt and equity securities are recorded at fair value. Unrealized holding gains and losses on available-for-sale investments are excluded from earnings and are reported as a separate component of shareholders’ equity and comprehensive income until realized. Realized gains and losses of available-for-sale investments are included in the Consolidated Statements of Earnings. The Company evaluates these investments for other-than-temporary impairment. Such evaluation involves a variety of considerations, including assessments of the risks and uncertainties associated with general economic conditions and distinct conditions affecting specific issuers. Factors considered by the Company include (i) the length of time and the extent to which the fair value has been below cost; (ii) the financial condition, credit worthiness, and near-term prospects of the issuer; (iii) the length of time to maturity; (iv) future economic conditions and market forecasts; (v) the Company’s intent and ability to retain its investment for a period of time sufficient to allow for recovery of market value; and (vi) an assessment of whether it is more likely than not that the Company will be required to sell its investment before recovery of fair value. Property, Plant and Equipment Depreciation is provided on a straight-line basis over the estimated useful lives of owned assets. Estimated useful lives range from 20 years for land improvements, 3 to 50 for buildings and building improvements and 3 to 20 for fixtures, plant and equipment. Leasehold improvements, equipment under capital lease and capital lease properties are amortized over their respective estimate of useful life or over the term of the lease, whichever is shorter. Major repairs, which extend the useful life of an asset, are capitalized; routine maintenance and repairs are charged against earnings. The majority of the Company’s fixtures and equipment uses the composite method of depreciation. Therefore, gains and losses on retirement or other disposition of such assets are included in earnings only when an operating location is closed, substantially remodeled or impaired. Property, plant and equipment consists of (in millions):
Depreciation expense for property, plant and equipment was $1.3 billion in fiscal 2016, $1.3 billion in fiscal 2015 and $923 million in fiscal 2014. The Company capitalizes application stage development costs for significant internally developed software projects, such as upgrades to the store point-of-sale system. These costs are amortized over a three to eight year period. Amortization expense for capitalized system development costs and software was $238 million in fiscal 2016, $178 million in fiscal 2015 and $127 million in fiscal 2014. Unamortized costs at August 31, 2016 and 2015 were $0.9 billion and $1.0 billion, respectively. Business Combinations Business combinations are accounted for under Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, using the acquisition method of accounting. The cost of an acquired company is assigned to the tangible and intangible assets purchased and the liabilities assumed on the basis of their fair values at the date of acquisition. The determination of fair values of assets and liabilities acquired requires estimates and the use of valuation techniques when a market value is not readily available. Any excess of purchase price over the fair value of net tangible and intangible assets acquired is allocated to goodwill. The final determination of the fair value of certain assets and liabilities is completed within the one year measurement period as allowed under ASC Topic 805, Business Combinations. Transaction costs associated with business combinations are expensed as they are incurred. Goodwill and Other Intangible Assets Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill and intangibles under ASC Topic 350, Intangibles – Goodwill and Other, which requires the Company to test goodwill and other indefinite-lived assets for impairment annually or whenever events or circumstances indicate that impairment may exist. Intangible assets are amortized on a straight line basis over their estimated useful lives. See Note 8, Goodwill and Other Intangible Assets for additional disclosure regarding the Company’s intangible assets. Warrants The warrants to acquire shares of AmerisourceBergen Corporation were accounted for as a derivative under ASC Topic 815, Derivatives and Hedging. The Company reports its warrants at fair value within other non-current assets in the Consolidated Balance Sheets and changes in the fair value of warrants are recognized in other income in the Consolidated Statements of Earnings. A deferred credit from the day-one valuation attributable to the warrants granted to Walgreens was amortized over the life of the warrants. See Note 10, Financial Instruments, for additional disclosure regarding the Company’s warrants. Financial Instruments The Company uses derivative instruments to hedge its exposure to interest rate and currency risks arising from operating and financing activities. In accordance with its risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes. Derivatives are recognized on the Consolidated Balance Sheets at their fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, it formally documents the hedge relationship and the risk management objective for undertaking the hedge which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The accounting for changes in fair value of a derivative instrument depends on whether the Company had designated it in a qualifying hedging relationship and further, on the type of hedging relationship. The Company applies the following accounting policies:
Cash receipts or payments on a settlement of a derivative contract are reported in the Consolidated Statements of Cash Flows consistent with the nature of the underlying hedged item. For derivative instruments designated as hedges, the Company assesses, both at the hedge’s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. Highly effective means that cumulative changes in the fair value of the derivative are between 80% and 125% of the cumulative changes in the fair value of the hedged item. In addition, when the Company determines that a derivative is not highly effective as a hedge, hedge accounting is discontinued. When it is probable that a hedged forecasted transaction will not occur, the Company discontinues hedge accounting for the affected portion of the forecasted transaction, and reclassifies any gains or losses in accumulated other comprehensive income (loss) to earnings in the Consolidated Statement of Earnings. When a derivative in a hedge relationship is terminated or the hedged item is sold, extinguished or terminated, hedge accounting is discontinued prospectively. Impaired Assets The Company tests long-lived assets for impairment whenever events or circumstances indicate that a certain asset may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the assets to the fair value, which is based on the discounted estimated future cash flows. Impairment charges included in selling, general and administrative expenses were $305 million in fiscal 2016, primarily related to the Company’s Cost Transformation Program (as defined below). Impairment charges recognized in fiscal 2015 and 2014 were $386 million and $167 million, respectively. Liabilities for Store Closings The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. The reserve for store closings, including $91 million from locations closed under the Company’s restructuring actions, was $466 million as of August 31, 2016 and $446 million as of August 31, 2015. See Note 4, Leases for additional disclosure regarding the Company’s reserve for future costs related to closed locations. Pension and Postretirement Benefits The Company has various defined benefit pension plans that cover some of its foreign employees. The Company also has postretirement healthcare plans that cover qualifying domestic employees. Eligibility and the level of benefits for these plans vary depending participants’ status, date of hire and or length of service. Pension and postretirement expenses and valuations are dependent on assumptions used by third party actuaries in calculating those amounts. These assumptions include discount rates, healthcare cost trends, long-term return on plan assets, retirement rates, mortality rates and other factors. See Note 15, Retirement Benefits, for additional disclosure regarding the Company’s pension and postretirement benefits. The Company funds its pension plans in accordance with applicable regulations. Noncontrolling Interests The Company accounts for its less than 100% interest in consolidated subsidiaries in accordance with ASC Topic 810, Consolidation, and accordingly, the Company presents noncontrolling interests as a component of equity on its Consolidated Balance Sheets and reports the noncontrolling interest net earnings or loss as Net earnings attributable to noncontrolling interests in the Consolidated Statement of Earnings. Currency Assets and liabilities of non-U.S. dollar functional currency operations are translated into U.S. dollars at end-of-period exchange rates while revenues, expenses and cash flows are translated at average monthly exchange rates over the period. Equity is translated at historical exchange rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. For U.S. dollar functional currency operations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Revenues and expenses are recorded at average monthly exchange rates over the period, except for those expenses related to nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Gains or losses from foreign currency remeasurement and transactions are included in selling, general and administrative expenses within the Consolidated Statements of Earnings. For all periods presented, there were no material operational gains or losses from foreign currency transactions. Revenue Recognition Revenue is recognized when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured. The following revenue recognition policies have been established for the Company’s reportable segments. Retail Pharmacy USA and Retail Pharmacy International The Company recognizes revenue at the time the customer takes possession of the merchandise, after making appropriate adjustments for estimated returns. Revenue does not include sales related taxes. In certain international locations, the Company initially estimates revenue based on expected reimbursements from governmental agencies for dispensing prescription drugs and providing optical services. The estimates are based on historical experience and are updated to actual reimbursement amounts. Pharmaceutical Wholesale Wholesale revenue is recognized upon shipment of goods, which is generally also the day of delivery. When the Company acts in the capacity of an agent or a logistics service provider, revenue is the fee received for the service and is recognized when the services have been performed. The Company has determined it is the agent when providing logistics services, which is based on its assessment of the following criteria: (i) whether it is the primary obligor in the arrangement, (ii) whether it has latitude in establishing the price, changing the product or performing part of the service, (iii) whether it has discretion in supplier selection, (iv) whether it is involved in the determination of service specifications, and (v) whether it is exposed to credit risk. Cost of Sales Cost of sales includes the purchase price of goods and services sold, store and warehouse inventory loss, inventory obsolescence, manufacturing costs, certain direct product design and development costs and supplier rebates. In addition to product costs, cost of sales includes manufacturing costs, warehousing costs for retail operations, purchasing costs, freight costs, cash discounts and vendor allowances. Cost of sales for our Retail Pharmacy USA segment is derived based upon point-of-sale scanning information with an estimate for shrinkage and is adjusted based on periodic inventory counts. Vendor Allowances and Supplier Rebates Vendor allowances are principally received as a result of purchases, sales or promotion of vendors’ products. Allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. Those allowances received for promoting vendors’ products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising costs incurred, with the excess treated as a reduction of inventory costs. Rebates or refunds received by the Company from its suppliers, mostly in cash, are considered as an adjustment of the prices of the supplier’s products purchased by the Company. Selling, General and Administrative Expenses Selling, general and administrative expenses mainly consist of salaries and employee costs, occupancy costs, depreciation and amortization, credit and debit card fees and expenses directly related to stores. In addition, other costs included are headquarters’ expenses, advertising costs (net of vendor advertising allowances), wholesale warehousing costs and insurance. Advertising Costs Advertising costs, which are reduced by the portion funded by vendors, are expensed as incurred or when services have been received. Net advertising expenses, which are included in selling, general and administrative expenses, were $598 million in fiscal 2016, $491 million in fiscal 2015 and $265 million in fiscal 2014. Points Earned Through Loyalty Programs The Company’s primary rewards programs. Balance® Rewards and Boots Advantage Card, are accrued as a charge to cost of sales at the time a point is earned. Points are funded internally and through vendor participation, and are credited to cost of sales at the time a vendor-sponsored point is earned. Breakage is recorded as points expire as a result of a member’s inactivity or if the points remain unredeemed after three years. Breakage income, which is reported in cost of sales, was not significant in fiscal 2016, 2015 or 2014. Insurance The Company obtains insurance coverage for catastrophic exposures as well as those risks required by law to be insured. In general, the Company’s U.S. subsidiaries retain a significant portion of losses related to workers’ compensation, property, comprehensive general, pharmacist and vehicle liability, while non-U.S. subsidiaries manage their exposures through insurance coverage with third-party carriers. Management regularly reviews the probable outcome of claims and proceedings, the expenses expected to be incurred, the availability and limits of the insurance coverage, and the established accruals for liabilities. Liabilities for losses are recorded based upon the Company’s estimates for both claims incurred and claims incurred but not reported and are not discounted. The provisions are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. Stock Compensation Plans In accordance with ASC Topic 718, Compensation – Stock Compensation, the Company recognizes compensation expense on a straight-line basis over the employee’s vesting period or to the employee’s retirement eligible date, if earlier. See Note 14, Stock Compensation Plans for more information on the Company’s stock-based compensation plans. Income Taxes The Company accounts for income taxes according to the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to tax laws using rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. In determining the provision for income taxes, the Company uses income, permanent differences between book and tax income, the relative proportion of foreign and domestic income, enacted statutory income tax rates, projections of income subject to Subpart F rules and unrecognized tax benefits related to current year results. Discrete events such as the assessment of the ultimate outcome of tax audits, audit settlements, recognizing previously unrecognized tax benefits due to lapsing of the applicable statute of limitations, recognizing or de-recognizing benefits of deferred tax assets due to future year financial statement projections and changes in tax laws are recognized in the period in which they occur. The Company is subject to routine income tax audits that occur periodically in the normal course of business. U.S. federal, state, local and foreign tax authorities raise questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. In evaluating the tax benefits associated with the various tax filing positions, the Company records a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more likely than not to be realized. Adjustments are made to the liability for unrecognized tax benefits in the period in which the Company determines the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available. Earnings Per Share The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. Outstanding options to purchase common shares that were anti-dilutive and excluded from earnings per share totaled 2.5 million, 2.5 million and 3.5 million in fiscal 2016, 2015 and 2014, respectively. New Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (“FASB) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the effect this ASU will have on our consolidated statement of cash flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. This ASU is effective for fiscal years beginning after December 15, 2019 (fiscal 2021), including interim periods within those fiscal years, with early adoption permitted. The Company does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position. In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the employee share-based payment accounting of stock compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term must be applied prospectively. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement must be applied retrospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. This ASU is effective for annual periods after December 15, 2016 (fiscal 2018), and interim periods within those fiscal years, with early adoption permitted. The Company is early adopting this guidance at the beginning of Fiscal 2017 and does not expect adoption will have a material impact on the Company's results of operations, cash flows or financial position. In March 2016, the FASB issued ASU 2016-04, Liabilities – Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products. This ASU addresses diversity in practice related to the de-recognition of a prepaid store-value product liability. The ASU amends the guidance on extinguishing financial liabilities for certain prepaid store-value products. If an entity selling prepaid store-value products expects to be entitled to an amount that will not be redeemed, the entity will recognize the expected breakage in proportion to the pattern of rights expected to be exercised by the product holder to the extent that it is probable that a significant reversal of the breakage amount will not subsequently occur. The ASU is effective for annual periods beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted, including adoption before the effective date of ASU 2015-14, Revenue from Contracts with Customers (described below). The amendments in this ASU should be applied either using a modified retrospective transition method by means of a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is effective or retrospectively to each period presented. The Company is currently evaluating the effect the ASU will have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. There are two approaches for amortizing the right-of use asset. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. If there is no sale for the seller-lessee, the buyer-lessor does not account for a purchase. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company’s financial position. The impact on the Company’s results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company’s cash position. In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10). This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previous held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is permitted, for fiscal years or interim periods that have not yet been issued as of the beginning of the fiscal year of adoption. The Company is evaluating the effect of adopting this new accounting guidance. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). This ASU simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement of financial position. This ASU may be applied either prospectively to all deferred tax assets and liabilities, or retrospectively to all periods presented for annual periods beginning after December 16, 2016 and interim periods thereafter (fiscal 2018), with early adoption permitted, and may require additional disclosure based on the application method selected. The Company prospectively early adopted this ASU in the fourth quarter of 2016. The adoption did not result in a material reclassification in our statement of financial position. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), an update to ASU 2014-09. This ASU amends ASU 2014-09 to defer the effective date by one year for annual reporting periods beginning after December 15, 2017 (fiscal 2019). Subsequently, the FASB has also issued accounting standards updates which clarify the guidance. This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Early adoption is permitted for annual reporting periods beginning after December 15, 2016 (fiscal 2018). In transition, the ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance including the transition method. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This ASU simplifies current accounting treatments by requiring entities to measure most inventories at “the lower of cost and net realizable value” rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position. |
Restructuring |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring | 3. Restructuring On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on the Retail Pharmacy USA segment, but includes activities from all segments and are expected to be substantially complete by the end of the Company’s 2017 fiscal year. The Company estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of between $1.3 billion and $1.5 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. The Company incurred pre-tax charges of $424 million related to the Cost Transformation Program during fiscal 2016. The Company incurred pre-tax charges of $542 million related to the Cost Transformation Program in fiscal 2015. From inception through August 31, 2016, the Company incurred pre-tax charges of $966 million ($448 million related to asset impairment charges, $293 million in real estate costs and $225 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses. Restructuring charges are recognized as the costs are incurred over time in accordance with GAAP. In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources within the Retail Pharmacy USA segment in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. For fiscal 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. In fiscal 2014, the Company incurred pre-tax charges of $209 million. All charges related to this plan have been recorded within selling, general and administrative expenses. Restructuring costs by segment are as follows (in millions):
|
Leases |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | 4. Leases Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales. The Company continuously evaluates its real estate portfolio in conjunction with its capital needs. The Company has entered into several sale-leaseback transactions. In fiscal 2016, 2015 and 2014, the Company recorded proceeds from sale-leaseback transactions of $60 million, $867 million and $67 million, respectively. In other transactions, the Company negotiated fixed rate renewal options which constitute a form of continuing involvement, resulting in the assets remaining on the balance sheet and a corresponding finance lease obligation. Annual minimum rental commitments under all leases having an initial or remaining non-cancelable term of more than one year are shown below (in millions):
The capital and finance lease amounts include $1.7 billion of imputed interest and executory costs. Total minimum lease payments have not been reduced by minimum sublease rentals of $199 million on leases due in the future under non-cancelable subleases. The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. In fiscal 2016, 2015 and 2014, the Company recorded charges of $127 million, $252 million and $177 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company’s store optimization plan and Cost Transformation Program. These charges are reported in selling, general and administrative expenses in the Consolidated Statements of Earnings. The changes in reserve for facility closings and related lease termination charges include the following (in millions):
The Company remains secondarily liable on 79 leases. For leases on which the Company remains secondarily liable, the maximum potential undiscounted future payments are $340 million at August 31, 2016. Lease option dates vary, with some lease terms extending up to 2039. Rental expense, which includes common area maintenance, insurance and taxes, where appropriate, was as follows (in millions):
|
Equity Method Investments |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments | 5. Equity Method Investments Equity method investments as of August 31, 2016 and 2015 were as follows (in millions, except percentages):
AmerisourceBergen Investment On March 18, 2016, the Company exercised warrants to purchase 22,696,912 shares of AmerisourceBergen Corporation (“AmerisourceBergen”) common stock at an exercise price of $51.50 per share for an aggregate exercise price payment of $1.17 billion. On August 25, 2016, the Company exercised additional warrants to purchase 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share for an aggregate exercise price payment of $1.19 billion. As of August 31, 2016, the Company owned 56,854,867 AmerisourceBergen common shares representing approximately 24% of the outstanding AmerisourceBergen common stock and accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings attributable to the Company’s investment being classified within the operating income of its Pharmaceutical Wholesale segment. Due to the timing and availability of financial information of AmerisourceBergen, we account for this equity method investment on a financial reporting lag of two months. Due to the change in accounting method to equity method effective March 18, 2016 and the two-month reporting lag, the Company’s results for fiscal 2016 include approximately three and a half months of equity method income. Equity earnings from AmerisourceBergen is reported as a separate line in the Consolidated Statements of Earnings. The level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at August 31, 2016 is $4.9 billion. The Company’s investment in AmerisourceBergen carrying value exceeded its proportionate share of the net assets of AmerisourceBergen by $4.5 billion. This premium of $4.5 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets. Other Investments The Company’s other equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company’s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. The Company reported $44 million and $24 million of post-tax equity earnings from equity method investments other than AmerisourceBergen and Alliance Boots for fiscal 2016 and 2015, respectively. Post-tax equity earnings from the historical Walgreens other equity method investments in fiscal 2014 were immaterial. Also in fiscal 2015, the Company accounted for its 45% investment in Alliance Boots using the equity method of accounting. The Company utilized a three-month reporting lag in recording equity income in Alliance Boots, which was eliminated on December 31, 2014. The Company’s share of Alliance Boots earnings was recorded as Equity earnings in Alliance Boots in the Consolidated Statements of Earnings. The Company’s investment was recorded as Equity investment in Alliance Boots in the Consolidated Balance Sheets. Summarized Financial Information Summarized financial information for the Company’s equity method investment in Alliance Boots is as follows:
|
Available-for-Sale Investments |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available-for-Sale Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available-for-Sale Investments | 6. Available-for-Sale Investments A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):
On March 18, 2016, the Company exercised warrants to purchase 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share, which resulted in a change in method of accounting for the Company’s investment to the equity method of accounting. In conjunction with the change to the equity method of accounting, the Company recognized a gain of $268 million of Other Comprehensive Income to Other income (expense) within the Consolidated Statements of Earnings. See Note 5, Equity Method Investments, and Note 10, Financial Instruments for further information. In fiscal 2016, there were $7 million of available-for-sale securities sold. In fiscal 2015, subsequent to the Second Step Transaction, $52 million of acquired available-for-sale securities were sold. In 2014, there were no sales of available-for-sale investments. Gains and losses related to these disposals were not significant. The Company has $32 million and $36 million of available-for-sale investments classified within other current assets in the Consolidated Balance Sheets at August 31, 2016 and 2015, respectively. |
Acquisitions |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions | 7. Acquisitions Alliance Boots The Second Step Transaction closed on December 31, 2014, resulting in the acquisition by the Company of 55% of the issued and outstanding share capital of Alliance Boots, increasing its interest to 100%. The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. As a result of the closing of the Second Step Transaction, the Company increased its ownership in WBAD, a global sourcing enterprise between Walgreens and Alliance Boots, to 100%. Because Walgreens held, prior to the Second Step Transaction, a 50% direct interest and an additional indirect interest in WBAD through its 45% ownership of Alliance Boots, the financial results of WBAD were fully consolidated into the Walgreens financial statements with the remaining 27.5% effective interest being recorded as a noncontrolling interest. The acquisition of the 27.5% noncontrolling interest was accounted for as an equity transaction with no gain or loss recorded in the statement of earnings under ASC Topic 805, Business Combinations. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000. The Company has completed the purchase accounting of the Second Step Transaction. The total purchase price of the Second Step Transaction of $15.9 billion included £3.133 billion in cash ($4.9 billion at the December 31, 2014 spot rate of $1.56 to £1.00) and 144.3 million of the Company’s common shares at a fair value of $11.0 billion (based on the December 30, 2014 closing market price of $76.05). Of the total purchase price, $13.3 billion was allocated to acquire the 55% ownership interest in Alliance Boots and $2.6 billion was allocated to acquire the noncontrolling interest in WBAD. The purchase price attributed to the acquisition of the noncontrolling interest in WBAD was determined based on the relative fair value of Alliance Boots and WBAD, respectively. The impact of the equity transaction is as follows (in millions):
The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).
As a result of the Company acquiring the remaining 55% interest in Alliance Boots, the Company’s previously held 45% interest was re-measured at fair value, resulting in a gain of $563 million. The gain has been recognized as Gain on previously held equity interest in the Consolidated Statements of Earnings for the fiscal year ended August 31, 2015. The fair value of the previously held equity interest of $8.1 billion in Alliance Boots was determined using the income approach methodology. The fair value for trade names and trademarks was determined using the relief from royalty method of the income approach; pharmacy licenses and customer relationships were determined using the excess earnings method of the income approach; and loyalty card holders were determined using the incremental cash flow method, which is a form of the income approach. Personal property fair values were determined primarily using the indirect cost approach, while real property fair values were determined using the income, market and/or cost approach. The fair value measurements of the previously held equity interest and intangible assets are based on significant inputs not observable in the market, and thus represent Level 3 measurements. The fair value estimates for the previously held equity interest and intangible assets are based on (i) projected discounted cash flows, (ii) historical and projected financial information, (iii) synergies including cost savings, and (iv) attrition rates, as relevant, that market participants would consider when estimating fair values. The identified definite and indefinite lived intangible assets were as follows:
The goodwill of $14.9 billion arising from the Second Step Transaction primarily reflects the expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the Company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces. Following the completion of the Second Step Transaction, the Company realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company determined that the goodwill should be allocated across all segments recognizing that each segment will benefit from the expected synergies. The goodwill allocated to the Retail Pharmacy USA segment of $7.3 billion is comprised of $3.5 billion of synergy benefits allocable to the segment on a source of procurement benefit basis and $3.8 billion determined on a “with-and-without” basis. The source of procurement benefit basis allocates the synergy benefits to the segment whose purchase gave rise to the benefit. The “with-and-without” basis computes the difference between the fair value of the pre-existing business before the combination and its fair value after the combination. Of the remaining goodwill, $3.9 billion was allocated to the Retail Pharmacy International segment and $3.7 billion was allocated to the Pharmaceutical Wholesale segment. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes. The Company incurred legal and other professional services costs related to the Second Step Transaction, which were included in selling, general and administrative expenses, of $87 million in fiscal 2015. The fair value of the assets acquired includes inventory having an estimated fair value of $3.7 billion. This fair value includes a $106 million fair value adjustment to capitalize the estimated profit in acquired finished goods inventory as of the date of the Second Step Transaction, which was expensed to cost of sales over the first inventory turn. The following table presents supplemental unaudited condensed pro forma consolidated information for 2015 and 2014 as if the Second Step Transaction had occurred on September 1, 2013, the first day of the Company’s fiscal 2014. The unaudited condensed pro forma information reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair valuation of assets acquired, the impact of acquisition financing, transaction costs and the related income tax effects. The unaudited condensed pro forma information does not include any anticipated synergies that may be achievable subsequent to the date of the Second Step Transaction. The unaudited condensed pro forma information also excludes certain non-recurring items such as transaction related costs. Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.
Actual results from Alliance Boots operations included in the Consolidated Statements of Earnings since December 31, 2014, the date of the Second Step Transaction, are as follows (in millions, except per share amounts):
Other Acquisitions and Divestitures The aggregate purchase price of all business and intangible assets acquired, net of cash received, was $126 million for fiscal 2016. These acquisitions included an international beauty brand and prescription files resulting in an increase of $23 million to goodwill and $95 million to intangible assets. The remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed and contingent considerations. Operating results of the businesses acquired have been included in the Consolidated Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported. The aggregate purchase price of all businesses acquired in fiscal 2015, excluding Alliance Boots, net of cash received was $371 million for fiscal 2015. In fiscal 2015, the Company acquired Liz Earle Beauty Co. Ltd, owner of the Liz Earle skincare brand in addition to other asset acquisitions, primarily pharmacy prescription files. These acquisitions resulted in an increase of $126 million to goodwill and $255 million to intangible assets. Any remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed. Operating results of the businesses acquired have been included in the Consolidated Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported. Additionally, in fiscal 2015 the Company completed the sale of a majority interest in its subsidiary, Walgreens Infusion Services to Madison Dearborn Partners (“MDP”). Walgreens Infusion Services became a new independent, privately-held company named Option Care Inc. |
Goodwill and Other Intangible Assets |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets | 8. Goodwill and Other Intangible Assets Goodwill and other indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. As part of the Company’s impairment analysis, we determined fair value for each reporting unit using both the income and market approaches. The income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows and discount rates. The market approach estimates fair value using comparable marketplace fair value data from within a comparable industry grouping. Based on the results of our testing, the fair values of each of the reporting units and other indefinite-lived intangible assets exceeded their carrying values, therefore, no impairment was recognized. The determination of the fair value of the reporting units and the allocation of that value to individual assets and liabilities within those reporting units requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include but are not limited to; the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization and capital expenditures. The allocation requires analyses to determine the fair value of assets and liabilities including, among other things, trade names and trademarks, pharmacy licenses, customer relationships and purchased prescription files. Although the Company believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting units, the amount of the goodwill impairment charge, or both. Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):
In fiscal 2016, the Company purchased an international beauty brand and prescription files resulting in an increase of $23 million to goodwill and $95 million to intangible assets. As a result of the Second Step Transaction, the Company recorded $14.9 billion of goodwill and $11.7 billion of intangible assets in conjunction with the purchase accounting. See Note 7, Acquisitions for additional information regarding the transaction. Additionally, in fiscal 2015 the Company completed the sale of a majority interest in its subsidiary, Walgreens Infusion Services. As a result, $706 million of goodwill allocated to this business was removed from the Consolidated Balance Sheets. The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):
Amortization expense for intangible assets was $396 million, $480 million and $282 million in fiscal 2016, 2015 and 2014, respectively. Estimated annual amortization expense for intangible assets recorded at August 31, 2016 is as follows (in millions):
|
Borrowings |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings | 9. Borrowings Borrowings consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted)
At August 31, 2016, the future maturities of long-term debt, excluding debt discounts and issuance costs and financing and capital lease obligations (see Note 4, Leases, for the future lease obligation maturities), consisted of the following ($ in millions):
$6.0 Billion Note Issuance On June 1, 2016, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and offering expenses) of $6.0 billion from a public offering of five series of U.S. dollar notes with varying maturities and interest rates. Total issuance costs relating to the notes, including underwriting discounts and offering expenses, were $30 million. In the event that the merger contemplated by the Merger Agreement with Rite Aid is not consummated on or prior to June 1, 2017 (the first anniversary of the issuance date of the notes) or if the Merger Agreement is terminated at any time on or prior to June 1, 2017, then Walgreens Boots Alliance will be required to redeem the notes due 2018, the notes due 2021 and the notes due 2023 (but not the notes due 2026 or notes due 2046) on the date described in the applicable note at a redemption price equal to 101% of the aggregate principal amount of the notes to be redeemed, plus accrued and unpaid interest from and including the date of initial issuance, or the most recent date to which interest has been paid, whichever is later, to, but excluding, the date of redemption. £700 Million and €750 Million Notes Issuance On November 20, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and offering expenses) of $2.0 billion from a public offering of three series of notes denominated in Euros and Pound Sterling with varying maturities and interest rates. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and offering expenses, were $11 million. $8.0 Billion Note Issuance On November 18, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and offering expenses) of $7.9 billion from a public offering of seven series of U.S. dollar notes with varying maturities and interest rates, the majority of which are fixed rate. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and offering expenses, were $42 million. The Company repaid the $750 million variable rate notes on their May 18, 2016 maturity date. The notes issued on June 1, 2016, November 20, 2014 and November 18, 2014 contain redemption terms which allow or require the Company to redeem the notes at defined redemption prices plus accrued and unpaid interest at redemption dates set forth in the applicable series of notes. Interest on the notes issued on June 1, 2016 and November 18, 2014 is payable semi-annually and interest on the notes issued on November 20, 2014 is payable annually. Bridge Credit Agreement, 2015 Term Loan Credit Agreement and 2016 Term Loan Credit Agreement On October 27, 2015, in connection with the pending acquisition of Rite Aid Corporation (the “Acquisition”), the Company entered into a $12.8 billion bridge credit facility commitment letter (as amended and restated, the “Bridge Commitment Letter”). On December 18, 2015, the Company entered into a Bridge Term Loan Credit Agreement (as amended, the “Bridge Credit Agreement”) and a Term Loan Credit Agreement (as amended, the “2015 Term Loan Credit Agreement). The Bridge Commitment Letter and the commitments contemplated thereby terminated upon entering into the Bridge Credit Agreement and 2015 Term Loan Credit Agreement. The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility and had initial aggregate commitments of $7.8 billion, which may be increased by the Company prior to the funding of the loans thereunder by up to $2.0 billion in certain circumstances. The Company can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. The 2015 Term Loan Credit Agreement is a $5.0 billion unsecured term loan facility comprising two tranches with maturities three and five years following the funding date or, if earlier, three and five years after October 27, 2016. The obligations of the lenders party to each of the Bridge Credit Agreement and the Term Loan Credit Agreement become effective upon the date of closing of the Rite Aid Acquisition. Upfront fees paid to date in connection with the Bridge Credit Agreement and 2015 Term Loan Credit Agreement total $30 million. On June 1, 2016, in connection with the $6.0 billion note issuance on the same date, the aggregate commitments under the Bridge Credit Agreement were reduced by $6.0 billion to $1.8 billion. On August 30, 2016, the Company entered into a $1.0 billion senior unsecured term loan facility (the “2016 Term Loan Credit Agreement”) comprising two tranches with maturities on March 30, 2017 and one year after the funding date, respectively. The obligations of the lender under the 2016 Term Loan Credit Agreement become effective upon the date of closing of the Acquisition. No upfront fees were paid in connection to the 2016 Term Loan Agreement. As a result of entering into the 2016 Term Loan Credit Agreement, the aggregate commitments under the Bridge Credit Agreement were reduced by $1.0 billion to $0.8 billion. As of August 31, 2016, there were no borrowings under the Bridge Credit Agreement, the 2015 Term Loan Credit Agreement or the 2016 Term Loan Credit Agreement. 2014 Term Loan Agreement and Revolving Credit Agreement On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the “Term Loan Agreement”), which provided Walgreens Boots Alliance and Walgreens with the ability to borrow up to £1.45 billion on an unsecured basis. As of August 31, 2016, Walgreens Boots Alliance had borrowed £1.45 billion ($1.9 billion) under the Term Loan Agreement. On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the “Revolving Credit Agreement”), with available credit of $3.0 billion, of which $500 million is available for the issuance of letters of credit. As of August 31, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement. On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the “364-Day Credit Agreement”). The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, the 364-Day Credit Agreement was amended to remove Walgreens as a borrower thereunder, eliminate Walgreens’ guarantee of all obligations of Walgreens Boots Alliance thereunder and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. On December 17, 2015, the Company terminated the 364-Day Credit Agreement. The 364-Day Credit Agreement remained undrawn as of the date of termination and would have matured on December 30, 2015. Debt covenants The Company’s credit facilities contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00. The credit facilities contain various other customary covenants. In the case of the Bridge Credit Agreement, the 2015 Term Loan Credit Agreement and the 2016 Term Loan Credit Agreement, such covenants are not in effect until the loans under each such credit facility are funded. Other Borrowings The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of August 31, 2016 or August 31, 2015, respectively. The Company had weighted average daily short-term borrowings of $14 million of commercial paper outstanding at a weighted average interest rate of 0.66% for the fiscal year ended August 31, 2016. The Company had average daily short-term borrowings of $82 million of commercial paper outstanding at a weighted average interest rate of 0.52% in fiscal 2015. Interest Interest paid, which is net of capitalized interest, was $580 million in fiscal 2016, $472 million in fiscal 2015 and $161 million in fiscal 2014. Interest capitalized as a part of significant construction projects during fiscal 2016, 2015 and 2014 was immaterial. |
Financial Instruments |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments | 10. Financial Instruments The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks. The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2016 and 2015 were as follows (in millions):
The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk. Fair Value Hedges In fiscal 2015, the Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six-month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges. On August 10, 2015, the Company terminated $500 million of the six-month LIBOR in arrears swaps and all of the one-month LIBOR in arrears swaps in connection with the repayment of the associated debt. The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk and did not have a material impact on the Company’s financial statements. The changes in fair value of the Company’s debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Balance Sheets (see Note 9, Borrowings). At August 31, 2016 and 2015, the cumulative fair value adjustments resulted in an increase in long-term debt of $2 million and $1 million, respectively. No material gains or losses were recorded from ineffectiveness during fiscal 2016, 2015 or 2014. Derivatives not Designated as Hedges The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of interest rate and foreign currency risks. Income or expense due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
Warrants On March 18, 2016, the Company exercised warrants to purchase 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share for an aggregate exercise price payment of $1.17 billion. On August 25, 2016, the Company exercised additional warrants to purchase 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share for an aggregate exercise price payment of $1.19 billion. See Note 5, Equity Method Investments and Note 6, Available-for-Sale Investments for further information. As of August 31, 2016, the Company holds no warrants to purchase AmerisourceBergen common stock. The Company reports its warrants at fair value. The fair value and balance sheet presentation of warrants was as follows (in millions):
The gains and losses due to changes in fair value of the warrants recognized in earnings were as follows (in millions):
Derivatives Credit Risk Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty. Derivatives Offsetting The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Balance Sheet. |
Fair Value Measurements |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | 11. Fair Value Measurements The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:
Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
There were no transfers between levels in fiscal 2016 or 2015. The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Borrowings for further details. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature. |
Commitments and Contingencies |
12 Months Ended |
---|---|
Aug. 31, 2016 | |
Commitments and Contingencies [Abstract] | |
Commitments and Contingencies | 12. Commitments and Contingencies The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company’s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company’s consolidated financial statements in a future fiscal period. Management’s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management’s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved. On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company’s definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions asserted claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement was subject to, among other things, court approval. On July 8, 2015, the Court preliminarily approved the settlement, and on November 20, 2015, the Court entered an order of final approval of the settlement. On December 17, 2015, a purported class member who had objected to the settlement appealed the Court’s order. The appeal was docketed with the United States Court of Appeals for the Seventh Circuit. Oral argument was held on June 2, 2016. On August 10, 2016, the Seventh Circuit issued an order reversing the district court’s judgment approving the settlement and remanding the case for further proceedings. On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of the securities class action that was filed on April 10, 2015, which is described below. On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court’s order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016. On September 30, 2016, the Court issued an order granting in part and denying in part Walgreen Co.’s motion to dismiss. As of August 31, 2016, the Company was aware of ten putative class action lawsuits (the “Rite Aid actions”) filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and Victoria Merger Sub, Inc. for claims arising out of the transactions contemplated by the Merger Agreement (the “Rite Aid Transactions”). Eight of the Rite Aid actions were filed in the Court of Chancery of the State of Delaware (the “Delaware actions”), one Rite Aid action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the “Pennsylvania action”), and one Rite Aid action was filed in the United States District Court for the Middle District of Pennsylvania (the “federal action”). The Delaware actions and the Pennsylvania action primarily allege that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger; and also allege that Walgreens Boots Alliance and Victoria Merger Sub, Inc. aided and abetted these alleged breaches of fiduciary duty. The federal action alleges, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The Delaware actions were consolidated, and plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote on the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the same Rite Aid shareholder vote. All such motions were denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. On April 15, 2016, the plaintiffs in the Delaware actions agreed to a settlement in principle related to this matter for an immaterial amount. In the Pennsylvania action, plaintiffs agreed to stay the litigation until after the Rite Aid Transactions have closed. |
Income Taxes |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | 13. Income Taxes The components of Earnings Before Income Tax Provision were (in millions):
The provision for income taxes consists of the following (in millions):
The difference between the statutory federal income tax rate and the effective tax rate is as follows:
The deferred tax assets and liabilities included in the Consolidated Balance Sheets consist of the following (in millions):
At August 31, 2016, the Company has recorded deferred tax assets of $373 million, primarily reflecting the benefit of $200 million in U.S. federal, $226 million in state and $837 million in non-U.S. ordinary and capital losses. In addition, these deferred tax assets include $55 million of income tax credits. Of these deferred tax assets, $139 million will expire at various dates from 2017 through 2036. The residual deferred tax assets of $234 million have no expiry date. The Company believes it is more likely than not that the benefit from certain deferred tax assets will not be realized. In recognition of this risk, the Company has recorded a valuation allowance of $305 million against those deferred tax assets as of August 31, 2016. Income taxes paid were $1.1 billion, $1.3 billion and $1.2 billion for fiscal years 2016, 2015 and 2014, respectively. ASC Topic 740, Income Taxes, provides guidance regarding the recognition, measurement, presentation and disclosure in the financial statement of tax positions taken or expected to be taken on a tax return, including the decision whether to file in a particular jurisdiction. As of August 31, 2016, unrecognized tax benefits of $252 million were reported as long-term liabilities on the Consolidated Balance Sheets while $51 million were reported as current tax liabilities. Both of these amounts include interest and penalties, when applicable. The following table provides a reconciliation of the total amounts of unrecognized tax benefits (in millions):
At August 31, 2016, 2015 and 2014, $237 million, $227 million and $105 million, respectively, of unrecognized tax benefits would favorably impact the effective tax rate if recognized. During the next twelve months, based on current knowledge, it is reasonably possible the amount of unrecognized tax benefits could decrease by up to $51 million due to anticipated tax audit settlements and the expirations of statutes of limitations associated with tax positions related to multiple tax jurisdictions. The Company recognizes interest and penalties in the income tax provision in its Consolidated Statements of Earnings. At August 31, 2016, and August 31, 2015, the Company had accrued interest and penalties of $34 million and $36 million, respectively. For the year ended August 31, 2016, the amount reported in income tax expense related to interest and penalties was $2 million. The Company files a consolidated U.S. federal income tax return as well as income tax returns in various states and multiple foreign jurisdictions. It is generally no longer under audit examination for U.S. federal income tax purposes for any years prior to fiscal 2015. With few exceptions, it is no longer subject to state and local income tax examinations by tax authorities for years before fiscal 2007. In foreign tax jurisdictions, the Company is generally no longer subject to examination by the tax authorities in Luxembourg prior to 2011, in Germany prior to 2011, in France prior to 2011, and in Turkey prior to 2011. With respect to the United Kingdom, a number of specific issues remain open to examination by the tax authorities back to 2000. The Company has received tax holidays from Swiss cantonal income taxes relative to certain of its Swiss operations. The income tax holidays are expected to extend through September 2022. The holidays had a beneficial impact of $116 million and $89 million during fiscal 2016 and 2015, respectively. This benefit is primarily included as part of the foreign income taxed at non-U.S. rates line in the effective tax rate reconciliation table above. At August 31, 2016, it is not practicable for the Company to determine the amount of the unrecognized deferred tax liability it has with respect to temporary differences related to investments in foreign subsidiaries and foreign corporate joint ventures that are essentially permanent in duration. |
Stock Compensation Plans |
12 Months Ended |
---|---|
Aug. 31, 2016 | |
Stock Compensation Plans [Abstract] | |
Stock Compensation Plans | 14. Stock Compensation Plans The Walgreens Boots Alliance, Inc. Omnibus Incentive Plan (the “Omnibus Plan”) which became effective in fiscal 2013, provides for incentive compensation to the Company’s non-employee directors, officers and employees, and consolidates into a single plan several previously existing equity compensation plans. The Company grants stock options, performance shares and restricted units under the Omnibus Plan. Performance shares issued under the Omnibus Plan offer performance-based incentive awards and equity-based awards to key employees. The fair value of each performance share granted assumes that performance goals will be achieved at 100 percent. If such goals are not met, no compensation expense is recognized and any recognized compensation expense is reversed. Restricted stock units are also equity-based awards with performance requirements that are granted to key employees. The performance shares and restricted stock unit awards are both subject to restrictions as to continuous employment except in the case of death, normal retirement or total and permanent disability. Total stock-based compensation expense for fiscal 2016, 2015 and 2014 was $115 million, $109 million and $114 million, respectively. The recognized tax benefit was $21 million, $7 million and $31 million for fiscal 2016, 2015 and 2014, respectively. Unrecognized compensation cost related to non-vested awards at August 31, 2016, was $111 million. This cost is expected to be recognized over a weighted average of three years. |
Retirement Benefits |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retirement Benefits [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retirement Benefits | 15. Retirement Benefits The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. Pursuant to the Second Step Transaction, the Company assumed a number of retirement benefit plans in the United Kingdom and other countries. The Company valued the assumed pension assets and liabilities on the acquisition date and uses an August 31 annual measurement date for its pension and post-retirement plans. Effective September 1, 2016, for UK and U.S. benefit plans using the yield curve approach, the Company will change the method used to calculate the service cost and interest cost components of net periodic benefit costs for pension and postretirement benefit plans and will measure these costs by applying the specific spot rates along the yield curve to the plans’ projected cash flows. The Company believes the new approach will provide a more precise measurement of service and interest costs by improving the correlation between projected cash flows and the corresponding spot yield curve rates. The change does not affect the measurement of the Company’s pension and other postretirement benefit obligations for those plans and will be accounted for as a change in accounting estimate, which is applied prospectively. This change is not expected to have a material impact to the 2017 full year results. Defined Benefit Pension Plans (non-U.S. plans) The principal defined benefit pension plan is the Boots Pension Plan covering certain employees in the United Kingdom (the “Boots Plan”). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010 with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. The Company also has two smaller defined benefit plans in the United Kingdom, both of which were closed to future accruals effective July 1, 2010. Defined benefit pension plan assets were invested in the following classes of securities as of August 31:
The investment strategy of the principal defined benefit pension plan is to hold approximately 85% of its assets in a diverse portfolio of high quality bonds with the remainder invested in equity and real estate assets backing longer term liabilities. Interest rate and inflation rate swaps are also employed to complement the role of fixed and index-linked bond holdings in liability risk management. The following table presents defined benefit pension plan assets using the fair value hierarchy as of August 31, 2016 (in millions).
Components of net periodic pension costs for the defined benefit pension plans (in millions):
Change in benefit obligations for the defined benefit pension plans (in millions):
Change in plan assets for the defined benefit pension plans (in millions):
Amounts recognized in the Consolidated Balance Sheets (in millions):
Pre-tax amounts recognized in accumulated other comprehensive (income) loss (in millions):
The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for all pension plans including accumulated benefit obligations in excess of plan assets at August 31, 2016 were as follows (in millions):
Estimated future benefit payments from defined benefit pension plans to participants are as follows (in millions):
The assumptions used in accounting for the defined benefit pension plans were as follows:
Based on current actuarial estimates, the Company plans to make contributions of $66 million to its defined benefit pension plans in fiscal 2017 and expects to make contributions beyond 2017, which will vary based upon many factors, including the performance of the Company’s pension investments. Defined Contribution Plans The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Board of Directors. The profit-sharing provision was an expense of $226 million, $158 million and $355 million in fiscal 2016, 2015 and 2014, respectively. The Company’s contributions were $225 million, $249 million and $328 million in fiscal 2015, 2014 and 2013, respectively. The Company also has certain contract based defined contribution arrangements. The principal one is the Alliance Healthcare & Boots Retirement Savings Plan, which is United Kingdom based and to which both the Company and participating employees contribute. The cost related to these arrangements recognized in the Consolidated Statement of Earnings for fiscal 2016 was $130 million and from the date of the Second Step Transaction through August 31, 2015 was $93 million. Postretirement Healthcare Plan The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company’s postretirement health benefit plan obligation was $466 and $431 million in fiscal 2016 and 2015 respectively and is not funded. The expected benefit to be paid net of the estimated federal subsidy during fiscal year 2017 is $11 million. |
Capital Stock |
12 Months Ended |
---|---|
Aug. 31, 2016 | |
Capital Stock [Abstract] | |
Capital Stock | 16. Capital Stock In connection with the Company’s capital policy, the Board of Directors has authorized share repurchase programs. In August 2014, the Company’s Board of Directors authorized the 2014 stock repurchase program which authorized the repurchase of up to $3.0 billion of the Company’s common stock prior to its expiration on August 31, 2016. The Company purchased 1.3 million and 8.2 million shares under the 2014 stock repurchase program in fiscal 2016 and 2015 at a cost of $110 million and $726 million, respectively. The Company determines the timing and amount of repurchases based on its assessment of various factors including prevailing market conditions, alternate uses of capital, liquidity, the economic environment and other factors. The timing and amount of these purchases may change at any time and from time to time. The Company has repurchased, and may from time to time in the future repurchase, shares on the open market through Rule 10b5-1 plans, which enable a company to repurchase shares at times when it otherwise might be precluded from doing so under insider trading laws. In addition, the Company continued to repurchase shares to support the needs of the employee stock plans. Shares totaling $1.0 billion were purchased to support the needs of the employee stock plans during fiscal 2016 as compared to $500 million and $705 million in fiscal 2015 and fiscal 2014, respectively. At August 31, 2016, 43.8 million shares of common stock were reserved for future issuances under the Company’s various employee benefit plans. |
Accumulated Other Comprehensive Income (Loss) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) | 17. Accumulated Other Comprehensive Income (Loss) The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for fiscal 2016, 2015 and 2014 (in millions):
|
Segment Reporting |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting | 18. Segment Reporting Prior to December 31, 2014, the Company’s operations were within one reportable segment. As a result of the closing of the Second Step Transaction on December 31, 2014, the Company has realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.
The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The “Eliminations” column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources. The segment information reflects the operating results of the Company’s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit. The Company’s Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which the Company acquired the 55% of Alliance Boots that it did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only eight months of results (January to August 2015) have been reported for these segments for fiscal 2015. To improve comparability, certain classification changes have been made to prior period results, this change has no impact on operating income. The following table reflects results of operations of the Company’s reportable segments (in millions):
The following table reconciles adjusted operating income to operating income (in millions):
No single customer accounted for more than 10% of the Company’s consolidated sales for any of the periods presented. Two payers accounted for approximately 22% of the Retail Pharmacy USA division’s sales in fiscal 2016 and one payer accounted for approximately 12% of the Retail Pharmacy USA division’s sales in fiscal 2015. One customer in the Retail Pharmacy International division accounted for approximately 18% of the division’s sales in fiscal 2016 and approximately 20% in fiscal 2015. Geographic data for sales is as follows (in millions):
Geographic data for long-lived assets, defined as property, plant and equipment is as follows (in millions):
|
Related Parties |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Parties [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Parties | 19. Related Parties The Company has a long-term pharmaceutical distribution agreement with AmerisourceBergen pursuant to which the Company sources branded and generic pharmaceutical products from AmerisourceBergen principally for its U.S. operations. Related party transactions (in millions):
Additionally, AmerisourceBergen receives sourcing services for generic pharmaceutical products through the Company’s global sourcing enterprise WBAD. |
Supplementary Financial Information |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplementary Financial Information [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplementary Financial Information | 20. Supplementary Financial Information There were no significant non-cash transactions in fiscal 2016. As a result of the Second Step Transaction, the Company had the following non-cash transactions in fiscal 2015: $9.0 billion for debt assumed; $11.0 billion for the Company’s common stock issued; $2.6 billion of consideration attributable to WBAD; $8.1 billion related to the fair value of the Company’s 45% investment in Alliance Boots; $26.6 billion in fair value of assets acquired; and $20.0 billion in fair value of liabilities and non-controlling interests assumed. Significant non-cash transactions in fiscal 2014 include $322 million for additional capital lease obligations. Included in the Consolidated Balance Sheets captions are the following assets and liabilities (in millions):
Summary of Quarterly Results (Unaudited) (In millions, except per share amounts)
|
Summary of Major Accounting Policies (Policies) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Major Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Presentation | Basis of Presentation The consolidated financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned companies in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and on various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any period may not be comparable to the same period in previous years. In addition, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion”. In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on the Company’s Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars. To improve comparability, certain classification changes have been made to prior periods to conform to current year classifications. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents | Cash and Cash Equivalents Cash and cash equivalents include cash on hand and all highly liquid investments with an original maturity of three months or less. Credit and debit card receivables from banks, which generally settle within two to seven business days, of $114 million and $165 million were included in cash and cash equivalents at August 31, 2016 and 2015, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash | Restricted Cash The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. As of August 31, 2016 and 2015, the amount of such restricted cash was $185 million, and $184 million respectively and is reported in Other current assets on the Consolidated Balance Sheets. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable | Accounts Receivable Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily include amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies), clients and members, as well as vendors and manufacturers. Charges to bad debt are based on estimates of recoverability using both historical write-offs and specifically identified receivables. The allowance for doubtful accounts for fiscal 2016, 2015 and 2014 was $166 million, $172 million and $173 million, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory | Inventory The Company values inventories on a lower of cost or market basis. Inventory includes product costs, inbound freight, direct labor, warehousing costs, overhead costs relating to the manufacture and distribution of products and vendor allowances not classified as a reduction of advertising expense. The Company’s Retail Pharmacy USA segment inventory is accounted for using the last-in-first-out (“LIFO”) method. At August 31, 2016 and 2015, Retail Pharmacy USA segment inventories would have been greater by $2.8 billion and $2.5 billion, respectively, if they had been valued on a lower of first-in-first-out (“FIFO”) cost or market basis. The total carrying value of the segment inventory accounted for under the LIFO method is $6.1 billion and $5.6 billion at August 31, 2016 and 2015, respectively. The Company’s Retail Pharmacy International and Pharmaceutical Wholesale segments’ inventory is accounted for using the FIFO method, except for retail inventory in the Retail Pharmacy International segment, which is primarily determined using the retail inventory method. Under the retail inventory method, cost is determined by applying a calculated cost-to-retail ratio across groupings of similar items. The cost-to-retail ratio is applied to ending inventory at its current owned retail valuation to determine the cost of ending inventory across groupings of similar items. Current owned retail valuation represents the retail price for which merchandise is offered for sale on a regular basis. Inherent in the retail method calculation are certain management judgments and estimates which can impact the owned retail valuation and, therefore, the ending inventory valuation at cost. The total carrying value of the inventory for Retail Pharmacy International and Pharmaceutical Wholesale segments is $2.9 billion and $3.1 billion at August 31, 2016 and 2015, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments | Equity Method Investments The Company uses the equity method to account for investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company’s proportionate share of the net income or loss of these companies is included in consolidated net earnings. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. See Note 5, Equity Method Investments for further information relating to the Company’s equity method investments. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments | Investments The Company’s investments consist principally of corporate debt, other debt securities, and equity securities of publicly-traded companies. The Company classifies its investments in securities at the time of purchase as held-to-maturity or available-for-sale, and re-evaluates such classifications on a quarterly basis. Held-to-maturity investments consist of debt securities that the Company has the intent and ability to hold until maturity. These securities are recorded at cost, adjusted for the amortization of premiums and discounts, which approximates fair value. Available-for-sale debt and equity securities are recorded at fair value. Unrealized holding gains and losses on available-for-sale investments are excluded from earnings and are reported as a separate component of shareholders’ equity and comprehensive income until realized. Realized gains and losses of available-for-sale investments are included in the Consolidated Statements of Earnings. The Company evaluates these investments for other-than-temporary impairment. Such evaluation involves a variety of considerations, including assessments of the risks and uncertainties associated with general economic conditions and distinct conditions affecting specific issuers. Factors considered by the Company include (i) the length of time and the extent to which the fair value has been below cost; (ii) the financial condition, credit worthiness, and near-term prospects of the issuer; (iii) the length of time to maturity; (iv) future economic conditions and market forecasts; (v) the Company’s intent and ability to retain its investment for a period of time sufficient to allow for recovery of market value; and (vi) an assessment of whether it is more likely than not that the Company will be required to sell its investment before recovery of fair value. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment | Property, Plant and Equipment Depreciation is provided on a straight-line basis over the estimated useful lives of owned assets. Estimated useful lives range from 20 years for land improvements, 3 to 50 for buildings and building improvements and 3 to 20 for fixtures, plant and equipment. Leasehold improvements, equipment under capital lease and capital lease properties are amortized over their respective estimate of useful life or over the term of the lease, whichever is shorter. Major repairs, which extend the useful life of an asset, are capitalized; routine maintenance and repairs are charged against earnings. The majority of the Company’s fixtures and equipment uses the composite method of depreciation. Therefore, gains and losses on retirement or other disposition of such assets are included in earnings only when an operating location is closed, substantially remodeled or impaired. Property, plant and equipment consists of (in millions):
Depreciation expense for property, plant and equipment was $1.3 billion in fiscal 2016, $1.3 billion in fiscal 2015 and $923 million in fiscal 2014. The Company capitalizes application stage development costs for significant internally developed software projects, such as upgrades to the store point-of-sale system. These costs are amortized over a three to eight year period. Amortization expense for capitalized system development costs and software was $238 million in fiscal 2016, $178 million in fiscal 2015 and $127 million in fiscal 2014. Unamortized costs at August 31, 2016 and 2015 were $0.9 billion and $1.0 billion, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations | Business Combinations Business combinations are accounted for under Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, using the acquisition method of accounting. The cost of an acquired company is assigned to the tangible and intangible assets purchased and the liabilities assumed on the basis of their fair values at the date of acquisition. The determination of fair values of assets and liabilities acquired requires estimates and the use of valuation techniques when a market value is not readily available. Any excess of purchase price over the fair value of net tangible and intangible assets acquired is allocated to goodwill. The final determination of the fair value of certain assets and liabilities is completed within the one year measurement period as allowed under ASC Topic 805, Business Combinations. Transaction costs associated with business combinations are expensed as they are incurred. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill and intangibles under ASC Topic 350, Intangibles – Goodwill and Other, which requires the Company to test goodwill and other indefinite-lived assets for impairment annually or whenever events or circumstances indicate that impairment may exist. Intangible assets are amortized on a straight line basis over their estimated useful lives. See Note 8, Goodwill and Other Intangible Assets for additional disclosure regarding the Company’s intangible assets. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants | Warrants The warrants to acquire shares of AmerisourceBergen Corporation were accounted for as a derivative under ASC Topic 815, Derivatives and Hedging. The Company reports its warrants at fair value within other non-current assets in the Consolidated Balance Sheets and changes in the fair value of warrants are recognized in other income in the Consolidated Statements of Earnings. A deferred credit from the day-one valuation attributable to the warrants granted to Walgreens was amortized over the life of the warrants. See Note 10, Financial Instruments, for additional disclosure regarding the Company’s warrants. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments | Financial Instruments The Company uses derivative instruments to hedge its exposure to interest rate and currency risks arising from operating and financing activities. In accordance with its risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes. Derivatives are recognized on the Consolidated Balance Sheets at their fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, it formally documents the hedge relationship and the risk management objective for undertaking the hedge which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The accounting for changes in fair value of a derivative instrument depends on whether the Company had designated it in a qualifying hedging relationship and further, on the type of hedging relationship. The Company applies the following accounting policies:
Cash receipts or payments on a settlement of a derivative contract are reported in the Consolidated Statements of Cash Flows consistent with the nature of the underlying hedged item. For derivative instruments designated as hedges, the Company assesses, both at the hedge’s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. Highly effective means that cumulative changes in the fair value of the derivative are between 80% and 125% of the cumulative changes in the fair value of the hedged item. In addition, when the Company determines that a derivative is not highly effective as a hedge, hedge accounting is discontinued. When it is probable that a hedged forecasted transaction will not occur, the Company discontinues hedge accounting for the affected portion of the forecasted transaction, and reclassifies any gains or losses in accumulated other comprehensive income (loss) to earnings in the Consolidated Statement of Earnings. When a derivative in a hedge relationship is terminated or the hedged item is sold, extinguished or terminated, hedge accounting is discontinued prospectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Impaired Assets | Impaired Assets The Company tests long-lived assets for impairment whenever events or circumstances indicate that a certain asset may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the assets to the fair value, which is based on the discounted estimated future cash flows. Impairment charges included in selling, general and administrative expenses were $305 million in fiscal 2016, primarily related to the Company’s Cost Transformation Program (as defined below). Impairment charges recognized in fiscal 2015 and 2014 were $386 million and $167 million, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Liabilities for Store Closings | Liabilities for Store Closings The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. The reserve for store closings, including $91 million from locations closed under the Company’s restructuring actions, was $466 million as of August 31, 2016 and $446 million as of August 31, 2015. See Note 4, Leases for additional disclosure regarding the Company’s reserve for future costs related to closed locations. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Postretirement Benefits | Pension and Postretirement Benefits The Company has various defined benefit pension plans that cover some of its foreign employees. The Company also has postretirement healthcare plans that cover qualifying domestic employees. Eligibility and the level of benefits for these plans vary depending participants’ status, date of hire and or length of service. Pension and postretirement expenses and valuations are dependent on assumptions used by third party actuaries in calculating those amounts. These assumptions include discount rates, healthcare cost trends, long-term return on plan assets, retirement rates, mortality rates and other factors. See Note 15, Retirement Benefits, for additional disclosure regarding the Company’s pension and postretirement benefits. The Company funds its pension plans in accordance with applicable regulations. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling Interests | Noncontrolling Interests The Company accounts for its less than 100% interest in consolidated subsidiaries in accordance with ASC Topic 810, Consolidation, and accordingly, the Company presents noncontrolling interests as a component of equity on its Consolidated Balance Sheets and reports the noncontrolling interest net earnings or loss as Net earnings attributable to noncontrolling interests in the Consolidated Statement of Earnings. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Currency | Currency Assets and liabilities of non-U.S. dollar functional currency operations are translated into U.S. dollars at end-of-period exchange rates while revenues, expenses and cash flows are translated at average monthly exchange rates over the period. Equity is translated at historical exchange rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. For U.S. dollar functional currency operations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Revenues and expenses are recorded at average monthly exchange rates over the period, except for those expenses related to nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Gains or losses from foreign currency remeasurement and transactions are included in selling, general and administrative expenses within the Consolidated Statements of Earnings. For all periods presented, there were no material operational gains or losses from foreign currency transactions. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | Revenue Recognition Revenue is recognized when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured. The following revenue recognition policies have been established for the Company’s reportable segments. Retail Pharmacy USA and Retail Pharmacy International The Company recognizes revenue at the time the customer takes possession of the merchandise, after making appropriate adjustments for estimated returns. Revenue does not include sales related taxes. In certain international locations, the Company initially estimates revenue based on expected reimbursements from governmental agencies for dispensing prescription drugs and providing optical services. The estimates are based on historical experience and are updated to actual reimbursement amounts. Pharmaceutical Wholesale Wholesale revenue is recognized upon shipment of goods, which is generally also the day of delivery. When the Company acts in the capacity of an agent or a logistics service provider, revenue is the fee received for the service and is recognized when the services have been performed. The Company has determined it is the agent when providing logistics services, which is based on its assessment of the following criteria: (i) whether it is the primary obligor in the arrangement, (ii) whether it has latitude in establishing the price, changing the product or performing part of the service, (iii) whether it has discretion in supplier selection, (iv) whether it is involved in the determination of service specifications, and (v) whether it is exposed to credit risk. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cost of Sales | Cost of Sales Cost of sales includes the purchase price of goods and services sold, store and warehouse inventory loss, inventory obsolescence, manufacturing costs, certain direct product design and development costs and supplier rebates. In addition to product costs, cost of sales includes manufacturing costs, warehousing costs for retail operations, purchasing costs, freight costs, cash discounts and vendor allowances. Cost of sales for our Retail Pharmacy USA segment is derived based upon point-of-sale scanning information with an estimate for shrinkage and is adjusted based on periodic inventory counts. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vendor Allowances and Supplier Rebates | Vendor Allowances and Supplier Rebates Vendor allowances are principally received as a result of purchases, sales or promotion of vendors’ products. Allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. Those allowances received for promoting vendors’ products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising costs incurred, with the excess treated as a reduction of inventory costs. Rebates or refunds received by the Company from its suppliers, mostly in cash, are considered as an adjustment of the prices of the supplier’s products purchased by the Company. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selling, General and Administrative Expenses | Selling, General and Administrative Expenses Selling, general and administrative expenses mainly consist of salaries and employee costs, occupancy costs, depreciation and amortization, credit and debit card fees and expenses directly related to stores. In addition, other costs included are headquarters’ expenses, advertising costs (net of vendor advertising allowances), wholesale warehousing costs and insurance. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Advertising Costs | Advertising Costs Advertising costs, which are reduced by the portion funded by vendors, are expensed as incurred or when services have been received. Net advertising expenses, which are included in selling, general and administrative expenses, were $598 million in fiscal 2016, $491 million in fiscal 2015 and $265 million in fiscal 2014. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Points Earned Through Loyalty Programs | Points Earned Through Loyalty Programs The Company’s primary rewards programs. Balance® Rewards and Boots Advantage Card, are accrued as a charge to cost of sales at the time a point is earned. Points are funded internally and through vendor participation, and are credited to cost of sales at the time a vendor-sponsored point is earned. Breakage is recorded as points expire as a result of a member’s inactivity or if the points remain unredeemed after three years. Breakage income, which is reported in cost of sales, was not significant in fiscal 2016, 2015 or 2014. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insurance | Insurance The Company obtains insurance coverage for catastrophic exposures as well as those risks required by law to be insured. In general, the Company’s U.S. subsidiaries retain a significant portion of losses related to workers’ compensation, property, comprehensive general, pharmacist and vehicle liability, while non-U.S. subsidiaries manage their exposures through insurance coverage with third-party carriers. Management regularly reviews the probable outcome of claims and proceedings, the expenses expected to be incurred, the availability and limits of the insurance coverage, and the established accruals for liabilities. Liabilities for losses are recorded based upon the Company’s estimates for both claims incurred and claims incurred but not reported and are not discounted. The provisions are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Compensation Plans | Stock Compensation Plans In accordance with ASC Topic 718, Compensation – Stock Compensation, the Company recognizes compensation expense on a straight-line basis over the employee’s vesting period or to the employee’s retirement eligible date, if earlier. See Note 14, Stock Compensation Plans for more information on the Company’s stock-based compensation plans. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | Income Taxes The Company accounts for income taxes according to the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to tax laws using rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. In determining the provision for income taxes, the Company uses income, permanent differences between book and tax income, the relative proportion of foreign and domestic income, enacted statutory income tax rates, projections of income subject to Subpart F rules and unrecognized tax benefits related to current year results. Discrete events such as the assessment of the ultimate outcome of tax audits, audit settlements, recognizing previously unrecognized tax benefits due to lapsing of the applicable statute of limitations, recognizing or de-recognizing benefits of deferred tax assets due to future year financial statement projections and changes in tax laws are recognized in the period in which they occur. The Company is subject to routine income tax audits that occur periodically in the normal course of business. U.S. federal, state, local and foreign tax authorities raise questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. In evaluating the tax benefits associated with the various tax filing positions, the Company records a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more likely than not to be realized. Adjustments are made to the liability for unrecognized tax benefits in the period in which the Company determines the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | Earnings Per Share The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. Outstanding options to purchase common shares that were anti-dilutive and excluded from earnings per share totaled 2.5 million, 2.5 million and 3.5 million in fiscal 2016, 2015 and 2014, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Pronouncements | New Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (“FASB) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the effect this ASU will have on our consolidated statement of cash flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. This ASU is effective for fiscal years beginning after December 15, 2019 (fiscal 2021), including interim periods within those fiscal years, with early adoption permitted. The Company does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position. In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the employee share-based payment accounting of stock compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term must be applied prospectively. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement must be applied retrospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. This ASU is effective for annual periods after December 15, 2016 (fiscal 2018), and interim periods within those fiscal years, with early adoption permitted. The Company is early adopting this guidance at the beginning of Fiscal 2017 and does not expect adoption will have a material impact on the Company's results of operations, cash flows or financial position. In March 2016, the FASB issued ASU 2016-04, Liabilities – Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products. This ASU addresses diversity in practice related to the de-recognition of a prepaid store-value product liability. The ASU amends the guidance on extinguishing financial liabilities for certain prepaid store-value products. If an entity selling prepaid store-value products expects to be entitled to an amount that will not be redeemed, the entity will recognize the expected breakage in proportion to the pattern of rights expected to be exercised by the product holder to the extent that it is probable that a significant reversal of the breakage amount will not subsequently occur. The ASU is effective for annual periods beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted, including adoption before the effective date of ASU 2015-14, Revenue from Contracts with Customers (described below). The amendments in this ASU should be applied either using a modified retrospective transition method by means of a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is effective or retrospectively to each period presented. The Company is currently evaluating the effect the ASU will have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. There are two approaches for amortizing the right-of use asset. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. If there is no sale for the seller-lessee, the buyer-lessor does not account for a purchase. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company’s financial position. The impact on the Company’s results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company’s cash position. In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10). This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previous held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is permitted, for fiscal years or interim periods that have not yet been issued as of the beginning of the fiscal year of adoption. The Company is evaluating the effect of adopting this new accounting guidance. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). This ASU simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement of financial position. This ASU may be applied either prospectively to all deferred tax assets and liabilities, or retrospectively to all periods presented for annual periods beginning after December 16, 2016 and interim periods thereafter (fiscal 2018), with early adoption permitted, and may require additional disclosure based on the application method selected. The Company prospectively early adopted this ASU in the fourth quarter of 2016. The adoption did not result in a material reclassification in our statement of financial position. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), an update to ASU 2014-09. This ASU amends ASU 2014-09 to defer the effective date by one year for annual reporting periods beginning after December 15, 2017 (fiscal 2019). Subsequently, the FASB has also issued accounting standards updates which clarify the guidance. This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Early adoption is permitted for annual reporting periods beginning after December 15, 2016 (fiscal 2018). In transition, the ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance including the transition method. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This ASU simplifies current accounting treatments by requiring entities to measure most inventories at “the lower of cost and net realizable value” rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position. |
Summary of Major Accounting Policies (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Major Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Property, Plant and Equipment | Property, plant and equipment consists of (in millions):
|
Restructuring (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Costs by Segment | Restructuring costs by segment are as follows (in millions):
|
Leases (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Future Minimum Lease Payments for Capital Lease and Operating Lease | Annual minimum rental commitments under all leases having an initial or remaining non-cancelable term of more than one year are shown below (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserve for Facility Closings and Related Lease Termination Charges | The changes in reserve for facility closings and related lease termination charges include the following (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Rental Expense | Rental expense, which includes common area maintenance, insurance and taxes, where appropriate, was as follows (in millions):
|
Equity Method Investments (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment | Equity method investments as of August 31, 2016 and 2015 were as follows (in millions, except percentages):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summarized Financial Information of Equity Method Investees | Summarized financial information for the Company’s equity method investment in Alliance Boots is as follows:
|
Available-for-Sale Investments (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available-for-Sale Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Cost and Fair Value of Available-for-Sale Securities | A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):
|
Acquisitions (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Impact of Equity Transaction | The impact of the equity transaction is as follows (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Business Acquisition Total Consideration Paid | The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Identified Definite and Indefinite Lived Intangible Assets | The identified definite and indefinite lived intangible assets were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Unaudited Pro Forma Results Prepared for Comparative Purposes | Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Actual Results from Business Operation | Actual results from Alliance Boots operations included in the Consolidated Statements of Earnings since December 31, 2014, the date of the Second Step Transaction, are as follows (in millions, except per share amounts):
|
Goodwill and Other Intangible Assets (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Goodwill | Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets by Major Class | The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | Estimated annual amortization expense for intangible assets recorded at August 31, 2016 is as follows (in millions):
|
Borrowings (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Borrowings | Borrowings consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-Term Debt |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Maturities of Long-Term Debt | At August 31, 2016, the future maturities of long-term debt, excluding debt discounts and issuance costs and financing and capital lease obligations (see Note 4, Leases, for the future lease obligation maturities), consisted of the following ($ in millions):
|
Financial Instruments (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notional Amounts of Derivative Instruments Outstanding | The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2016 and 2015 were as follows (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Derivative Assets at Fair Value | The Company reports its warrants at fair value. The fair value and balance sheet presentation of warrants was as follows (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Not Designated as Hedging Instrument [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gains and Losses due to Changes in Fair Value Recognized in Earnings | These derivative instruments are economic hedges of interest rate and foreign currency risks. Income or expense due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Not Designated as Hedging Instrument [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gains and Losses due to Changes in Fair Value Recognized in Earnings | The gains and losses due to changes in fair value of the warrants recognized in earnings were as follows (in millions):
|
Fair Value Measurements (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities Measured at Fair Value on a Recurring Basis | Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
|
Income Taxes (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Income before Income Tax, Domestic and Foreign | The components of Earnings Before Income Tax Provision were (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Provisions for Income Taxes | The provision for income taxes consists of the following (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Difference Between the Statutory Federal Income Tax Rate and the Effective Tax Rate | The difference between the statutory federal income tax rate and the effective tax rate is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred Tax Assets and Liabilities Included in the Consolidated Balance Sheet | The deferred tax assets and liabilities included in the Consolidated Balance Sheets consist of the following (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of the Total Amounts of Unrecognized Tax Benefits | The following table provides a reconciliation of the total amounts of unrecognized tax benefits (in millions):
|
Retirement Benefits (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retirement Benefits [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Percentage of Defined Benefit Pension Plan Assets | Defined benefit pension plan assets were invested in the following classes of securities as of August 31:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Defined Benefit Plans Using Fair Value Hierarchy | The following table presents defined benefit pension plan assets using the fair value hierarchy as of August 31, 2016 (in millions).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Net Periodic Benefit Costs | Components of net periodic pension costs for the defined benefit pension plans (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated and Projected Benefit Obligations | Change in benefit obligations for the defined benefit pension plans (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in Fair Value of Plan Assets | Change in plan assets for the defined benefit pension plans (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amounts Recognized in Balance Sheet | Amounts recognized in the Consolidated Balance Sheets (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-tax Amounts Recognized in Accumulated Other Comprehensive (Income) Loss | Pre-tax amounts recognized in accumulated other comprehensive (income) loss (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year | The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for all pension plans including accumulated benefit obligations in excess of plan assets at August 31, 2016 were as follows (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated Future Benefit Payments | Estimated future benefit payments from defined benefit pension plans to participants are as follows (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assumptions Used | The assumptions used in accounting for the defined benefit pension plans were as follows:
|
Accumulated Other Comprehensive Income (Loss) (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Accumulated Other Comprehensive Income (Loss) | The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for fiscal 2016, 2015 and 2014 (in millions):
|
Segment Reporting (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Revenue from Segments to Consolidated | The following table reflects results of operations of the Company’s reportable segments (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Operating Profit (Loss) from Segments to Consolidated | The following table reconciles adjusted operating income to operating income (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Geographic Data for Net Sales | Geographic data for sales is as follows (in millions):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Geographic Data for Long-Lived Assets | Geographic data for long-lived assets, defined as property, plant and equipment is as follows (in millions):
|
Related Parties (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Parties [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Related Party Transactions | Related party transactions (in millions):
|
Supplementary Financial Information (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplementary Financial Information [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities Included in Consolidated Balance Sheet Captions | Included in the Consolidated Balance Sheets captions are the following assets and liabilities (in millions):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Quarterly Results | Summary of Quarterly Results (Unaudited) (In millions, except per share amounts)
|
Organization (Details) £ in Millions, shares in Millions |
12 Months Ended | |
---|---|---|
Dec. 31, 2014
GBP (£)
Segment
shares
|
Aug. 31, 2016
Segment
|
|
Schedule of Equity Method Investments [Line Items] | ||
Number of reportable segment | Segment | 3 | 3 |
Common stock conversion ratio | 1 | |
Walgreens Boots Alliance [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
Increased ownership percentage of Alliance Boots | 55.00% | |
Total purchase price cash consideration | £ | £ 3,133 | |
Number of shares exchanged in acquisition (in shares) | shares | 144.3 |
Summary of Major Accounting Policies (Details) - USD ($) shares in Millions, $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Cash and Cash Equivalents [Abstract] | |||
Minimum number of days for settlement of credit and debit charges | 2 days | ||
Maximum number of days for settlement of credit and debit charges | 7 days | ||
Credit and debit card receivables | $ 114 | $ 165 | |
Restricted Cash [Abstract] | |||
Restricted cash | 185 | 184 | |
Accounts Receivable [Abstract] | |||
Allowance for doubtful accounts | 166 | 172 | $ 173 |
Inventory [Line Items] | |||
Inventory, LIFO Reserve | 2,800 | 2,500 | |
Total carrying value of inventory | 8,956 | 8,678 | |
Property, Plant and Equipment [Line Items] | |||
Property and equipment | 22,935 | 22,608 | |
Less: accumulated depreciation and amortization | 8,600 | 7,540 | |
Property and equipment, net | 14,335 | 15,068 | |
Depreciation expense for property and equipment | 1,300 | 1,300 | 923 |
Impaired Assets [Abstract] | |||
Impairment charges | 30 | 110 | |
Liabilities for Store Closings [Abstract] | |||
Reserve for store closings | 466 | 446 | |
Advertising Costs [Abstract] | |||
Net advertising expenses included in selling, general and administrative expenses | $ 598 | $ 491 | $ 265 |
Earnings Per Share [Abstract] | |||
Outstanding options to purchase common shares excluded from earnings per share calculations (in shares) | 2.5 | 2.5 | 3.5 |
Minimum [Member] | |||
Derivative [Line Items] | |||
Highly effective hedging percentage | 80.00% | ||
Maximum [Member] | |||
Derivative [Line Items] | |||
Highly effective hedging percentage | 125.00% | ||
Selling, General and Administrative Expenses [Member] | |||
Impaired Assets [Abstract] | |||
Impairment charges | $ 167 | ||
Retail Pharmacy USA [Member] | |||
Inventory [Line Items] | |||
Total carrying value of inventory | $ 6,100 | $ 5,600 | |
Retail Pharmacy International and Pharmaceutical Wholesale [Member] | |||
Inventory [Line Items] | |||
Total carrying value of inventory | 2,900 | 3,100 | |
Cost Transformation Restructuring Program [Member] | |||
Liabilities for Store Closings [Abstract] | |||
Reserve for store closings | 91 | ||
Cost Transformation Restructuring Program [Member] | Selling, General and Administrative Expenses [Member] | |||
Impaired Assets [Abstract] | |||
Impairment charges | $ 305 | 386 | |
Land and Land Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life of assets | 20 years | ||
Property and equipment | $ 3,738 | 3,687 | |
Buildings and Building Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment | $ 7,557 | 7,705 | |
Buildings and Building Improvements [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life of assets | 3 years | ||
Buildings and Building Improvements [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life of assets | 50 years | ||
Fixtures and Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment | $ 9,064 | 8,904 | |
Fixtures and Equipment [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life of assets | 3 years | ||
Fixtures and Equipment [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life of assets | 20 years | ||
Capitalized System Development Costs and Software [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment | $ 1,787 | 1,491 | |
Internally developed software amortization | 238 | 178 | $ 127 |
Unamortized capitalized software costs | $ 900 | 1,000 | |
Capitalized System Development Costs and Software [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of capitalized software costs | 3 years | ||
Capitalized System Development Costs and Software [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of capitalized software costs | 8 years | ||
Capital Lease Properties [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment | $ 789 | $ 821 |
Restructuring (Details) - USD ($) $ in Millions |
12 Months Ended | 24 Months Ended | ||
---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
Aug. 31, 2016 |
|
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | $ 424 | $ 559 | $ 209 | |
Retail Pharmacy USA [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 374 | 540 | 209 | |
Retail Pharmacy International [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 29 | 19 | 0 | |
Pharmaceutical Wholesale [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 21 | 0 | 0 | |
Asset Impairments [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 225 | 223 | 137 | |
Asset Impairments [Member] | Retail Pharmacy USA [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 215 | 216 | 137 | |
Asset Impairments [Member] | Retail Pharmacy International [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 10 | 7 | 0 | |
Asset Impairments [Member] | Pharmaceutical Wholesale [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 0 | 0 | 0 | |
Real Estate Costs [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 91 | 219 | 71 | |
Real Estate Costs [Member] | Retail Pharmacy USA [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 89 | 219 | 71 | |
Real Estate Costs [Member] | Retail Pharmacy International [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 1 | 0 | 0 | |
Real Estate Costs [Member] | Pharmaceutical Wholesale [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 1 | 0 | 0 | |
Severance and Other Business Transition and Exit Costs [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 108 | 117 | 1 | |
Severance and Other Business Transition and Exit Costs [Member] | Retail Pharmacy USA [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 70 | 105 | 1 | |
Severance and Other Business Transition and Exit Costs [Member] | Retail Pharmacy International [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 18 | 12 | 0 | |
Severance and Other Business Transition and Exit Costs [Member] | Pharmaceutical Wholesale [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Total restructuring costs | 20 | 0 | $ 0 | |
Lease Termination Costs [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Pre-tax charges incurred during the period | 17 | |||
Cost Transformation Program [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Pre-tax charges incurred during the period | 424 | $ 542 | $ 966 | |
Cost Transformation Program [Member] | Minimum [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Expected pre-tax charges | 1,300 | 1,300 | ||
Cost Transformation Program [Member] | Maximum [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Expected pre-tax charges | $ 1,500 | 1,500 | ||
Cost Transformation Program [Member] | Asset Impairments [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Pre-tax charges incurred during the period | 448 | |||
Cost Transformation Program [Member] | Real Estate Costs [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Pre-tax charges incurred during the period | 293 | |||
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member] | ||||
Restructuring Reserve Disclosures [Abstract] | ||||
Pre-tax charges incurred during the period | $ 225 |
Leases (Details) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016
USD ($)
Lease
|
Aug. 31, 2015
USD ($)
|
Aug. 31, 2014
USD ($)
|
|
Leases [Abstract] | |||
Interval period of renewal options | 5 years | ||
Proceeds from sale leaseback transactions | $ 60 | $ 867 | $ 67 |
Financing Obligation [Abstract] | |||
2017 | 18 | ||
2018 | 18 | ||
2019 | 18 | ||
2020 | 18 | ||
2021 | 18 | ||
Later | 1,267 | ||
Total minimum lease payments | 1,357 | ||
Capital Lease [Abstract] | |||
2017 | 68 | ||
2018 | 62 | ||
2019 | 59 | ||
2020 | 58 | ||
2021 | 57 | ||
Later | 966 | ||
Total minimum lease payments | 1,270 | ||
Operating Lease [Abstract] | |||
2017 | 3,066 | ||
2018 | 2,972 | ||
2019 | 2,826 | ||
2020 | 2,632 | ||
2021 | 2,403 | ||
Later | 20,190 | ||
Total minimum lease payments | 34,089 | ||
Imputed interest and executory costs | 1,700 | ||
Charges related to facilities that were closed or relocated | $ 127 | 252 | 177 |
Number of leases | Lease | 79 | ||
Changes in reserve for facility closings and related lease termination charges [Roll Forward] | |||
Balance at beginning of period | $ 446 | 257 | |
Provision for present value of non-cancellable lease payments on closed facilities | 134 | 231 | |
Assumptions about future sublease income, terminations and changes in interest rates | (34) | (6) | |
Interest accretion | 27 | 27 | |
Liability assumed through acquisition of Alliance Boots | 0 | 13 | |
Cash payments, net of sublease income | (107) | (76) | |
Balance at end of period | 466 | 446 | 257 |
Rent Expense [Abstract] | |||
Minimum rentals | 3,355 | 3,176 | 2,687 |
Contingent rentals | 60 | 38 | 5 |
Less: Sublease rental income | (49) | (46) | (22) |
Total rental expense | $ 3,366 | $ 3,168 | $ 2,670 |
Minimum [Member] | |||
Leases [Abstract] | |||
Initial term of operating lease | 15 years | ||
Operating Lease [Abstract] | |||
Sublease rentals | $ 199 | ||
Maximum [Member] | |||
Leases [Abstract] | |||
Initial term of operating lease | 25 years | ||
Operating Lease [Abstract] | |||
Potential undiscounted future payments | $ 340 |
Equity Method Investments, Equity Method Investment (Details) - USD ($) $ in Millions |
Aug. 31, 2016 |
Aug. 31, 2015 |
---|---|---|
Schedule of Equity Method Investments [Line Items] | ||
Carrying value | $ 6,174 | $ 1,242 |
AmerisourceBergen [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
Carrying value | $ 4,964 | |
Increased ownership percentage of Alliance Boots | 24.00% | |
Other [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
Carrying value | $ 1,210 | $ 1,242 |
Other [Member] | Minimum [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
Equity method investment ownership interest percentage | 12.00% | 12.00% |
Other [Member] | Maximum [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
Equity method investment ownership interest percentage | 50.00% | 50.00% |
Total [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
Carrying value | $ 6,174 | $ 1,242 |
Equity Method Investments (Details) - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | |||||
---|---|---|---|---|---|---|
Aug. 25, 2016 |
Mar. 18, 2016 |
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
Dec. 31, 2014 |
|
Schedule of Equity Method Investments [Line Items] | ||||||
Equity earnings | $ 44 | $ 24 | $ 0 | |||
AmerisourceBergen Corporation [Member] | ||||||
Schedule of Equity Method Investments [Line Items] | ||||||
Warrant issued to purchase common stock (in shares) | 22,696,912 | 22,696,912 | 0 | |||
Warrant exercise price (in dollars per share) | $ 52.50 | $ 51.50 | ||||
Warrants aggregate exercise price payment | $ 1,190 | $ 1,170 | ||||
Outstanding shares owned (in shares) | 56,854,867 | |||||
Percentage of outstanding common shares owned | 24.00% | |||||
Period of reporting lag | 2 months 15 days | |||||
Period of using equity method accounting | 3 months 15 days | |||||
Equity investment, exceeded its proportionate share of net assets | $ 4,500 | |||||
Other Investments [Member] | ||||||
Schedule of Equity Method Investments [Line Items] | ||||||
Equity earnings | $ 44 | $ 24 | ||||
Alliance Boots [Member] | ||||||
Schedule of Equity Method Investments [Line Items] | ||||||
Period of reporting lag | 3 months | |||||
Equity method investment ownership interest percentage | 45.00% | 45.00% |
Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) - USD ($) $ in Millions |
12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
||||||
Income Statement [Abstract] | ||||||||
Net sales | [1] | $ 13,071 | $ 37,579 | |||||
Gross Profit | [1] | 3,050 | 8,096 | |||||
Net Earnings | [1] | 723 | 1,444 | |||||
Share of earnings from equity method investments | $ 0 | $ 315 | [1] | $ 617 | [1] | |||
|
Available-for-Sale Investments (Details) - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | ||
---|---|---|---|
Mar. 18, 2016 |
Aug. 31, 2016 |
Aug. 31, 2015 |
|
Summary of cost and fair value of available-for-sale securities [Abstract] | |||
Amortized cost basis | $ 754 | ||
Gross unrealized gains | 430 | ||
Gross unrealized (losses) | (1) | ||
Fair value | 1,183 | ||
Available for sale securities, current | $ 32 | 36 | |
AmerisourceBergen Common Stock [Member] | |||
Summary of cost and fair value of available-for-sale securities [Abstract] | |||
Amortized cost basis | 717 | ||
Gross unrealized gains | 430 | ||
Gross unrealized (losses) | 0 | ||
Fair value | 1,147 | ||
Warrant to purchase common stock (in shares) | 22,696,912 | ||
Warrant exercise price (in dollars per share) | $ 51.50 | ||
Gain from reclassification of income from other comprehensive income to other income (expense) | $ 268 | ||
Sale of acquired available-for-sale securities | 7 | 52 | |
Corporate Bonds and Treasury Bills [Member] | |||
Summary of cost and fair value of available-for-sale securities [Abstract] | |||
Amortized cost basis | 30 | 37 | |
Gross unrealized gains | 2 | 0 | |
Gross unrealized (losses) | 0 | (1) | |
Fair value | $ 32 | $ 36 |
Acquisitions (Details) $ / shares in Units, £ in Millions |
Jan. 01, 2015
USD ($)
shares
|
Dec. 31, 2014
USD ($)
shares
|
Dec. 31, 2014
GBP (£)
shares
|
Aug. 31, 2016
shares
|
Aug. 31, 2015
shares
|
Dec. 30, 2014
$ / shares
|
---|---|---|---|---|---|---|
Business Acquisition [Line Items] | ||||||
Common shares transfer (in shares) | shares | 1,172,513,618 | 1,172,513,618 | ||||
Alliance Boots [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Acquisition, Percentage of issued and outstanding capital acquired | 55.00% | 55.00% | ||||
Noncontrolling interest | 100.00% | 100.00% | ||||
Total purchase price cash consideration | $ 4,874,000,000 | £ 3,133 | ||||
Spot rate | 1.56 | 1.56 | ||||
Purchase price consideration, common shares (in shares) | shares | 144,300,000 | 144,300,000 | ||||
Closing market price per share (in dollars per share) | $ / shares | $ 76.05 | |||||
Preliminary impact of equity transactions [Abstract] | ||||||
Consideration attributed to WBAD | $ 2,559,000,000 | |||||
Less: Carrying value of the Company's pre-existing noncontrolling interest | 130,000,000 | |||||
Impact to additional paid in capital | $ 2,429,000,000 | |||||
Alliance Boots [Member] | Previously Reported [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Equity method investment ownership interest percentage | 45.00% | |||||
Walgreens Boots Alliance Development GmbH [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Noncontrolling interest | 100.00% | 100.00% | 27.50% | |||
Ownership interest percentage prior to Second Step Transaction | 50.00% | |||||
Equity method ownership option to repurchase shares, amount | $ 100,000 | |||||
Alliance Healthcare Italia Distribuzione S.p.A. [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Equity method investment ownership interest percentage | 5.00% | |||||
Common shares transfer (in shares) | shares | 320 |
Acquisitions, Consideration Paid (Details) - Dec. 31, 2014 - Alliance Boots [Member] £ in Millions, $ in Millions |
USD ($) |
GBP (£) |
---|---|---|
Consideration paid [Abstract] | ||
Cash | $ 4,874 | £ 3,133 |
Common stock | 10,977 | |
Total consideration transferred | 15,851 | |
Less: consideration attributed to WBAD | (2,559) | |
Total consideration after attributed amount to WBAD | 13,292 | |
Fair value of the investment in Alliance Boots held before the Second Step Transaction | 8,149 | |
Total consideration | $ 21,441 |
Acquisitions, Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests (Details) - USD ($) $ in Millions |
12 Months Ended | |||
---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
Dec. 31, 2014 |
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] | ||||
Goodwill | $ 15,527 | $ 16,372 | $ 2,359 | |
Gain on previously held equity interest | 0 | 563 | $ 0 | |
Alliance Boots [Member] | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] | ||||
Cash and cash equivalents | $ 413 | |||
Accounts receivable | 3,799 | |||
Inventories | 3,713 | |||
Other current assets | 894 | |||
Property, plant and equipment | 3,806 | |||
Intangible assets | 11,691 | |||
Other non-current assets | 2,217 | |||
Trade accounts payable, accrued expenses and other liabilities | (7,696) | |||
Borrowings | (9,010) | |||
Deferred income taxes | (2,452) | |||
Other non-current liabilities | (383) | |||
Noncontrolling interests | (412) | |||
Total identifiable net assets and noncontrolling interests | 6,580 | |||
Goodwill | $ 14,861 | |||
Gain on previously held equity interest | $ 563 | |||
Fair value of previously held equity interest | $ 8,100 |
Acquisitions, The Preliminary Identified Definite and Indefinite Lived Intangible Assets (Details) $ in Millions |
12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2014
USD ($)
Segment
|
Aug. 31, 2016
USD ($)
Segment
|
Aug. 31, 2015
USD ($)
|
Aug. 31, 2014
USD ($)
|
|
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Goodwill | $ 23 | $ 14,972 | ||
Number of reportable segments | Segment | 3 | 3 | ||
Selling, general and administrative expenses | $ 23,910 | 22,400 | $ 17,992 | |
Fair value of the assets acquired | 3,700 | |||
Estimated manufacturing profit in acquired finished goods inventory capitalized | 106 | |||
Retail Pharmacy International [Member] | ||||
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Goodwill | 23 | 4,036 | ||
Retail Pharmacy USA [Member] | ||||
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Goodwill | 0 | 7,290 | ||
Goodwill arising from synergies | 3,500 | |||
Goodwill based on a with and without analysis | 3,800 | |||
Pharmaceutical Wholesale [Member] | ||||
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Goodwill | $ 0 | 3,646 | ||
Alliance Boots [Member] | ||||
Definite-Lived Intangible Assets [Roll Forward] | ||||
Amount | $ 2,545 | |||
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Amount | 9,146 | |||
Selling, general and administrative expenses | $ 87 | |||
Trade Names and Trademarks [Member] | Alliance Boots [Member] | ||||
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Amount | 6,657 | |||
Pharmacy Licenses [Member] | Alliance Boots [Member] | ||||
Indefinite-Lived Intangible Assets [Roll Forward] | ||||
Amount | $ 2,489 | |||
Customer Relationships [Member] | Alliance Boots [Member] | ||||
Definite-Lived Intangible Assets [Roll Forward] | ||||
Weighted-Average Useful Life | 12 years | |||
Amount | $ 1,311 | |||
Loyalty Card Holders [Member] | Alliance Boots [Member] | ||||
Definite-Lived Intangible Assets [Roll Forward] | ||||
Weighted-Average Useful Life | 20 years | |||
Amount | $ 742 | |||
Trade Names and Trademarks [Member] | Alliance Boots [Member] | ||||
Definite-Lived Intangible Assets [Roll Forward] | ||||
Weighted-Average Useful Life | 9 years | |||
Amount | $ 399 | |||
Favorable Lease Interests [Member] | Alliance Boots [Member] | ||||
Definite-Lived Intangible Assets [Roll Forward] | ||||
Weighted-Average Useful Life | 7 years | |||
Amount | $ 93 |
Acquisitions, Unaudited Pro Forma Results Prepared for Comparative Purposes (Details) - Alliance Boots [Member] - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | |
---|---|---|
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Business Acquisition [Line Items] | ||
Net sales | $ 116,491 | $ 113,896 |
Net earnings | $ 4,278 | $ 3,884 |
Net earnings per common share [Abstract] | ||
Basic (in dollars per share) | $ 4.10 | $ 3.54 |
Diluted (in dollars per share) | $ 4.06 | $ 3.50 |
Acquisitions, Actual Results from Alliance Boots Operations Included in the Consolidated Condensed Statements of Earnings (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | 12 Months Ended | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
May 31, 2016 |
Feb. 29, 2016 |
Nov. 30, 2015 |
Aug. 31, 2015 |
May 31, 2015 |
Feb. 28, 2015 |
Nov. 30, 2014 |
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
Dec. 31, 2014 |
||||
Net earnings per common share [Abstract] | |||||||||||||||
Basic (in dollars per share) | [1] | $ 0.95 | $ 1.02 | $ 0.86 | $ 1.02 | $ 0.02 | $ 1.19 | $ 1.96 | $ 0.90 | $ 3.85 | $ 4.05 | ||||
Diluted (in dollars per share) | [1] | $ 0.95 | $ 1.01 | $ 0.85 | $ 1.01 | $ 0.02 | $ 1.18 | $ 1.93 | $ 0.89 | $ 3.82 | $ 4.00 | ||||
Aggregate purchase price net of cash received | $ 0 | $ 4,461 | $ 0 | ||||||||||||
Goodwill | 23 | 14,972 | |||||||||||||
Alliance Boots [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Net sales | 22,470 | ||||||||||||||
Net earnings | $ 853 | ||||||||||||||
Net earnings per common share [Abstract] | |||||||||||||||
Basic (in dollars per share) | $ 0.82 | ||||||||||||||
Diluted (in dollars per share) | $ 0.81 | ||||||||||||||
Intangible assets | $ 11,691 | ||||||||||||||
Other Acquisitions and Divestitures [Member] | |||||||||||||||
Net earnings per common share [Abstract] | |||||||||||||||
Aggregate purchase price net of cash received | 126 | $ 371 | |||||||||||||
Goodwill | 23 | 126 | |||||||||||||
Intangible assets | $ 95 | $ 255 | $ 95 | $ 255 | |||||||||||
|
Goodwill and Other Intangible Assets, Schedule of Goodwill (Details) - USD ($) $ in Millions |
12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
|||||||
Goodwill [Roll Forward] | ||||||||
Net book value - Beginning Period | $ 16,372 | $ 2,359 | ||||||
Acquisitions | 23 | 14,972 | ||||||
Sale of business | (4) | (706) | [1] | |||||
Other | [2] | 0 | (3) | |||||
Currency translation adjustments | (864) | (250) | ||||||
Net book value - Ending Period | 15,527 | 16,372 | ||||||
Retail Pharmacy USA [Member] | ||||||||
Goodwill [Roll Forward] | ||||||||
Net book value - Beginning Period | 8,940 | 2,359 | ||||||
Acquisitions | 0 | 7,290 | ||||||
Sale of business | (4) | (706) | [1] | |||||
Other | [2] | 100 | (3) | |||||
Currency translation adjustments | 0 | 0 | ||||||
Net book value - Ending Period | 9,036 | 8,940 | ||||||
Retail Pharmacy International [Member] | ||||||||
Goodwill [Roll Forward] | ||||||||
Net book value - Beginning Period | 3,898 | 0 | ||||||
Acquisitions | 23 | 4,036 | ||||||
Sale of business | 0 | 0 | [1] | |||||
Other | [2] | (113) | 0 | |||||
Currency translation adjustments | (439) | (138) | ||||||
Net book value - Ending Period | 3,369 | 3,898 | ||||||
Pharmaceutical Wholesale [Member] | ||||||||
Goodwill [Roll Forward] | ||||||||
Net book value - Beginning Period | 3,534 | 0 | ||||||
Acquisitions | 0 | 3,646 | ||||||
Sale of business | 0 | 0 | [1] | |||||
Other | [2] | 13 | 0 | |||||
Currency translation adjustments | (425) | (112) | ||||||
Net book value - Ending Period | $ 3,122 | $ 3,534 | ||||||
|
Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions |
12 Months Ended | |||
---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
Dec. 31, 2014 |
|
Goodwill [Line Items] | ||||
Goodwill | $ 15,527 | $ 16,372 | $ 2,359 | |
Amortization expense for intangible assets | 396 | $ 480 | $ 282 | |
Alliance Boots [Member] | ||||
Goodwill [Line Items] | ||||
Goodwill | $ 14,861 | |||
Intangible assets | $ 11,691 | |||
International Beauty Brand [Member] | ||||
Goodwill [Line Items] | ||||
Goodwill | 23 | |||
Intangible assets | $ 95 |
Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) - USD ($) $ in Millions |
Aug. 31, 2016 |
Aug. 31, 2015 |
---|---|---|
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amortizable Intangible Assets | $ 4,044 | $ 4,387 |
Accumulated amortization | 1,439 | 1,090 |
Total amortizable intangible assets, net | 2,605 | 3,297 |
Total Indefinite-Lived intangible assets | 7,697 | 9,054 |
Total intangible assets, net | 10,302 | 12,351 |
Customer Relationships and Loyalty Card Holders [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amortizable Intangible Assets | 1,867 | 2,139 |
Accumulated amortization | 275 | 173 |
Purchased Prescription Files [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amortizable Intangible Assets | 932 | 885 |
Accumulated amortization | 600 | 470 |
Favorable Lease Interests and Non-compete Agreements [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amortizable Intangible Assets | 619 | 594 |
Accumulated amortization | 388 | 299 |
Trade Names and Trademarks [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amortizable Intangible Assets | 532 | 675 |
Accumulated amortization | 105 | 83 |
Total Indefinite-Lived intangible assets | 5,604 | 6,590 |
Purchasing and Payer Contracts [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amortizable Intangible Assets | 94 | 94 |
Accumulated amortization | 71 | 65 |
Pharmacy Licenses [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total Indefinite-Lived intangible assets | $ 2,093 | $ 2,464 |
Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Millions |
Aug. 31, 2016
USD ($)
|
---|---|
Estimated annual intangible assets amortization expense [Abstract] | |
2017 | $ 357 |
2018 | 319 |
2019 | 293 |
2020 | 243 |
2021 | $ 199 |
Borrowings, Short-Term Borrowings (Details) - USD ($) $ in Millions |
12 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
||||||
Short-Term Borrowings [Abstract] | |||||||
Other | $ 323 | $ 1,068 | |||||
Unsecured Pound Sterling Variable Rate Term Loan Due 2019 [Member] | |||||||
Short-Term Borrowings [Abstract] | |||||||
Unsecured notes | [1] | $ 63 | 0 | ||||
Maturity year | [1] | 2019 | |||||
Unsecured Variable Rate Notes Due 2016 [Member] | |||||||
Short-Term Borrowings [Abstract] | |||||||
Unsecured notes | [1] | $ 0 | 747 | ||||
Maturity year | [1] | 2016 | |||||
Other Short-Term Debt [Member] | |||||||
Short-Term Borrowings [Abstract] | |||||||
Other | [1],[2] | $ 260 | 321 | ||||
Total short-term borrowings | [1] | $ 323 | $ 1,068 | ||||
|
Borrowings, Long-Term Debt (Details) - USD ($) $ in Millions |
12 Months Ended | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Other | [1],[2] | $ 32 | $ 44 | ||||||||||||||||
Total long-term debt | [1] | 18,705 | 13,315 | ||||||||||||||||
Unsecured Pound Sterling Variable Rate Term Loan Due 2019 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[3] | $ 1,833 | 2,229 | ||||||||||||||||
Maturity year | [1],[3] | 2019 | |||||||||||||||||
1.750% unsecured notes due 2018 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5] | $ 1,246 | 0 | ||||||||||||||||
Stated interest rate | [1],[4],[5] | 1.75% | |||||||||||||||||
Maturity year | [1],[4],[5] | 2018 | |||||||||||||||||
2.600% unsecured notes due 2021 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[6] | $ 1,493 | 0 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[6] | 2.60% | |||||||||||||||||
Maturity year | [1],[4],[5],[6] | 2021 | |||||||||||||||||
3.100% unsecured notes due 2023 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[6] | $ 744 | 0 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[6] | 3.10% | |||||||||||||||||
Maturity year | [1],[4],[5],[6] | 2023 | |||||||||||||||||
3.450% unsecured notes due 2026 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[3],[4],[5] | $ 1,885 | 0 | ||||||||||||||||
Stated interest rate | [1],[3],[4],[5] | 3.45% | |||||||||||||||||
Maturity year | [1],[3],[4],[5] | 2026 | |||||||||||||||||
4.650% unsecured notes due 2046 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[3],[4],[5] | $ 590 | 0 | ||||||||||||||||
Stated interest rate | [1],[3],[4],[5] | 4.65% | |||||||||||||||||
Maturity year | [1],[3],[4],[5] | 2046 | |||||||||||||||||
1.750% Unsecured Notes due 2017 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5] | $ 746 | 746 | ||||||||||||||||
Stated interest rate | [1],[4],[5] | 1.75% | |||||||||||||||||
Maturity year | [1],[4],[5] | 2017 | |||||||||||||||||
2.700% Unsecured Notes Due 2019 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5] | $ 1,244 | 1,243 | ||||||||||||||||
Stated interest rate | [1],[4],[5] | 2.70% | |||||||||||||||||
Maturity year | [1],[4],[5] | 2019 | |||||||||||||||||
3.300% Unsecured Notes Due 2021 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5] | $ 1,242 | 1,241 | ||||||||||||||||
Stated interest rate | [1],[4],[5] | 3.30% | |||||||||||||||||
Maturity year | [1],[4],[5] | 2021 | |||||||||||||||||
3.800% Unsecured Notes Due 2024 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[3],[4],[5] | $ 1,987 | 1,985 | ||||||||||||||||
Stated interest rate | [1],[3],[4],[5] | 3.80% | |||||||||||||||||
Maturity year | [1],[3],[4],[5] | 2024 | |||||||||||||||||
4.500% Unsecured Notes Due 2034 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[3],[4],[5] | $ 494 | 494 | ||||||||||||||||
Stated interest rate | [1],[3],[4],[5] | 4.50% | |||||||||||||||||
Maturity year | [1],[3],[4],[5] | 2034 | |||||||||||||||||
4.800% Unsecured Notes Due 2044 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[7] | $ 1,492 | 1,491 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[7] | 4.80% | |||||||||||||||||
Maturity year | [1],[4],[5],[7] | 2044 | |||||||||||||||||
2.875% Unsecured Pound Sterling Notes Due 2020 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[6] | $ 521 | 612 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[6] | 2.875% | |||||||||||||||||
Maturity year | [1],[4],[5],[6] | 2020 | |||||||||||||||||
3.600% Unsecured Pound Sterling Notes Due 2025 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[6] | $ 391 | 459 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[6] | 3.60% | |||||||||||||||||
Maturity year | [1],[4],[5],[6] | 2025 | |||||||||||||||||
2.125% Unsecured Euro Notes Due 2026 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[7] | $ 830 | 836 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[7] | 2.125% | |||||||||||||||||
Maturity year | [1],[4],[5],[7] | 2026 | |||||||||||||||||
3.100% Unsecured Notes Due 2022 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[8] | $ 1,194 | 1,193 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[8] | 3.10% | |||||||||||||||||
Maturity year | [1],[4],[5],[8] | 2022 | |||||||||||||||||
4.400% Unsecured Notes Due 2042 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[5],[8] | $ 492 | 492 | ||||||||||||||||
Stated interest rate | [1],[4],[5],[8] | 4.40% | |||||||||||||||||
Maturity year | [1],[4],[5],[8] | 2042 | |||||||||||||||||
5.250% Unsecured Notes Due 2019 [Member] | |||||||||||||||||||
Long-Term Debt [Abstract] | |||||||||||||||||||
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment | [1],[4],[8] | $ 249 | $ 250 | ||||||||||||||||
Stated interest rate | [1],[4],[8] | 5.25% | |||||||||||||||||
Maturity year | [1],[4],[8] | 2019 | |||||||||||||||||
|
Borrowings, Long-Term Debt by Future Maturity (Details) $ in Millions |
Aug. 31, 2016
USD ($)
|
---|---|
Long Term Debt by Future Maturity [Abstract] | |
2017 | $ 323 |
2018 | 2,137 |
2019 | 416 |
2020 | 2,808 |
2021 | 2,024 |
Later | 11,442 |
Total estimated future maturities | $ 19,150 |
Borrowings, Note Issuances (Details) $ in Millions |
12 Months Ended |
---|---|
Aug. 31, 2016
USD ($)
| |
Total $6.0 billion debt issuance [Member] | |
Long-Term Debt [Abstract] | |
Net proceeds from notes payable | $ 6,000 |
Total issuance costs | 30 |
Fair value of the notes | $ 6,200 |
Percentage of principal amount of fixed rate notes can be redeemed | 101.00% |
Total $8.0 Billion Debt Issuance [Member] | |
Long-Term Debt [Abstract] | |
Repayment of debt | $ 750 |
Net proceeds from notes payable | 7,900 |
Total issuance costs | 42 |
Fair value of the notes | 7,700 |
Maximum aggregate outstanding amount of indebtedness | 2,000 |
Total $4.0 Billion Debt Issuance [Member] | |
Long-Term Debt [Abstract] | |
Fair value of the notes | 1,800 |
Total $1.0 Billion Debt Issuance [Member] | |
Long-Term Debt [Abstract] | |
Fair value of the notes | 300 |
Total 700 million Pounds Debt Issuance [Member] | |
Long-Term Debt [Abstract] | |
Fair value of the notes | 1,000 |
Total 750 million Euros Debt Issuance [Member] | |
Long-Term Debt [Abstract] | |
Fair value of the notes | 900 |
Total 700 million Pounds and 750 million Euros Debt Issuance [Member] | |
Long-Term Debt [Abstract] | |
Net proceeds from notes payable | 2,000 |
Total issuance costs | $ 11 |
Borrowings, Loan Agreements and Other Borrowings (Details) £ in Millions, $ in Millions |
3 Months Ended | 12 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
May 31, 2016
USD ($)
|
Aug. 31, 2016
USD ($)
Tranche
|
Aug. 31, 2015
USD ($)
|
Aug. 31, 2014
USD ($)
|
Aug. 31, 2016
GBP (£)
|
Dec. 18, 2015
USD ($)
|
Oct. 27, 2015
USD ($)
|
Nov. 10, 2014
USD ($)
|
|
Line of Credit Facility [Line Items] | ||||||||
Senior unsecured bridge facility | $ 7,800 | $ 12,800 | ||||||
Additional senior unsecured bridge facility | 2,000 | |||||||
Interest paid, net of capitalized interest | $ 580 | $ 472 | $ 161 | |||||
Commercial Paper [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Balance outstanding at fiscal year-end | 0 | 0 | ||||||
Average daily short-term borrowings | $ 14 | $ 82 | ||||||
Weighted-average interest rate | 0.66% | 0.52% | 0.66% | |||||
Additional Bridge Loan [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Maximum borrowing capacity | $ 5,000 | |||||||
Senior unsecured bridge facility | $ 3,000 | |||||||
Term of credit agreement | 90 days | |||||||
Bridge Credit Agreement [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Term of credit agreement | 364 days | |||||||
Reduced commitment amount | $ 6,000 | |||||||
Reduced commitment amount after issuance of notes | $ 1,800 | |||||||
Term Loan [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Maximum borrowing capacity | $ 1,900 | £ 1,450 | ||||||
Amount borrowed | £ | £ 1,450 | |||||||
Term Loan [Member] | Maximum [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Debt to total capitalization ratio | 0.60 | 0.60 | ||||||
Revolving Credit Facility [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Maximum borrowing capacity | $ 0 | $ 3,000 | ||||||
Term of facility | 5 years | |||||||
Letter of Credit [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Maximum borrowing capacity | $ 500 | |||||||
364-Day Credit Agreement [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Amount borrowed | $ 750 | |||||||
2015 Credit Agreements [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Fees related to borrowings | 30 | |||||||
2016 Credit Agreements [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Maximum borrowing capacity | 1,000 | |||||||
Reduced commitment amount | 1,000 | |||||||
Reduced commitment amount after issuance of notes | $ 800 | |||||||
Number of tranches | Tranche | 2 | |||||||
Tranche One [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Term of credit agreement | 3 years | |||||||
Tranche Two [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Term of credit agreement | 5 years |
Financial Instruments (Details) - USD ($) $ in Millions |
12 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
Aug. 10, 2015 |
||||
Effect of Fair Value Hedges on Results of Operations [Abstract] | |||||||
Cumulative fair value adjustments resulted in increase in long-term debt | $ 2 | $ 1 | |||||
Interest Rate Swaps [Member] | Six-month LIBOR [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Fair value | $ 750 | ||||||
Fixed interest rate percentage | 5.25% | ||||||
Cash Flow Hedges [Abstract] | |||||||
Derivative notional amount terminated | $ 500 | ||||||
Interest Rate Swaps [Member] | One-month LIBOR [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Fair value | $ 250 | ||||||
Fixed interest rate percentage | 5.25% | ||||||
Interest Rate Swaps [Member] | Derivatives Designated as Hedges [Member] | Other Non-currents Assets [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 250 | $ 250 | ||||
Fair value | 3 | 2 | |||||
Interest Rate Swaps [Member] | Derivatives Not Designated as Hedges [Member] | Interest Expense, Net [Member] | |||||||
Effect of Fair Value Hedges on Results of Operations [Abstract] | |||||||
Gains and losses due to changes in fair value of derivative instruments | 0 | 1 | $ 0 | ||||
Foreign Currency Forwards [Member] | Derivatives Designated as Hedges [Member] | Other Current Assets [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 1,205 | |||||
Fair value | 34 | ||||||
Foreign Currency Forwards [Member] | Derivatives Designated as Hedges [Member] | Other Current Liabilities [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 495 | |||||
Fair value | 9 | ||||||
Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Selling, General and Administrative Expenses [Member] | |||||||
Effect of Fair Value Hedges on Results of Operations [Abstract] | |||||||
Gains and losses due to changes in fair value of derivative instruments | 19 | 78 | 0 | ||||
Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Other Income (Expenses) [Member] | |||||||
Effect of Fair Value Hedges on Results of Operations [Abstract] | |||||||
Gains and losses due to changes in fair value of derivative instruments | (12) | 72 | 0 | ||||
Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Other Current Assets [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 1,177 | |||||
Fair value | 16 | ||||||
Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Other Current Liabilities [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 41 | |||||
Fair value | 0 | ||||||
Basis Swaps [Member] | Derivatives Designated as Hedges [Member] | Other Current Assets [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 1 | |||||
Fair value | 0 | ||||||
Basis Swaps [Member] | Derivatives Not Designated as Hedges [Member] | Other Current Liabilities [Member] | |||||||
Derivatives, Fair Value [Line Items] | |||||||
Notional | [1] | 2 | |||||
Fair value | 1 | ||||||
Second Step Transaction Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Other Income (Expenses) [Member] | |||||||
Effect of Fair Value Hedges on Results of Operations [Abstract] | |||||||
Gains and losses due to changes in fair value of derivative instruments | 0 | (166) | 0 | ||||
Warrants [Member] | Other Income (Expenses) [Member] | |||||||
Effect of Fair Value Hedges on Results of Operations [Abstract] | |||||||
Gains and losses due to changes in fair value of derivative instruments | $ (546) | $ 759 | $ 366 | ||||
|
Financial Instruments, Warrants (Details) - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | ||||
---|---|---|---|---|---|
Aug. 25, 2016 |
Mar. 18, 2016 |
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
AmerisourceBergen Corporation [Member] | |||||
Warrants [Abstract] | |||||
Warrant to purchase common stock (in shares) | 22,696,912 | 22,696,912 | 0 | ||
Warrant exercise price (in dollars per share) | $ 52.50 | $ 51.50 | |||
Warrants aggregate exercise price payment | $ 1,190 | $ 1,170 | |||
Interest Rate Swaps [Member] | Derivatives Not Designated as Hedges [Member] | Interest Expense, Net [Member] | |||||
Warrants [Abstract] | |||||
Gains and losses due to changes in fair value of derivative instruments | $ 0 | $ 1 | $ 0 | ||
Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Selling, General and Administrative Expenses [Member] | |||||
Warrants [Abstract] | |||||
Gains and losses due to changes in fair value of derivative instruments | 19 | 78 | 0 | ||
Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Other Income (Expenses) [Member] | |||||
Warrants [Abstract] | |||||
Gains and losses due to changes in fair value of derivative instruments | (12) | 72 | 0 | ||
Second Step Transaction Foreign Currency Forwards [Member] | Derivatives Not Designated as Hedges [Member] | Other Income (Expenses) [Member] | |||||
Warrants [Abstract] | |||||
Gains and losses due to changes in fair value of derivative instruments | 0 | (166) | 0 | ||
Warrants [Member] | Other Income (Expenses) [Member] | |||||
Warrants [Abstract] | |||||
Gains and losses due to changes in fair value of derivative instruments | (546) | 759 | $ 366 | ||
Warrants [Member] | Derivatives Not Designated as Hedges [Member] | Other Non-currents Assets [Member] | |||||
Warrants [Abstract] | |||||
Derivative asset | $ 0 | $ 2,140 |
Fair Value Measurements (Details) - Recurring [Member] - USD ($) $ in Millions |
Aug. 31, 2016 |
Aug. 31, 2015 |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Restricted Cash [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [1] | $ 185 | $ 184 | ||||||||||||
Money Market Funds [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [2] | 9,133 | 2,043 | ||||||||||||
Available-for-sale Investments [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [3] | 32 | 1,183 | ||||||||||||
Interest Rate Swaps [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [4] | 3 | 2 | ||||||||||||
Foreign Currency Forwards [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [5] | 16 | 34 | ||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 9 | |||||||||||||
Warrants [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [6] | 2,140 | |||||||||||||
Basis Swaps [Member] | |||||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 1 | |||||||||||||
Level 1 [Member] | Restricted Cash [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [1] | 185 | 184 | ||||||||||||
Level 1 [Member] | Money Market Funds [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [2] | 9,133 | 2,043 | ||||||||||||
Level 1 [Member] | Available-for-sale Investments [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [3] | 32 | 1,183 | ||||||||||||
Level 1 [Member] | Interest Rate Swaps [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [4] | 0 | 0 | ||||||||||||
Level 1 [Member] | Foreign Currency Forwards [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [5] | 0 | 0 | ||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 0 | |||||||||||||
Level 1 [Member] | Warrants [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [6] | 0 | |||||||||||||
Level 1 [Member] | Basis Swaps [Member] | |||||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 0 | |||||||||||||
Level 2 [Member] | Restricted Cash [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [1] | 0 | 0 | ||||||||||||
Level 2 [Member] | Money Market Funds [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [2] | 0 | 0 | ||||||||||||
Level 2 [Member] | Available-for-sale Investments [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [3] | 0 | 0 | ||||||||||||
Level 2 [Member] | Interest Rate Swaps [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [4] | 3 | 2 | ||||||||||||
Level 2 [Member] | Foreign Currency Forwards [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [5] | 16 | 34 | ||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 9 | |||||||||||||
Level 2 [Member] | Warrants [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [6] | 2,140 | |||||||||||||
Level 2 [Member] | Basis Swaps [Member] | |||||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 1 | |||||||||||||
Level 3 [Member] | Restricted Cash [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [1] | 0 | 0 | ||||||||||||
Level 3 [Member] | Money Market Funds [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [2] | 0 | 0 | ||||||||||||
Level 3 [Member] | Available-for-sale Investments [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [3] | 0 | 0 | ||||||||||||
Level 3 [Member] | Interest Rate Swaps [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [4] | 0 | 0 | ||||||||||||
Level 3 [Member] | Foreign Currency Forwards [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [5] | 0 | 0 | ||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | 0 | |||||||||||||
Level 3 [Member] | Warrants [Member] | |||||||||||||||
Assets [Abstract] | |||||||||||||||
Fair value of assets | [6] | $ 0 | |||||||||||||
Level 3 [Member] | Basis Swaps [Member] | |||||||||||||||
Liabilities [Abstract] | |||||||||||||||
Fair value of liabilities | [5] | $ 0 | |||||||||||||
|
Commitments and Contingencies (Details) |
Aug. 31, 2016
Lawsuit
|
---|---|
Loss Contingencies [Line Items] | |
Number of lawsuits filed | 10 |
Court of Chancery of the State of Delaware [Member] | |
Loss Contingencies [Line Items] | |
Number of lawsuits filed | 8 |
State of Pennsylvania in the Court of Common Pleas of Cumberland County [Member] | |
Loss Contingencies [Line Items] | |
Number of lawsuits filed | 1 |
Middle District of Pennsylvania [Member] | |
Loss Contingencies [Line Items] | |
Number of lawsuits filed | 1 |
Income Taxes (Details) - USD ($) $ in Millions |
12 Months Ended | |||||
---|---|---|---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
||||
Schedule of Income before Income Tax, Domestic and Foreign [Abstract] | ||||||
U.S. | $ 2,577 | $ 2,725 | $ 3,386 | |||
Non - U.S. | 2,567 | 2,586 | 171 | |||
Earnings Before Income Tax Provision | 5,144 | 5,311 | 3,557 | |||
Current provision [Abstract] | ||||||
Federal | 999 | 846 | 1,207 | |||
State | 56 | 121 | 109 | |||
Non - U.S. | 371 | 128 | 35 | |||
Total current provisions for income taxes | 1,426 | 1,095 | 1,351 | |||
Deferred provision [Abstract] | ||||||
Federal | (183) | (23) | 183 | |||
State | 6 | (16) | (3) | |||
Non - U.S. - Tax Law Change | (182) | 0 | 0 | |||
Non - U.S. - Excluding Tax Law Change | (70) | 0 | (5) | |||
Total deferred provision for income taxes | (429) | (39) | 175 | |||
Income tax provision | $ 997 | $ 1,056 | $ 1,526 | |||
Difference Between the Statutory Federal Income Tax Rate and the Effective Tax Rate [Abstract] | ||||||
Federal statutory rate | 35.00% | 35.00% | 35.00% | |||
State income taxes, net of federal benefit | 0.80% | 1.30% | 1.90% | |||
Loss on Alliance Boots call option | [1] | 0.00% | 0.00% | 8.50% | ||
Deferred tax asset recognition | [1] | 0.00% | (4.10%) | 0.00% | ||
Gain on previously held equity interest | 0.00% | (5.80%) | 0.00% | |||
Foreign income taxed at non-U.S. rates | (7.80%) | (6.20%) | (3.10%) | |||
Non-taxable income | (4.40%) | (2.60%) | 0.00% | |||
Non-deductible expenses | 1.10% | 2.30% | 0.30% | |||
Tax Law changes | (3.50%) | 0.00% | 0.00% | |||
Tax Credits | (1.50%) | 0.00% | 0.00% | |||
Other | (0.30%) | 0.00% | 0.30% | |||
Effective income tax rate | 19.40% | 19.90% | 42.90% | |||
Remaining ownership subject to call option | 55.00% | |||||
Nondeductible loss on exercise of call option | $ 0 | $ 0 | $ 866 | |||
Deferred tax assets [Abstract] | ||||||
Postretirement benefits | 190 | 130 | ||||
Compensation and benefits | 205 | 224 | ||||
Insurance | 75 | 68 | ||||
Accrued rent | 169 | 167 | ||||
Outside basis difference | 134 | 73 | ||||
Bad debts | 65 | 67 | ||||
Tax attributes | 373 | 341 | ||||
Stock compensation | 97 | 119 | ||||
Deferred income | 150 | 0 | ||||
Other | 195 | 93 | ||||
Subtotal deferred tax assets | 1,653 | 1,282 | ||||
Less: Valuation allowance | 305 | 125 | ||||
Total deferred tax assets | 1,348 | 1,157 | ||||
Deferred tax liabilities [Abstract] | ||||||
Accelerated depreciation | 1,205 | 1,234 | ||||
Inventory | 388 | 420 | ||||
Intangible assets | 1,418 | 1,822 | ||||
Equity method investment | 978 | 333 | ||||
Deferred income | 0 | 889 | ||||
Total deferred tax liabilities | 3,989 | 4,698 | ||||
Net deferred tax liabilities | 2,641 | 3,541 | ||||
Operating Loss Carryforwards [Line Items] | ||||||
Income tax credits | 55 | |||||
Income taxes paid | 1,100 | 1,300 | 1,200 | |||
Deferred tax assets operating loss carryforwards subject to expiration | 139 | |||||
Deferred tax assets operating loss carryforwards not subject to expiration | 234 | |||||
Unrecognized tax benefit reported in current income tax liabilities | 51 | |||||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ||||||
Balance at beginning of year | 261 | 193 | 208 | |||
Gross increases related to business combination | 0 | 84 | 0 | |||
Gross increases related to tax positions in a prior period | 21 | 45 | 55 | |||
Gross decreases related to tax positions in a prior period | (47) | (75) | (82) | |||
Gross increases related to tax positions in the current period | 68 | 63 | 46 | |||
Settlements with taxing authorities | (17) | (45) | (22) | |||
Currency | (11) | 0 | 0 | |||
Lapse of statute of limitations | (6) | (4) | (12) | |||
Balance at end of year | 269 | 261 | 193 | |||
Unrecognized tax benefits would favorably impact the effective tax rate if recognized | $ 237 | 227 | $ 105 | |||
Number of months of increase (decrease) in unrecognized tax benefit with respect to uncertain unrecognized tax positions (in months) | 12 | |||||
Accrued Interest and penalties in income tax provision | $ 34 | 36 | ||||
Interest and penalties included in income tax expense | 2 | |||||
Unrecorded deferred tax liability for temporary differences related to foreign subsidiaries | $ 116 | $ 89 | ||||
Minimum [Member] | ||||||
Operating Loss Carryforwards [Line Items] | ||||||
Operating loss carryforwards, expiration dates | Jan. 01, 2017 | |||||
Maximum [Member] | ||||||
Operating Loss Carryforwards [Line Items] | ||||||
Operating loss carryforwards, expiration dates | Dec. 31, 2036 | |||||
U.S. Federal [Member] | ||||||
Operating Loss Carryforwards [Line Items] | ||||||
Deferred tax assets, operating loss carryforwards | $ 200 | |||||
State [Member] | ||||||
Operating Loss Carryforwards [Line Items] | ||||||
Deferred tax assets, operating loss carryforwards | 226 | |||||
Non-U.S. [Member] | ||||||
Operating Loss Carryforwards [Line Items] | ||||||
Deferred tax assets, operating loss carryforwards | $ 837 | |||||
|
Stock Compensation Plans (Details) - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Stock Compensation Plans [Abstract] | |||
Total stock-based compensation expense | $ 115 | $ 109 | $ 114 |
Stock-based compensation, recognized tax benefit, | 21 | $ 7 | $ 31 |
Unrecognized compensation cost related to non-vested awards | $ 111 | ||
Compensation cost not yet recognized period for recognition | 3 years |
Retirement Benefits (Details) $ in Millions |
12 Months Ended | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016
USD ($)
PensionPlan
|
Aug. 31, 2015
USD ($)
|
Aug. 31, 2014
USD ($)
|
Aug. 31, 2016
USD ($)
|
Aug. 31, 2015
USD ($)
|
||||||||||||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||||||||||||||||
Number of defined benefit plans | PensionPlan | 2 | |||||||||||||||||||||||
Defined benefit pension plan, investments holding percentage | 85.00% | |||||||||||||||||||||||
Cash contributions to defined benefit pension plans | $ 66 | |||||||||||||||||||||||
Profit sharing provision expense | 226 | $ 158 | $ 355 | |||||||||||||||||||||
Contributions to profit sharing | 225 | 249 | 328 | |||||||||||||||||||||
Cost recognized in the consolidated condensed statements of earnings | 130 | 93 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | ||||||||||||||||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||||||||||||||||
Defined benefit plan obligation | 8,635 | [1] | 8,635 | [1] | 8,827 | [1] | $ 9,463 | $ 8,635 | [1] | |||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | 9,428 | 8,936 | [1] | 8,987 | [1] | 9,428 | 8,936 | [1] | ||||||||||||||||
Components of net periodic benefit costs [Abstract] | ||||||||||||||||||||||||
Service costs | 4 | 3 | [1] | |||||||||||||||||||||
Interest costs | 308 | 214 | [1] | |||||||||||||||||||||
Expected returns on plan assets | (247) | (173) | [1] | |||||||||||||||||||||
Curtailments | (2) | (2) | ||||||||||||||||||||||
Total postretirement benefit costs | 63 | 42 | [1] | |||||||||||||||||||||
Change in benefit obligation [Roll Forward] | ||||||||||||||||||||||||
Benefit obligation at beginning of year | [1] | 8,635 | 8,827 | |||||||||||||||||||||
Service costs | 4 | 3 | [1] | |||||||||||||||||||||
Interest costs | 308 | 214 | [1] | |||||||||||||||||||||
Amendments | (2) | (2) | [1] | |||||||||||||||||||||
Net actuarial (gain) loss | 2,272 | (103) | [1] | |||||||||||||||||||||
Benefits paid | (277) | (186) | [1] | |||||||||||||||||||||
Currency translation adjustments | (1,477) | (118) | [1] | |||||||||||||||||||||
Benefit obligation at end of year | 9,463 | 8,635 | [1] | 8,827 | [1] | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [1] | 8,936 | 8,987 | |||||||||||||||||||||
Employer contributions | 75 | 152 | [1] | |||||||||||||||||||||
Benefits paid | (277) | (186) | [1] | |||||||||||||||||||||
Return on assets | 2,216 | 91 | [1] | |||||||||||||||||||||
Currency translation adjustments | (1,522) | (108) | [1] | |||||||||||||||||||||
Plan assets at fair value at end of year | $ 9,428 | $ 8,936 | [1] | $ 8,987 | [1] | |||||||||||||||||||
Amounts recognized in the Consolidated Balance Sheets [Abstract] | ||||||||||||||||||||||||
Other non-current assets | 155 | 468 | ||||||||||||||||||||||
Accrued expenses and other liabilities | (6) | (1) | ||||||||||||||||||||||
Other non-current liabilitries | (184) | (166) | ||||||||||||||||||||||
Net (liability) asset recognized at end of year | (35) | 301 | ||||||||||||||||||||||
Amounts recognized in accumulated other comprehensive (income) loss [Abstract] | ||||||||||||||||||||||||
Net actuarial (gain) loss | (258) | 21 | [1] | |||||||||||||||||||||
Accumulated benefit obligations in excess of plan assets [Abstract] | ||||||||||||||||||||||||
Projected benefit obligation | 9,463 | 8,635 | ||||||||||||||||||||||
Accumulated benefit obligation | 9,457 | 8,624 | ||||||||||||||||||||||
Fair value of plan assets | $ 9,428 | $ 8,936 | ||||||||||||||||||||||
Weighted-average assumptions used to determine benefit obligations [Abstract] | ||||||||||||||||||||||||
Discount rate | 2.17% | 3.87% | ||||||||||||||||||||||
Rate of compensation increase | 2.44% | 2.55% | ||||||||||||||||||||||
Weighted-average assumptions used to determine net periodic benefit cost [Abstract] | ||||||||||||||||||||||||
Discount rate | 3.87% | 3.77% | ||||||||||||||||||||||
Expected long-term return on plan assets | 3.05% | 2.99% | ||||||||||||||||||||||
Rate of compensation increase | 2.55% | 2.66% | ||||||||||||||||||||||
Estimated future benefit payments and federal subsidy [Abstract] | ||||||||||||||||||||||||
2017 | $ 264 | |||||||||||||||||||||||
2018 | 237 | |||||||||||||||||||||||
2019 | 248 | |||||||||||||||||||||||
2020 | 266 | |||||||||||||||||||||||
2021 | 279 | |||||||||||||||||||||||
2022-2026 | 1,641 | |||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | $ 25 | $ 25 | 38 | $ 25 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | 25 | |||||||||||||||||||||||
Plan assets at fair value at end of year | 38 | 25 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | 8,407 | 8,407 | 8,977 | 8,407 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | 8,407 | |||||||||||||||||||||||
Plan assets at fair value at end of year | 8,977 | 8,407 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | 504 | 504 | 413 | 504 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | 504 | |||||||||||||||||||||||
Plan assets at fair value at end of year | $ 413 | $ 504 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Equity Securities [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Percentage of defined benefit pension plan assets investment of fair market value | 8.90% | 9.50% | ||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [2] | $ 834 | $ 852 | 834 | 852 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [2] | 852 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [2] | 834 | 852 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Equity Securities [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [2] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [2] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [2] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Equity Securities [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [2] | 852 | 852 | 834 | 852 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [2] | 852 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [2] | 834 | 852 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Equity Securities [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [2] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [2] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [2] | $ 0 | $ 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Percentage of defined benefit pension plan assets investment of fair market value | 78.80% | 81.50% | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Fixed Interest Government Bonds [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | $ 267 | $ 267 | 265 | 267 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 267 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 265 | 267 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Fixed Interest Government Bonds [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Fixed Interest Government Bonds [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 265 | 267 | 265 | 267 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 267 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 265 | 267 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Fixed Interest Government Bonds [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Index Linked Government Bonds [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 3,502 | 1,006 | 3,502 | 1,006 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 1,006 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 3,502 | 1,006 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Index Linked Government Bonds [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Index Linked Government Bonds [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 1,006 | 1,006 | 3,502 | 1,006 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 1,006 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 3,502 | 1,006 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Index Linked Government Bonds [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [3] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [3] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [3] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Corporate Bonds [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [4] | 5,535 | 5,535 | 3,663 | 5,535 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [4] | 5,535 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [4] | 3,663 | 5,535 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Corporate Bonds [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [4] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [4] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [4] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Corporate Bonds [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [4] | 3,663 | 5,535 | 3,663 | 5,535 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [4] | 5,535 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [4] | 3,663 | 5,535 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Corporate Bonds [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [4] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [4] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [4] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Other Bonds [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [5] | 472 | 472 | 472 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [5] | 472 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [5] | 472 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Other Bonds [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [5] | 0 | 0 | 0 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [5] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [5] | 0 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Other Bonds [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [5] | 472 | 472 | 472 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [5] | 472 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [5] | 472 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Debt Securities [Member] | Other Bonds [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [5] | 0 | 0 | 0 | ||||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [5] | $ 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [5] | $ 0 | ||||||||||||||||||||||
Boots and Other Pension Plans [Member] | Real Estate [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Percentage of defined benefit pension plan assets investment of fair market value | 4.30% | 5.60% | ||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [6] | $ 502 | $ 502 | 411 | 502 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [6] | 502 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [6] | 411 | 502 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Real Estate [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [6] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [6] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [6] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Real Estate [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [6] | 0 | 0 | 0 | 0 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [6] | 0 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [6] | 0 | 0 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Real Estate [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [6] | 411 | 502 | 411 | 502 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [6] | 502 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [6] | $ 411 | $ 502 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Other [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Percentage of defined benefit pension plan assets investment of fair market value | 8.00% | 3.40% | ||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [7] | $ 302 | $ 302 | 753 | 302 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [7] | 302 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [7] | 753 | 302 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Other [Member] | Level 1 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [7] | 25 | 25 | 38 | 25 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [7] | 25 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [7] | 38 | 25 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Other [Member] | Level 2 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [7] | 713 | 275 | 713 | 275 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [7] | 275 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [7] | 713 | 275 | |||||||||||||||||||||
Boots and Other Pension Plans [Member] | Other [Member] | Level 3 [Member] | ||||||||||||||||||||||||
Defined benefit pension plan assets investment in the classes of securities [Abstract] | ||||||||||||||||||||||||
Amount of defined benefit pension plan assets investment of fair market value | [7] | 2 | 2 | 2 | 2 | |||||||||||||||||||
Change in plan assets [Roll Forward] | ||||||||||||||||||||||||
Plan assets at fair value at beginning of year | [7] | 2 | ||||||||||||||||||||||
Plan assets at fair value at end of year | [7] | 2 | 2 | |||||||||||||||||||||
Postretirement Health Benefit Plan [Member] | ||||||||||||||||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||||||||||||||||
Defined benefit plan obligation | 466 | 431 | 466 | $ 431 | ||||||||||||||||||||
Expected benefit to be paid net of estimated federal subsidy during fiscal year 2017 | $ 11 | |||||||||||||||||||||||
Change in benefit obligation [Roll Forward] | ||||||||||||||||||||||||
Benefit obligation at beginning of year | 431 | |||||||||||||||||||||||
Benefit obligation at end of year | $ 466 | $ 431 | ||||||||||||||||||||||
|
Capital Stock (Details) - USD ($) shares in Millions, $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Equity, Class of Treasury Stock [Line Items] | |||
Stock repurchased during current fiscal year, value | $ 1,000 | $ 500 | $ 705 |
Shares of common stock reserved for future issuances (in shares) | 43.8 | ||
2014 Share Repurchase Program [Member] | |||
Equity, Class of Treasury Stock [Line Items] | |||
Purchase of shares under stock repurchase program (in shares) | 1.3 | 8.2 | |
Value of shares purchased under stock repurchase program | $ 110 | $ 726 | |
Common Stock [Member] | 2014 Share Repurchase Program [Member] | |||
Equity, Class of Treasury Stock [Line Items] | |||
Share repurchase program, authorized maximum amount | $ 3,000 |
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | $ 31,300 | $ 20,617 | $ 19,558 |
Other comprehensive income (loss) before reclassification adjustments | (2,731) | (580) | 353 |
Amounts reclassified from accumulated OCI | (266) | 305 | |
Tax benefit (provision) | 219 | (75) | (125) |
Net other comprehensive income (loss) | (2,834) | (356) | 228 |
Ending Balance | 30,281 | 31,300 | 20,617 |
Pension/Post-retirement Obligations [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | 29 | 15 | 63 |
Other comprehensive income (loss) before reclassification adjustments | (303) | 23 | (77) |
Amounts reclassified from accumulated OCI | 0 | 0 | |
Tax benefit (provision) | 62 | (9) | 29 |
Net other comprehensive income (loss) | (241) | 14 | (48) |
Ending Balance | (212) | 29 | 15 |
Unrecognized Gain (Loss) on Available-for-Sale Investments [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | 259 | 107 | 1 |
Other comprehensive income (loss) before reclassification adjustments | (148) | 247 | 170 |
Amounts reclassified from accumulated OCI | (268) | 0 | |
Tax benefit (provision) | 159 | (95) | (64) |
Net other comprehensive income (loss) | (257) | 152 | 106 |
Ending Balance | 2 | 259 | 107 |
Unrealized Gain (Loss) on Cash Flow Hedges [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | (40) | (27) | 0 |
Other comprehensive income (loss) before reclassification adjustments | 0 | (14) | (43) |
Amounts reclassified from accumulated OCI | 5 | (5) | |
Tax benefit (provision) | (2) | 6 | 16 |
Net other comprehensive income (loss) | 3 | (13) | (27) |
Ending Balance | (37) | (40) | (27) |
Share of OCI of Equity Method Investments [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | 0 | (113) | (95) |
Other comprehensive income (loss) before reclassification adjustments | (1) | (57) | (27) |
Amounts reclassified from accumulated OCI | 0 | 230 | |
Tax benefit (provision) | 0 | (60) | 9 |
Net other comprehensive income (loss) | (1) | 113 | (18) |
Ending Balance | (1) | 0 | (113) |
Cumulative Translation Adjustments [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | (462) | 154 | (61) |
Other comprehensive income (loss) before reclassification adjustments | (2,279) | (779) | 330 |
Amounts reclassified from accumulated OCI | (3) | 80 | |
Tax benefit (provision) | 0 | 83 | (115) |
Net other comprehensive income (loss) | (2,282) | (616) | 215 |
Ending Balance | (2,744) | (462) | 154 |
AOCI Total [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Beginning Balance | (214) | 136 | (92) |
Net other comprehensive income (loss) | (2,778) | (350) | 228 |
Ending Balance | $ (2,992) | $ (214) | $ 136 |
Segment Reporting (Details) $ in Millions |
12 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Dec. 31, 2014
Segment
|
Aug. 31, 2016
USD ($)
Segment
Customer
|
Aug. 31, 2015
USD ($)
Customer
|
Aug. 31, 2014
USD ($)
|
||||
Segment Reporting [Abstract] | |||||||
Number of reportable segments | Segment | 3 | 3 | |||||
Segment Reporting Information [Line Items] | |||||||
Number of customers | Customer | 0 | ||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | $ 117,351 | $ 103,444 | $ 76,392 | ||||
Adjusted Operating Income | 7,208 | 6,157 | 4,866 | ||||
Depreciation and amortization | 1,718 | 1,742 | 1,316 | ||||
Additions to property, plant and equipment | 1,325 | 1,251 | 1,106 | ||||
Cost transformation | (424) | (542) | |||||
Acquisition-related amortization | (369) | (485) | (282) | ||||
LIFO provision | (214) | (285) | (132) | ||||
Acquisition-related costs | (102) | (87) | (82) | ||||
Legal settlement | (47) | ||||||
Asset impairment | (30) | (110) | |||||
Store closures and other optimization costs | (56) | (271) | |||||
Gain (loss) on sale of business | (17) | 9 | |||||
Adjustments to equity earnings in AmerisourceBergen | (21) | ||||||
Adjustments to equity earnings in Alliance Boots | 93 | 86 | |||||
Operating Income | 6,001 | $ 4,668 | 4,194 | ||||
Walgreens Boots Alliance [Member] | |||||||
Segment Reporting Information [Line Items] | |||||||
Ownership percentage of WBA | 55.00% | ||||||
Alliance Boots [Member] | |||||||
Segment Reporting Information [Line Items] | |||||||
Equity interest in Alliance Boots | 45.00% | 45.00% | |||||
Retail Pharmacy USA [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | $ 83,802 | $ 80,974 | 76,392 | ||||
Retail Pharmacy USA [Member] | Revenues [Member] | |||||||
Segment Reporting Information [Line Items] | |||||||
Number of customers | Customer | 2 | 1 | |||||
Concentration risk | 22.00% | 12.00% | |||||
Retail Pharmacy International [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | [1] | $ 13,256 | $ 8,657 | 0 | |||
Retail Pharmacy International [Member] | Revenues [Member] | |||||||
Segment Reporting Information [Line Items] | |||||||
Number of customers | Customer | 1 | ||||||
Concentration risk | 18.00% | 20.00% | |||||
Pharmaceutical Wholesale [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | $ 22,571 | $ 15,327 | 0 | ||||
Reportable Segments [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | 117,351 | 103,444 | 76,392 | ||||
Reportable Segments [Member] | Retail Pharmacy USA [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | 83,802 | 80,974 | 76,392 | ||||
Adjusted Operating Income | 5,357 | 5,098 | 4,866 | ||||
Depreciation and amortization | 1,134 | 1,217 | 1,316 | ||||
Additions to property, plant and equipment | 777 | 951 | 1,106 | ||||
Reportable Segments [Member] | Retail Pharmacy International [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | [1] | 13,256 | 8,657 | 0 | |||
Adjusted Operating Income | [1] | 1,155 | 616 | 0 | |||
Depreciation and amortization | [1] | 401 | 393 | 0 | |||
Additions to property, plant and equipment | [1] | 444 | 249 | 0 | |||
Reportable Segments [Member] | Pharmaceutical Wholesale [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | 20,293 | 13,813 | 0 | ||||
Adjusted Operating Income | 708 | 450 | 0 | ||||
Depreciation and amortization | 166 | 120 | 0 | ||||
Additions to property, plant and equipment | 104 | 51 | 0 | ||||
Intersegment Eliminations [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | [1] | (2,278) | (1,514) | 0 | |||
Adjusted Operating Income | [1] | (12) | (7) | 0 | |||
Depreciation and amortization | [1] | 17 | 12 | 0 | |||
Additions to property, plant and equipment | [1] | 0 | 0 | 0 | |||
Intersegment Eliminations [Member] | Retail Pharmacy USA [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | 0 | 0 | 0 | ||||
Intersegment Eliminations [Member] | Retail Pharmacy International [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | [1] | 0 | 0 | 0 | |||
Intersegment Eliminations [Member] | Pharmaceutical Wholesale [Member] | |||||||
Segment Reporting Information, Operating Income (Loss) [Abstract] | |||||||
Sales | $ 2,278 | $ 1,514 | $ 0 | ||||
|
Segment Reporting, Geographic Data (Details) - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Sales | $ 117,351 | $ 103,444 | $ 76,392 |
Long-Lived Assets | 14,335 | 15,068 | |
Other [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Sales | 2,675 | 1,833 | 0 |
Long-Lived Assets | 175 | 181 | |
Reportable Geographical Components [Member] | United States [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Sales | 83,802 | 80,974 | 76,392 |
Long-Lived Assets | 10,924 | 11,327 | |
Reportable Geographical Components [Member] | United Kingdom [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Sales | 14,081 | 9,235 | 0 |
Long-Lived Assets | 2,611 | 2,835 | |
Reportable Geographical Components [Member] | Europe [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Sales | 16,793 | 11,402 | $ 0 |
Long-Lived Assets | $ 625 | $ 725 |
Related Parties (Details) - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Related Parties [Abstract] | |||
Purchases, net | $ 41,889 | $ 39,360 | $ 31,439 |
Trade accounts payable | $ 3,456 | $ 2,867 | $ 2,360 |
Supplementary Financial Information (Details) - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
|
Non-cash transactions [Abstract] | |||
Non-cash transactions for debt assumed | $ 0 | $ 9,000 | |
Non-cash transaction for common stock issued in relation to the second step transaction | 11,000 | ||
Business Acquisition [Line Items] | |||
Consideration received | $ 401 | 439 | |
Fair value of assets acquired | 26,600 | ||
Liabilities assumed | 20,000 | ||
Capital lease obligations | $ 322 | ||
Walgreens Boots Alliance [Member] | |||
Business Acquisition [Line Items] | |||
Purchase consideration transferred | $ 8,100 | ||
Ownership percentage | 45.00% | ||
Walgreens Boots Alliance Development GmbH [Member] | |||
Business Acquisition [Line Items] | |||
Consideration received | $ 2,600 |
Supplementary Financial Information, Assets and Liabilities Included in Consolidated Balance Sheet Captions (Details) - USD ($) $ in Millions |
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
---|---|---|---|
Accounts receivable [Abstract] | |||
Accounts receivable | $ 6,426 | $ 7,021 | |
Allowance for doubtful accounts | (166) | (172) | $ (173) |
Net, Total | 6,260 | 6,849 | |
Other non-current assets [Abstract] | |||
Investment in AmerisourceBergen | 0 | 1,147 | |
Warrants | 0 | 2,140 | |
Other | 467 | 805 | |
Other non-current assets, Total | 467 | 4,092 | |
Accrued expenses and other liabilities [Abstract] | |||
Accrued salaries and wages | 1,398 | 1,357 | |
Other | 4,086 | 3,868 | |
Accrued expenses and other liabilities, Total | $ 5,484 | $ 5,225 |
Supplementary Financial Information, Summary of Quarterly Results (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | 12 Months Ended | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2016 |
May 31, 2016 |
Feb. 29, 2016 |
Nov. 30, 2015 |
Aug. 31, 2015 |
May 31, 2015 |
Feb. 28, 2015 |
Nov. 30, 2014 |
Aug. 31, 2016 |
Aug. 31, 2015 |
Aug. 31, 2014 |
||||||||||||||
Supplementary Financial Information [Abstract] | ||||||||||||||||||||||||
Sales | $ 28,636 | [1] | $ 29,498 | [1] | $ 30,184 | [1] | $ 29,033 | [1] | $ 28,522 | [1] | $ 28,795 | [1] | $ 26,573 | [1] | $ 19,554 | [1] | $ 117,351 | [1] | $ 103,444 | [1] | $ 76,392 | |||
Gross Profit | 7,155 | [1] | 7,433 | [1] | 7,867 | [1] | 7,419 | [1] | 7,195 | [1] | 7,420 | [1] | 6,842 | [1] | 5,296 | [1] | 29,874 | [1] | 26,753 | [1] | 21,569 | |||
Net Earnings attributable to Walgreens Boots Alliance, Inc. | $ 1,030 | [1] | $ 1,103 | [1] | $ 930 | [1] | $ 1,110 | [1] | $ 26 | [1] | $ 1,302 | [1] | $ 2,042 | [1] | $ 850 | [1] | $ 4,173 | [1] | $ 4,220 | [1] | $ 1,932 | |||
Net earnings per common share [Abstract] | ||||||||||||||||||||||||
Basic (in dollars per share) | [1] | $ 0.95 | $ 1.02 | $ 0.86 | $ 1.02 | $ 0.02 | $ 1.19 | $ 1.96 | $ 0.90 | $ 3.85 | $ 4.05 | |||||||||||||
Diluted (in dollars per share) | [1] | 0.95 | 1.01 | 0.85 | 1.01 | 0.02 | 1.18 | 1.93 | 0.89 | 3.82 | 4.00 | |||||||||||||
Cash Dividends Declared Per Common Share (in dollars per share) | $ 0.3750 | [1] | $ 0.3600 | [1] | $ 0.3600 | [1] | $ 0.3600 | [1] | $ 0.3600 | [1] | $ 0.3375 | [1] | $ 0.3375 | [1] | $ 0.3375 | [1] | $ 1.4550 | [1] | $ 1.3725 | [1] | $ 1.28 | |||
|
%:3)(Y) H(%%"HG(,
M9U;5Q*EJ,JH:,5=K8A]\L0B4\5AK1.!L:OBX;\MY!],,$L--(2&A9%;/E*"5
M8"[;##>68Z3 2(F1RHXJ\+@_A'#K*^ C8T.,,&$@PM#C<2S<[DQ8R\3Y,\&8
MN9$$EM4VX'9Z<2YLDQ4F"DQ$CEZ/"\O&YC)D;;%3K]CIU*A=6%2(J1S':&
MTQ9F*3!28J2ZZLN\LMJMK*8+ES.]!+'20B3%2(:1'",%1DI"F*=>=87,2^OV
MZ()\;<#L?C8$N3=M5EMC=VW< 3BO'.@._:3]KNZ$]&*2W5T&DXX6\XE4T'2.W4HVZMC^?FF85NIAT2->W-0
M-3>2']RY^WSXK_X!4$L#!!0 ( "V+5$GGZ%:P@@( (\( 9 >&PO
M=V]R:W-H965T ,'AV-2FU.)7($Q /7292I ?664E@:-);G,30MN?!R,
M3Q+?UC$?S"HD/ORV@"*_]P %8A^/+"U2&(.%EI#8(PN%U%^2S"V(2)9 H
MOBX0?18PDP^1$8B^5&K03&I2-4R$<@=4 833_#)4&PB'Y(:RQ]:$8TB87!=(
MK DG(!#9;"8F8<,LL+TJ!JI R*%3@TZ473>;6LVF8#9VF#4,<3@UQ (YF!H8
MG%ZWFEFM9F U<5C-8)$X=;C-OFWI[VZ!"9/K;G.KVQP6<1A9Y5 VAU>0<59V
MDKEA$Z#0:E9/*[>9PRU "TR( ZLF+,&N^@*%47R#:60W/7V#K=^#R30"TQEQ
M_(^J"2.NW54#A?$ME<9VT_!!3D*7:8"(
#HE.SAV1 [:BW,
MOP,HG/9T0Y?"BVP[%PJL+-C*JZ6&WDKLB8%F3^\VNT,>$!'P6\)DSV(2O!\1
M7T/R6.]I%BR @LH%!>&7$]R#4D'(-_X[:[ZW#,3S>%'_&:?U[H_"PCVJ/[)V
MG3>;45)#(T;E7G#Z!?,(MT&P0F7CEU2C=:@7"B5:O*55]G&=TA_.9]IU I\)
M?"7\R*+QU"C:?!!.E(7!B=A!A+/;[#S.FB8.7A:GDG->L%,0
MNL DXB%A-BN">?6K+3B]1N>IQ=?T[25]FQQN9X?;KP7R2X$\">2?C9@PAP63
M?VC"SO94@VGCU;&DPK%W:4O7ZGH[[^(ALG=X60RBA2=A6ME;9)!:V)]A.P_[]
M^I*&=E4M+_',Y)PS9WPI)S3OM@=PY%-);;>T=V[8,&;K'A2W5SB ]G]:-(H[
MGYJ.V<$ ;R))299GV0U37&A:E;'V:JH21R>%AE=#[*@4-W]V('':TA4]%MY$
MU[M08%7)%EXC%&@K4!,#[9;>KS:[(B BX)> R9[$)'C?([Z'Y*79TBQ8 FU
M"PK<+P=X "F#D&_\,6M^M0S$T_BH_A2G]>[WW,(#RM^B<;TWFU'20,M'Z=YP
M>H9YA.L@6*.T\4OJT3I41PHEBG^F5>BX3NE/7LRTRX1\)N0+X3:+QE.C:/.1
M.UZ5!B=B!Q[.;K7Q:3GW]/7Y_1UK@)(EZ9>&_6CQTU31R\*H]57MR7[!B$+C")N$^8U8)@7OUJ
MBYQ>H^>IQ=?T]25]G1RN$WV3?2U07 H42:#XWX@)LY\QF\]#LK,]56"Z>'4L
MJ7'4+FWI4EUNYT,>S^0#7I4#[^ 7-YW0EAS0^9.-!] B.O#MLYL-);U_/TLB
MH74A_.9CDZY42AP.IP>RO-+J'5!+ P04 " MBU1)[_4#;:,! "Q P
M&0 'AL+W=O9?,"K
DG OT(LB7P_84(&PQ*SO%Z
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M4]H^@U=(
GF7*.3BP(5)PQG QHY8-3OF]"($BD,:-+0$L?4/K@64FN8);^_6S6")):
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MH%VV%O2@/)-O/8.\!4:09+Q2%.WB"EU